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The  thesis  is divided  in  three main parts: Part  I  consists of a general 
introduction  organized  in  two  chapters,  one  focusing  on  bacteria  and  their 
resistance to antibiotics and to the  innate  immune system, and a second one 
concerning  an overview on  the  general  aspects of  carbon monoxide  and  its 
relation  with  biological  systems  and  bacteria.  Part  II  comprises  the 
experimental  results  obtained  during  this  work,  which  is  divided  in  three 
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Nowadays,  the growing  increase of antibiotic  resistance  represents a 
global public health  concern. Hence,  it  is  crucial  to understand  the mode of 
action  of  antimicrobial  agents  and  to  develop  new  strategies  to  control 
bacterial  infections.  The work presented  in  this  thesis  contributes with new 
insights into the mechanisms that underpin the action of antimicrobial agents 
against pathogenic bacteria through: (i) the study of a putative nitroreductase 
of  Staphylococcus  aureus  and  its  involvement  in  nitrofurans  activation;  (ii) 
elucidation  of  the mechanisms  that  sustain  the  antibacterial  activity  of  the 
recently discovered Carbon Monoxide‐Releasing Molecules (CO‐RMs); and (iii) 
evaluation of the bactericidal effect of CO‐RMs on Helicobacter pylori.  
The  bactericidal  effect  of  nitrofuran  antibiotics  is  dependent  on  the 
reduction of their nitro group by bacterial nitroreductases. Sequence analysis 
of  the  S.  aureus  genome  allowed  identification  of  a  novel  putative 
nitroreductase,  SA0UHSC_00833,  herein  named  NtrA.  To  analyse  the  NtrA 
contribution  to nitrofurans activation, a mutant  strain  lacking  this gene was 
constructed and its resistance to nitrofurans was evaluated. Furthermore, the 
biochemical characterization of NtrA was performed. To achieve this, the ntrA 
gene  was  cloned,  and  the  recombinant  protein  expressed,  purified  and 
analysed.  The  results  revealed  that:  (i)  the  S.  aureus  strain  lacking  the ntrA 
nitroreductase  gene  is  more  resistant  to  nitrofurans;  (ii)  the  increased 
resistance  is  related with a  lower nitroreductase activity observed  in mutant 
cell  extracts;  and  (iii)  the  S.  aureus  nitroreductase  NtrA  is  able  to  reduce 
nitrofurans, with  specific  activities of 20  and 15 µmol.min‐1.mg protein‐1  for 




S.  aureus  nitroreductase NtrA was  also  found  to  be  involved  in  the 
metabolism  of  S‐Nitrosoglutathione  (GSNO),  a  biological  nitric  oxide  (NO) 
donor. Several lines of evidence supported this conclusion, namely: (i) the high 
induction of the ntrA gene transcription observed in cells of S. aureus exposed 
to GSNO;  (ii)  the higher  susceptibility  to GSNO killing of  the S. aureus  strain 
deleted  in ntrA gene; and (iii) the ability of the recombinant NtrA to detoxify 
GSNO with a significant activity of 1.5 µmol.min‐1.mg protein‐1. 
Altogether,  S. aureus NtrA  showed  to be  a bifunctional enzyme  that 
besides promoting nitrofurans activation also protects bacteria from the GSNO 
deleterious  effects.  Importantly,  a  phylogenetic  analysis  based  on  the 
alignment of several nitroreductase amino acid sequences revealed that NtrA 
is member of a novel family of bacterial nitroreductases.  
The  second  part  of  the work was  devoted  to  the  study  of  CO‐RMs, 
which  were  previously  reported  to  efficiently  eliminate  pathogens  such  as 
Escherichia  coli,  S.  aureus  and  Pseudomonas  aeruginosa.  Until  now,  the 
antimicrobial effect of CO‐RMs has been attributed only  to  the  inhibition of 
the aerobic  respiratory chain due  to  the expected binding of CO  to  terminal 
oxidases. However,  CO‐RMs were  reported  to  be more  potent  bactericides 
than  the  CO  gas,  implying  that  other mechanisms  support  the  antibacterial 
activity of these drugs. Previous DNA microarray experiments showed that CO‐
RMs  alter  the  transcription  of  several  genes  involved  in  oxidative  stress 
response,  suggesting  that  this  effect  also  played  a  role.  The  present  work 
demonstrated  that  E.  coli  cells  exposed  to  CO‐RMs  contain  higher  levels  of 
intracellular reactive oxygen species  (ROS). Furthermore,  it was seen that:  (i) 
supplementation  of  cell  medium  with  the  antioxidants  glutathione  and 
cysteine abolished  the antimicrobial effect of CO‐RMs;  (ii)  strains deleted  in 




damage, and a strain deleted  in recA, a gene product  involved  in DNA repair, 




generate  hydroxyl  radicals  per  se  in  aqueous  solution, which was  abolished 
upon  scavenging of  the CO molecule.  In  conclusion,  this work  revealed  that 
CO‐RMs mediate bacterial cell death through ROS formation. 
In the last part of this thesis, the bactericidal action of CO‐RMs toward 
H.  pylori  was  demonstrated.  Indeed,  CO‐RMs  were  shown  to  cause  a 
significant decrease  in H. pylori  viability. Moreover,  this effect was not only 
observed  for  a  laboratory  strain  but  also  for  several  clinical  isolates. 
Interestingly,  one  of  the mechanisms  of  CO‐RMs  bactericidal  action  on  H. 
pylori was  found  to  occur  through  inhibition  of  urease,  an  enzyme  that  is 
essential for survival and pathogenesis of this bacterium. 
Additionally,  CORM‐2  was  proven  to  enhance  the  H.  pylori 
susceptibility  to  the  antibiotics  commonly  used  to  eradicate  the  pathogen, 
namely, metronidazole,  clarithromycin and amoxicillin. Actually,  the minimal 




Overall,  the work presented  in  this  thesis has contributed  to a better 
understanding of the molecular basis of action of nitrofurans and CO‐RMs. In 




RMs,  ROS  formation was  demonstrated  to  be  an  important  factor  of  their 
antibacterial properties. Finally, CO‐RMs were shown, for the first time, to be 







antibióticos  representa um problema de  saúde pública  global. Por  isso,  é 
fundamental  entender  o modo  de  acção  dos  agentes  antimicrobianos  e 
desenvolver  novas  estratégias  para  controlar  as  infecções  bacterianas. O 
trabalho  apresentado  nesta  tese  contribuiu  com  novos  dados  sobre  os 
mecanismos  que  sustentam  a  acção  de  agentes  antimicrobianos  contra 
bactérias  patogénicas  através  de:  (i)  o  estudo  de  uma  nitroredutase 
hipotética  de  Staphylococcus  aureus  e  do  seu  envolvimento  na  activação 
dos antibióticos nitrofuranos; (ii) a elucidação dos mecanismos que estão na 








sua  resistência  a  estes  antibióticos.  Além  disso,  realizou‐se  também  a 
caracterização bioquímica da NtrA. Para este fim, o gene ntrA foi clonado e 
a  proteína  recombinante  expressa,  purificada  e  analisada.  Os  resultados 
revelaram que: (i) a estirpe de S. aureus, cujo gene ntrA foi interrompido é 
mais  resistente  aos  nitrofuranos;  (ii)  o  aumento  da  resistência  está 
relacionado  com  a  menor  actividade  de  nitroredutase  observada  em 
extractos  de  células mutadas;  e  (iii)  a  nitroredutase NtrA  de  S.  aureus  é 
capaz  de  reduzir  nitrofuranos,  com  actividades  específicas  de  20  e  15 
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μmol.min‐1.mg  proteina‐1,  para  a  nitrofurazona  e  nitrofurantoina, 
respectivamente.  Estes  valores  estão  dentro  da  gama  de  actividades 
normalmente observados para as nitroredutases canónicas. 
Foi ainda demonstrado que a nitroredutase NtrA de S. aureus está 
envolvida  no  metabolismo  da  S‐nitrosoglutationa  (GSNO),  um  dador 
biológico  de  óxido  nítrico  (NO). Várias  evidências  apoiam  esta  conclusão, 
nomeadamente:  (i)  a  indução  da  transcrição  do  gene  ntrA  observada  em 










A  segunda parte do  trabalho  foi dedicada  ao estudo dos CO‐RMs, 
que  foram  anteriormente  descritos  como  eficazes  a  eliminar  agentes 
patogénicos,  tais  como  Escherichia  coli,  S.  aureus  e  Pseudomonas 
aeruginosa.  Até  agora,  o  efeito  antimicrobiano  dos  CO‐RMs  foi  atribuído 
apenas à  inibição da cadeia respiratória aeróbica devido à afinidade do CO 
para  as oxidases  terminais. No entanto, os CO‐RMs  são bactericidas mais 
potentes do que o próprio CO gás,  sugerindo que outros mecanismos  são 
responsáveis pela actividade antibacteriana destes compostos. Experiências 
anteriores  de  DNA  microarrays  mostraram  que  os  CO‐RMs  alteram  a 
transcrição  de  vários  genes  envolvidos  na  resposta  ao  stress  oxidativo, 
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sugerindo  que  este  stress  possa  também  ter  um  papel  na  acção  destes 
compostos.  O  presente  trabalho  demonstrou  que  as  células  de  E.  coli 
expostas aos CO‐RMs contêm níveis mais elevados de espécies reactivas de 
oxigénio  (ERO)  intracelulares.  Além  disso,  mostrou‐se  que:  (i)  a 





cujo  produto  está  envolvido  na  reparação  do  DNA,  exibiu  maior 
susceptibilidade a estes  compostos;  (iv) após  tratamento  com CORM‐2 os 
níveis  intracelulares  de  ferro  livre  aumentaram  quatro  vezes,  sendo  os 
centros  de  ferro‐enxofre  a  fonte mais  provável  de  ferro;  e  (v)  o  CORM‐2 
promoveu a oxidação de grupos tióis  livres. Além disso, em solução aquosa os 
CO‐RMs provaram ser capazes de gerar per se o radical hidroxilo, o que não se 
observou  quando  o  grupo  CO  não  está  presente  na molécula.  Este  trabalho 
permitiu  então  concluir que os CO‐RMs medeiam  a morte  celular bacteriana 
através da formação de ERO. 
Na última parte desta tese, a acção bactericida do CO‐RMs em H. pylori 
foi  demonstrada. De  facto,  os  CO‐RMs  causam  uma  redução  significativa  na 
viabilidade  de  H.  pylori.  Este  efeito  não  foi  somente  observado  para  uma 
estirpe de  laboratório mas também para os vários  isolados clínicos que foram 
estudados.  Foi  interessante  observar  que  um  dos  mecanismos  da  acção 
bactericida dos CO‐RMs em H. pylori ocorre através da inibição da urease, uma 
enzima que é essencial para a sobrevivência e patogenicidade desta bactéria.  
Adicionalmente,  o  CORM‐2  aumentou  a  susceptibilidade  de H.  pylori 
aos  antibióticos  habitualmente  utilizados  para  a  sua  erradicação,  como  o 




diminui  significativamente  na  presença  de  doses  sub‐letais  de  CORM‐2.  É 
importante  notar  que  em  células  de mamíferos,  tais  como macrófagos,  foi 
menor a viabilidade de H. pylori quando previamente tratada com CORM‐2. 
Em  suma,  o  trabalho  apresentado  nesta  tese  contribuiu  para  uma 
melhor compreensão da base molecular de acção dos nitrofuranos e dos CO‐
RMs. Em particular, o papel da nitroredutase bifuncional NtrA de S. aureus na 
















BCA      Bicinchoninic acid method 
BHI      Brain heart infusion 
BMPO      5‐tert‐butoxycarbonyl 5‐mwthyl‐1‐pyrroline N‐oxide 
ßCD       ß‐cyclodextrin    
CFU      Colony forming units 
CH      Clarithromycin 
CO      Carbon monoxide 
CO2      Carbon dioxide 
CO3
•‐    Carbonate  
CoA      Coenzyme  
CODH      Carbon Monoxide dehydrogenase 








DMSO      Dimethyl sulfoxide 
DNA      Deoxyribonucleic acid 
DNIC      Dinitrosyl‐iron‐dithiol complexes 
DTNB      5,5´Dithiobis‐(2‐nitrobenzoic acid) 
e‐        Electron 
eNOS      Endothelial nitric oxide synthase 
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EPR      Electron paramagnetic resonance 
FAD      Flavin adenine dinucleotide 
FALDH    Glutathione‐dependent formaldehyde dehydrogenase  
FCS    Fetal calf serum 
FDP      Flavodiiron protein 
Fe    Iron     
Fe‐S      Iron‐sulphur cluster     
FI      Fluorescence intensity 
FMN      Flavin mononucleotide  
g      EPR g‐factor 
GDH      Glutamate dehydrogenase 
GOGAT    Glutamate synthase 
GSH      Glutathione  
GSNO      S‐Nitrosoglutathione 
GSNOR    GSNO reductase 
H+      Proton 
Hb      Haemoglobin 
HBA      Horse blood‐agar 
Hcp      Hybrid‐cluster protein 
Hmp      Flavohaemoglobin 
HO      Haem oxygenase 
H2O2      Hydrogen peroxide 
HOCl    Hypochlorous acid 
HUS      Haemolytic uremic syndrome 
I         Identity 




IL‐1      Interleukin 10 
IL‐6      Interleukin 6 
INF‐γ    Interferon‐γ 
IPTG            Isopropyl‐ß‐D‐thiogalactopyranoside 
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Kat          Catalase 
KCa      Large conductance calcium‐activated potassium 
kcat      Catalytic constant 
KM       Michaelis‐Menten constant 
Da      Dalton 
LB      Luria‐Bertani 
LPS      Lipopolysaccharides 
M      Molar 
MALT    Mucosa‐associated lymphoid‐tissue 
MAPK      Mitogen‐activated protein kinase 
MBC      Minimal bactericidal concentration 
MIC      Minimal inhibitory concentration 
MCC      Metal carbonyl complexes  
Mo        Molybdenum 
MOI      Multiplicity of infection 
MPO      Myeloperoxidase 
MRSA    Methicillin‐resisitant S. aureus 
MS      Minimal salts 
MTZ      Metronidazole 
NAC      N‐acetyl cysteine 
NADH      ß‐nicotinamide adenine dinucleotide, reduced form 
NADP      ß‐nicotinamide adenine dinucleotide phosphate, oxidized form 
NADPH    ß‐nicotinamide adenine dinucleotide phosphate, reduced form 











NOS      Nitric oxide synthase 
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Nrf      Pentahaem nitrite reductases 







OD      Optical density 
PAMP                Pathogen‐associated molecular pattern  
PBS      Phosphate buffer 
PCR      Polymerase chain reaction 
Phox      NADPH oxidase 
PPI    Proton pump inhibitor 
ppm    Parts per million 
RNA      Ribonucleic acid 
RNS      Reactive nitrogen species 
ROS      Reactive oxygen species 
RT‐PCR    Reverse transcriptase‐polimerase chain reaction 
Ru      Ruthenium 
S             Similarity 
SDS‐PAGE    Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SE          Standard error 
sGC      Soluble guanylate cyclase 
SMX           Sulfamethoxazole 
SNAP    S‐nitroso N‐acetyl DL‐penicillamine 





TNF‐α      Tumor necrosis factor‐α 
TSA      TSB‐agar 
TSB      Tryptic soy broth 
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      “The microbes always have the last word” - Louis Pasteur 










1.1 Pathogenic bacteria 
            The human body is exposed to millions of microorganisms, being 
estimated that it contains 10 times more bacterial than human cells 
(Shanahan, 2002; Tlaskalova-Hogenova et al., 2004). The majority of bacteria 
are not harmful and some of them have developed beneficial and essential 
relationships with the host, constituting the normal microflora (Hooper & 
Gordon, 2001). However, some bacteria are able to cause damage or illness to 
the host, being considered as pathogens. The ability to cause disease results 
from the outcome of host-pathogen interactions, which will depend on the 
damage that microorganism will inflict to the host, and the defense 
mechanisms of both host and bacteria (Casadevall & Pirofski, 2000; Medzhitov 
et al., 2012). When the host is not able to counteract a situation of bacterial 
infection, the use of antibiotics is required. However, the development and 
spread of antibiotic-resistant bacteria represents one of the most significant 
global health challenges for this century (Bush et al., 2011). 
 
 1.1.1 Escherichia coli  
The Gram-negative bacterium E. coli was first identified from feces of 
neonate and breast-fed infant by Theodor Escherich in 1885 (Escherich, 1989). 
This rod-shaped bacterium is by far the most well studied model organism and 
one of the first to have its genome completely sequenced, with approximately 
4.6 million base pairs of DNA (Blattner et al., 1997). Most E. coli strains are 
commonly regarded as non-pathogenic and along with other facultative 
anaerobe species have been identified in the normal microflora of the 
anaerobic environment of the colon (Eckburg et al., 2005; Tenaillon et al., 
2010). In fact, E. coli cells typical colonize the gastrointestinal tract of human 
infants within a few hours after birth, and bacteria can coexist in the host with 
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mutual benefits for decades. E. coli strains may benefit from the dietary fibers 
degraded by anaerobes and on other hand, limit oxygen content of the 
intestines and produce vitamin K (Ramotar et al., 1984; Kaper et al., 2004; 
Jones et al., 2007; Tenaillon et al., 2010). Nevertheless, some E. coli strains 
have virulence factors, that can cause a broad spectrum of diseases that fall 
into two categories: intestinal pathologies, such as diarrhea, and 
extraintestinal pathologies including urinary tract infections (UTIs), haemolytic 
uremic syndrome (HUS), sepsis and meningitis (Finlay & Falkow, 1997; Russo & 
Johnson, 2003; Kaper et al., 2004; Belanger et al., 2011). It is estimated that 
pathogenic strains of E. coli are responsible for more than 2 million human 
deaths worldwide per year, particularly due to diarrhea among young children 
and septicemia, a bloodstream infection derived from urinary tract infections 
(Kosek et al., 2003; Russo & Johnson, 2003). The most notorious pathogenic 
strain is the enterohaemorrhagic E. coli 0157:H7, which is a potentially fatal 
food-borne pathogen that causes haemorrhagic diarrhea and HUS, that may 
lead to acute renal failure (Karmali et al., 1983; Riley et al., 1983). According to 
the World Health Organization (WHO), up to 10% of patients with 
enterohaemorrhagic E. coli infections may develop HUS, with a fatality rate 
ranging from 3 to 5%. In 2011, an outbreak of haemorrhagic gastroenteritis 
and HUS caused by E. coli 0104:H4 occurred in Germany (Askar et al., 2011). 
Data collected by WHO show that from May to end of June 2011, 896 patients 
(including 33 deaths) developed HUS and 3241 patients presented 
enterohaemorrhagic gastroenteritis worldwide (including 17 deaths) (Askar et 
al., 2011; Wu et al., 2011).  
Urinary tract infections are among the most common humans bacterial 
infectious diseases, being in its majority (70-95%) caused by uropathogenic E. 
coli (Foxman, 2002; Russo & Johnson, 2003; Guay, 2008). For several decades, 










the combination of trimethoprim and sulfamethoxazole antibiotics 
(TMP/SMX), which inhibits sequential steps in bacterial tetrahydrofolic acid 
synthesis, has been used as first-line drug of choice to treat UTIs (Warren et 
al., 1999; Nicolle, 2003; Vouloumanou et al., 2011). However, there is a 
concern about the emergence of E. coli resistance to TMP/SMX. In fact, 
increasing values of antibiotic resistance over 20% have been reported in 
several European countries and in United States of America (Huovinen et al., 
1995; Huovinen, 2001; Mazzei et al., 2006). Hence, fluoroquinolone, an 
antibiotic that interferes with DNA replication, has been used as an alternative 
antimicrobial agent (Hooper, 1999; Guay, 2008). However, in some countries 
resistance to fluoroquinolones exceeds now 10-25%, and fosfomycin, an 
inhibitor of cell wall synthesis, and nitrofurantoin (see section 1.2) are used as 
alternative treatments (Guay, 2001, , 2008; Michalopoulos et al., 2011). Some 
β-lactams drugs such as aminopenicillins and cephalosporins are also active 
against E. coli by blocking cell wall synthesis (Nickel, 2005). However, these 
antibacterial agents are not usually recommended because, in general, they 
are less effective than non-β-lactams such as TMP/SMX or fluoriquinolones. 
Furthermore, E. coli exhibits high levels of resistance to β-lactams antibiotics 
(Nicolle, 2002; Nickel, 2005; Guay, 2008; Gagliotti et al., 2011). Accordingly 
with European Antimicrobial Resistance Surveillance System 
(www.ecdc.europa.eu/en/activities/surveillance/EARS-Net), the number of 
bloodstream infections caused by E. coli increased remarkably by 71% in the 
last years (2002 to 2009), associated with an alarming increase of 
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 1.1.2 Staphylococcus aureus 
 S. aureus are Gram-positive spherical bacteria usually arranged in 
pairs, short chains or in clusters, which were first isolated from pus from an 
abscess by Alexander Ogston in the late 1800s (Ogston, 1882; Madigan et al., 
2000). This facultative anaerobic pathogen is an opportunistic commensal 
bacterium, being mainly found in 
upper respiratory tract, especially in 
nose and pharynx, and in skin surface 
of healthy individuals (Figure 1.1) 
(Wertheim et al., 2005). The 
asymptomatic colonization provides a 
reservoir from which infection may 
occur when host defenses are 
breached (Kluytmans et al., 1997; 
Wertheim et al., 2005). Upon 
breaching the epithelium, this 
versatile pathogen is capable of 
causing from skin and soft-tissue infections (SSTIs), such as pimples, boils, acne 
and cellulites, most treatable with antibiotics, to life-threatening diseases 
including pneumonia, meningitis, arthritis, osteomyelitis, septicemia and toxic 
shock syndrome (Lowy, 1998; Stevens et al., 2005; Klevens et al., 2007; 
Gordon & Lowy, 2008). S. aureus infections have been recognized as a major 
worldwide health concern due to the emergence of antibiotic resistant strains. 
Actually, soon after the introduction in 1941 of the ß-lactam penicillin, 
antibiotic resistant strains rapidly spread, initially in hospitals and 
subsequently into the community (Rammelkamp & Maxon, 1942; Lowy, 2003). 
By the late of 1960s, more than 80% of both community and hospital-acquired 
Figure 1.1| S. aureus carriage rates per
body site in adults from general






























staphylococcal isolates were resistant to penicillin (Chambers, 2001; Lowy, 
2003). Interestingly, the community-acquired isolates were often resistant 
only to penicillin, whereas hospital strains were typically resistant to several 
antibiotics (Chambers, 2001). In 1961, the penicillin derivative - methicillin was 
introduced in clinical practice to treat staphylococcal infections; again less 
than one year later, methicillin-resistant S. aureus strains (MRSA) were 
reported (Barber, 1961). Although until 1990s, MRSA remained a problem 
restricted to hospitals and other health care-associated settings, in the 
following years MRSA arose in patients without prior healthcare contact and 
became a widespread cause of community infections (Lyon et al., 1984; Udo et 
al., 1993; Herold et al., 1998). Outbreaks of community acquired MRSA 
infections have been reported worldwide, and although usually described as a 
cause of superficial mild SSTIs (around 90% cases), some strains appear to be 
especially virulent, causing severe infections such sepsis, necrotizing fasciitis, 
necrotizing pneumonia and endocarditis (Chambers, 2001; Francis et al., 2005; 
Gonzalez et al., 2005; Seybold et al., 2006; Chambers & Deleo, 2009; Kallen et 
al., 2009). Fortunately, the prevalence of community acquired MRSA is still 
low in Portugal (Tavares et al., 2010). Although methicillin is no longer in 
clinical use, the term MRSA remains to describe S. aureus strains resistant to 
β-lactam antibiotics (Foster, 2004; Grundmann et al., 2010). Unlike healthcare-
associated MRSA, which typically are resistant to multiple antibiotics as 
macrolides, tetracyclines, gentamicin and lincosamides, the community 
isolates are often resistant only to ß-lactam antibiotics (Chambers, 2001; Feng 
et al., 2008; LaPlante et al., 2008; Dryden et al., 2010). In fact, antimicrobial 
compounds, such as TMP/SMX, clindamycin, tetracyclines, fluoroquinolones 
and linezoid have been used to successfully treat community acquired 
staphylococcal infections (Bhambri & Kim, 2009; Dryden et al., 2010). The 
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Figure 1.2| Target sites of the main antibiotics used against S. aureus infections.








































severe nosocomial S. aureus infections have been treated with linezolid, 
daptomycin, and combinations of tetracycline plus rifampicin or fusidic acid 
and clindamycin plus rifampicin (Dryden et al., 2010). The glycopeptide 
vancomycin has been shown to be the most effective therapeutic agent and is 
used as the “last resort” against infections caused by MRSA multidrug-
resistant. Nevertheless in 1997, the first vancomycin intermediate-resistant S. 
aureus (VISA) was identified in Japan, and subsequently also reported in other 
countries, reveling that emergence of vancomycin resistance was globally 
spread (Hiramatsu et al., 1997; Smith et al., 1999). More recently, reports of 
complete vancomycin resistant S. aureus (VRSA) arose, which is even more 
alarming (Appelbaum, 2006). Combinations of vancomycin with 
aminoglycoside, fusicid acid or rifampicin have also been used to treat more 
serious infections caused by S. aureus (Dryden et al., 2010). Figure 1.2 
summarizes the target sites of the main antibiotics used against 




















1.1.3 Helicobacter pylori  
H. pylori was first isolated from the gastric epithelium of a patient with 
chronic active gastritis by Warren and Marshall in the early 1980s (Warren & 
Marshall, 1983). In 2005, these two researchers won the Nobel Prize in 
Physiology or Medicine for the discovery and role of H. pylori in gastric 
diseases. H. pylori is a Gram-negative bacterium and usually presents a spiral-
shaped morphology; however, after prolonged cultivation in vitro and in 
response to stresses such as starvation and antibiotic treatment, bacteria may 
be converted to a coccoid shape, which is described to be viable but 
nonculturable (Berry et al., 1995; Kusters et al., 1997; Enroth et al., 1999; 
Kusters et al., 2006).  
This microaerophilic flagellated pathogen colonizes the stomach of 
more than half world´s population causing gastritis and being a predisposing 
condition to the development of severe upper gastrointestinal diseases 
including duodenal or gastric ulcers (1 to 10% of infected patients), gastric 
cancer (in 0.1 to 3%) and gastric mucosa-associated lymphoid-tissue (MALT) 
lymphoma (in <0.1%) (Dunn et al., 1997a; Everhart, 2000; Farinha & Gascoyne, 
2005; Houghton & Wang, 2005; McColl, 2010; Sachs & Scott, 2012). Hence, H. 
pylori is classified by the WHO as a class I carcinogen since 1994 (Conference, 
1994).  
H. pylori is unique in its capacity to efficiently colonize the acidic gastric 
environment and despite the host immune response, bacteria can persist for 
the lifetime of the host unless eradicated with antimicrobials. The diverse 
outcome of H. pylori infection is attributed to bacteria virulence factors, host 
genomic predisposition and environmental factors (Graham & Yamaoka, 2000; 
Clyne et al., 2007; Wu et al., 2008). In particular, several studies have reported 
that H. pylori strains mutated in the virulence factors, such as urease or 
Introduction| Chapter 1 
12 
 
enter in the periplasm space. Ammonia is also able to diffuse through the outer
membrane to neutralize the medium acidity. Cytoplasmatic ammonia can also
neutralize protons entering the cytoplasm. Flagella and spiral-shaped
morphology of the bacterium allow the penetration through the mucus layer to
reach gastric epithelial cells, to which it sticks via specialized adhesins. OM-
outer membrane and IM- inner membrane. Adapted from (Algood & Cover,
2006; Zanotti & Cendron, 2010; Scott et al., 2007)
Figure 1.3| Colonization
factors of H. pylori. During
infection, the bacterium




ammonia (NH3), which is
then converted to
ammonium (NH4+) by















flagella, are unable to colonize animal models. These findings reveal the 
extreme importance of both virulence factors in enabling the adherence of 
pathogen to the gastric epithelium (Eaton et al., 1991; Eaton et al., 1992; 
Eaton & Krakowka, 1994; Tsuda et al., 1994; Andrutis et al., 1995). Indeed, 
urease allows bacterial survival in the acidic pH of the gastric lumen (described 
below), whereas flagella and the spiral-shaped morphology let bacteria bore 
into the gastric mucus to reach stomach's epithelial cell layer, where bacterial 
adhesins mediate close interaction with the host cells (Figure 1.3) (Marshall et 





























The role of urease in mediating H. pylori acid resistance is attributable 
to its ability to hydrolyze urea, present in gastric juice, to carbon dioxide (CO2) 
and ammonia (NH3) (Marshall et al., 1990). The ammonia generated by urease 
activity consumes protons (H+) neutralizing the gastric juice, enabling H. pylori 
to survive and multiply in the stomach (Figure 1.3) (Eaton et al., 1991; Scott et 
al., 2007; Zanotti & Cendron, 2010). Importantly, ammonia also has a cytotoxic 
effect on gastric epithelial cells (Smoot et al., 1990).  
H. pylori urease is a 1.1 MDa spherical assembly of 12 catalytic units, 
each composed of UreA-UreB subunits (Ha et al., 2001). Besides these two 
structural subunits, four accessory proteins (UreEFGH) are involved in urease 
assembly by mediating incorporation of nickel into the apoenzyme (Cussac et 
al., 1992; Burne & Chen, 2000; Zanotti & Cendron, 2010). This nickel-
containing enzyme represents 6% of total H. pylori cell proteins and can be 
found in the cytoplasm as well as on bacterial surface upon autolysis of 
neighboring bacteria (Hu & Mobley, 1990; Phadnis et al., 1996; Dunn et al., 
1997b; Ha et al., 2001; Stingl & De Reuse, 2005). Although, it is well 
established that cytoplasmatic urease protects H. pylori against gastric acidity, 
the role of surface urease during H. pylori gastric colonization remains under 
debate. Some authors argue that extracellular urease does not contribute to 
acid resistance of H. pylori since the purified enzyme is irreversible inactivated 
at a pH<4. On the other hand, others reported that bacteria without 
extracellular urease activity are susceptible to an external pH of 3, and that 
urease supramolecular assembly plays a critical role in the activity of the 
enzyme as it protects the active sites, remaining the activity unaffected down 
to pH of 3 (Bauerfeind et al., 1997; Krishnamurthy et al., 1998; Ha et al., 2001; 
Stingl & De Reuse, 2005). 
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Due to the key role of urease in host stomach´s colonization, urease 
inhibitors constitute potential drugs for treatment of gastric infections 
(Follmer, 2010; Kosikowska & Berlicki, 2011). In fact, new strategies to 
eliminate H. pylori infections are urgently needed since a dramatic fall in 
eradication rates has been reported worldwidely in the last years, mainly due 
to the increased emergence of antibiotic resistance (Selgrad & Malfertheiner, 
2011). 
H. pylori eradication is usually done by the so-called triple therapy, 
which combines two antibiotics (clarithromycin, amoxicillin and 
metronidazole) with a proton pump inhibitor (PPI, e.g. omeprazole) to reduce 
gastric acid production (Coelho et al., 2000; Gisbert et al., 2005; Chey & Wong, 
2007; Malfertheiner et al., 2007; Wolle & Malfertheiner, 2007). However, 
triple therapy has become progressively less effective with treatment success 
rates being, in most countries currently lower that 80%, mainly due to 
antibiotic resistance (Megraud, 2004; Wolle & Malfertheiner, 2007; Graham & 
Fischbach, 2010; Yakoob et al., 2010; Rimbara et al., 2011). Therefore, triple 
clarithromycin-based therapy should be avoided unless infection is known to 
be susceptible to clarithromycin or in areas with proven low macrolide 
resistance rates (i.e. ≤20%) (Chuah et al., 2011; Rimbara et al., 2011). 
Importantly, resistance to clarithromycin cannot be overcome by increasing 
the dose or duration of therapy (Rimbara et al., 2011). Clarithromycin 
resistance is mainly associated with mutations in the 23S ribosomal RNA inside 
50S ribosomal subunits, which results in conformational changes that leads to 
a decrease binding affinity of the drug to H. pylori ribossomes, allowing normal 
bacterial protein synthesis (Versalovic et al., 1996; Occhialini et al., 1997; 
Taylor et al., 1997). In case of low resistance to clarithromycin and in 
populations with less than 40% of metronidazole resistance, PPI-










clarithromycin-metronidazole is recommended (Malfertheiner et al., 2007). 
Nevertheless, metronidazole resistance is also problematic and although it can 
be partially overcome by increasing the dose of antibiotic and the duration of 
therapy, it may cause intolerable side effects and pill burden, which 
compromises treatment (Rimbara et al., 2011). Metronidazole action is similar 
to that described to nitrofurans (see section 1.2 and 1.2.1), since this 
nitroimidazole antibiotic also needs to be converted to cytotoxic forms 
through reduction of the nitro group to exert antimicrobial effects (Lindmark 
& Muller, 1976). Several studies have shown that oxygen insensitive-
nitroreductase rdxA, NAD(P)H flavin oxidoreductase frxA and ferredoxin-like 
protein fdxB contribute to the activation of metronidazole in H. pylori. In 
agreement, metronidazole resistance is usually associated with mutations in 
these genes (Goodwin et al., 1998; Kwon et al., 2000; Jenks & Edwards, 2002; 
Mendz & Megraud, 2002). On the contrary, amoxicillin resistance is not a 
major concern since the resistance rate remains so far low (Yakoob et al., 
2010). 
Due to the increase inefficiency of the triple therapy, the use of four-
drug regiments has been recommended. Such treatment include quadruple or 
sequential therapy comprising PPI plus three antibiotics (clarithromycin, 
metronidazole and amoxicillin), or a bismuth-containing quadruple therapy 
(PPI plus bismuth salts, metronidazole and tetracycline). So far, these 
treatments have provided better eradication rates (Fischbach & Evans, 2007; 
Chuah et al., 2011; Rimbara et al., 2011; Selgrad & Malfertheiner, 2011; 
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1.2 Nitrofurans as antimicrobial agents 
Nitrofurans are a class of synthetic antimicrobials that include 
nitrofurantoin and nitrofurazone. These compounds remain clinically effective 
against a wide range of bacteria, including those responsible for UTIs as E. coli 
(see section 1.1.1) (Chamberlain, 1976; Johnson et al., 1993; Guay, 2001). 
Although, S. aureus is a relatively uncommon cause of UTIs in the general 
population (<1%), it is quite usual among patients submitted to urinary tract 
catheterization and to genitourinary procedures (Barrett et al., 1999; 
Goldstein, 2000; Muder et al., 2006; Guay, 2008). Importantly, the majority of 
staphylococcal isolates from patients with catheter-associated UTIs are MRSA 
(Muder et al., 2006).  
Nitrofurantoin is currently used as an oral antibiotic for the treatment 
of genitourinary infections and although, 
nitrofurazone is primarily utilized as a topical 
antibiotic in burns and skin grafts, a 
nitrofurazone-impregnated catheter can be 
utilized to prevent catheter-associated urinary 
tract infections (Johnson et al., 1993; Guay, 
2001). Although the bactericidal action of 
nitrofurans has yet to be fully elucidated, 
reduction of nitro group by nitroreductases 
(NTR, see section 1.2.1) is essential for its activation (McCalla et al., 1970; 
Bryant & DeLuca, 1991; McOsker & Fitzpatrick, 1994). Therefore, mutations in 
genes encoding nitroreductases result in increased bacterial resistance to 
nitrofurans (McCalla et al., 1978; Bryant et al., 1981; Whiteway et al., 1998). 
Following activation, the actual antimicrobial action of these prodrugs remains 
largely unknown, but it is believed to be due to the inhibition of bacterial 
Figure 1.4| Chemical structures
of nitrofurantoin (A) and
nitrofurazone (B). Adapted
from (Mottier et al., 2005).
A
B










enzymes involved, at least, in DNA and RNA synthesis and carbohydrate 
metabolism (McCalla et al., 1970; Streeter & Hoener, 1988; Shah & Wade, 
1989; McOsker & Fitzpatrick, 1994). The multiple target sites of nitrofuran 
antibiotics may explain the reduced ability of bacteria to develop resistance 
toward these drugs (Guay, 2001). In particular, several reports have 
demonstrated that MRSA isolates from catheter-associated UTIs are 
susceptibility to both nitrofurantoin and nitrofurazone (Shah & Wade, 1989; 
Flournoy & Robinson, 1990; Johnson et al., 1993; Johnson et al., 1999). The 
observations that S. aureus are still susceptibility to nitrofurans even after 
several decades of use are of clinical importance (Chamberlain, 1976; McOsker 
& Fitzpatrick, 1994; Guay, 2001).  
 
1.2.1 Nitroreductases 
Nitroreductases are the enzymes responsible for nitrofurans activation 
(McCalla et al., 1978; McCoy et al., 1981; Roldan et al., 2008). These enzymes 
that reduce the nitro group are divided into two groups based on oxygen 
sensitivity: type I-oxygen insensitive and type II-oxygen sensitive enzymes 
(Peterson et al., 1979).  
Type I-oxygen insensitive nitroreductases are the best-studied 
enzymes, and although usually found in bacteria, they rarely occur in 
eukaryotes (Knox et al., 1993; Ueda et al., 2003; Roldan et al., 2008). This type 
of nitroreductases are FMN binding proteins and NAD(P)H-dependent 
enzymes. Nitroreductases catalyze the sequential reduction of nitro group 
through the addition of two electrons from NAD(P)H to yield a nitroso 
intermediate, which is reduced to amine via a hydroxilamine derivative. In 
itself, hydroxylamine has toxic, carcinogenic and mutagenic properties (Figure 
1.5) (Peterson et al., 1979; Bryant et al., 1981; Roldan et al., 2008).  
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Type II-oxygen sensitive nitroreductases are FAD- or FMN-containing 
enzymes that mediate one-electron reduction of the nitro group forming a 
nitro anion radical, which in the presence of oxygen produces superoxide 
anion in a futile cycle, regenerating the parental nitro-compound. Thus, these 
enzymes only mediate reduction of nitrofurans under anaerobic conditions 
(Figure 1.5) (Mason & Holtzman, 1975a, 1975b; Peterson et al., 1979). The 
former type of nitroreductases is found in E. coli and several Clostridium 
strains (McCalla et al., 1975; Peterson et al., 1979; Angermaier & Simon, 
1983). In general, nitrofuran reduction in eukaryotic cells is mediated by this 
type of nitoreductases (Wolpert et al., 1973; Adams & Rickert, 1995).  
 
 
Figure 1.5| General scheme of nitrofurans reduction by nitroreductases
(NTR). The oxygen-insensitive nitroreductases (type I) catalyze the
reduction of the nitro group of nitrofurans by addition of a pair of electrons
forming the nitroso and hydroxylamino intermediates and finally the amine
formation. The oxygen-sensitive nitroreductases (type II) catalyze the
single-electron reduction of the nitro group to produce a nitro anion
radical, which can be reoxidized aerobically to the original structure with
the concomitant production of superoxide anion (O2•-) in a futile cycle.


























Although bacteria may contain both types of nitroreductases, as is the 
case of E. coli, it seems to be those from type I that underpin nitrofurans 
action. In fact, bacterial resistance to nitrofurans is usually attributed to 
mutations in genes encoding oxygen insensitive nitroreductases (McCalla et 
al., 1970; McCalla et al., 1975; McCalla et al., 1978; Sastry & Jayaraman, 1984; 
Whiteway et al., 1998). Table 1.1 summarizes the most relevant bacterial 
oxygen-insensitive (type I) nitroreductases reported to promote reduction of 
nitrofuran antibiotics.  
 
Table 1.1| Bacterial oxygen-insensitive nitroreductases (NTR) mediating 









NfsA 27 NADPH 
(Bryant et al., 1981)  
(Zenno et al., 1996a) 
(Zenno et al., 1998a) 
NfsB 24 NAD(P)H 
(Bryant et al., 1981) 
 (Zenno et al., 1996c) 
(Zenno et al., 1996b) 
(Zenno et al., 1996a) 
Enterobacter 
cloacae 
NR 27 NAD(P)H 
(Bryant & DeLuca, 1991) 
(Koder & Miller, 1998) 
Synechocystis sp. DrgA 26 NAD(P)H (Takeda et al., 2007) 
Bacillus subtilis NfrA1 29 NADPH (Zenno et al., 1998b) 
S. aureus NfrA 29 NADPH (Streker et al., 2005) 
H. pylori 
RdxA 26 NAD(P)H (Olekhnovich et al., 2009) 
FrxA 25 NAD(P)H (Sisson et al., 2002) 
Adapted from (Roldan et al., 2008). 
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 Bacterial oxygen insensitive nitroreductases are divided into two main 
groups according to their similarity with E. coli nitroreductases, NfsA and NfsB, 
which share very low identity (Zenno et al., 1996a; Zenno et al., 1996c, 1996b; 
Roldan et al., 2008). The NfsA group, composed by B. subtilis NfrA1 and S. 
aureus NfrA is usually NADPH-dependent whereas NfsB group (Enterobacter 
NR, Synechocystis DrgA, and H. pylori RdxA and FrxA) may use both NADH and 
NADPH as electron donors (Table 1.1) (Bryant et al., 1981; Zenno et al., 1996a; 
Zenno et al., 1996c, 1996b; Whiteway et al., 1998; Zenno et al., 1998a; Roldan 
et al., 2008). In spite of low degree of amino acid sequence similarity, the two 
groups of bacterial insensitive nitroreductases share similar structure and 
biochemical properties as all occur as homodimers (24-30 kDa subunits) with a 
characteristic α+ß-fold, contain FMN as cofactor and catalyze, besides 
nitrofurans, the reduction of a broad range of substrates (Zenno et al., 1996a; 
Zenno et al., 1996c; Parkinson et al., 2000; Kobori et al., 2001; Haynes et al., 
2002; Race et al., 2005; Roldan et al., 2008).  
 More interestingly, several bacterial nitroreductases have been 
described to protect against oxidative stress, which together with nitrosative 
stress are imposed to bacteria by mammalian immune system (see section 
1.3). In particular, it was shown that E. coli nfsA is induced by paraquat as a 
member of the soxRS regulon, which is involved in the control of oxidative 
stress response in E. coli (Liochev et al., 1999). Moreover, B. subtilis nfrA1 and 
S. aureus nfrA are also induced under oxidative stress conditions (Mostertz et 
al., 2004; Streker et al., 2005). Interestingly, B. subtilis NfrA1 is able to rapidly 
scavenge hydrogen peroxide (H2O2) (Cortial et al., 2010). Furthermore, S. 
aureus NfrA nitroreductase exhibits disulfide reductase activity, which allows a 
thiol-disulfide balance that is quite important since oxidation of thiols resulting 
in disulfide bond formation is one major effect of oxidative stress on proteins 










(see section 1.3) (Streker et al., 2005). The study of a S. aureus nitroreductase, 
which is involved in nitrosative stress response, is presented in Chapter 3. 
 Besides their role in antibiotic activation and stress responses, 
nitroreductases have been suggested for medical applications as cancer 
therapy (Knox et al., 1993; Connors & Knox, 1995; Green et al., 2004; Searle et 
al., 2004). In particular, several studies have been carried out with E. coli 
nitroreductases in order to promote activation of prodrugs in tumor cells 
(Searle et al., 2004; Vass et al., 2009).  
 Additionally, bacterial nitroreductases can be used for biodegradation 
and bioremediation of nitroaromatic pollutant compounds (Spain, 1995; 
Rieger et al., 2002; Lewis et al., 2004; Ramos et al., 2005; Symons & Bruce, 
2006). 
 
1.3 Innate immune system response against bacteria 
The mammalian immune system is constituted by innate and adaptive 
defense mechanisms, which cooperate to protect host cells against microbial 
infections (Medzhitov, 2007). The adaptive immunity is characterized by its 
high degree of specificity and the property of memory, being its response 
mediated by lymphocytes (B and T cells), which produce immune molecules 
such as antibodies, cytokines and antigen binding receptors (Medzhitov, 
2007). The innate immunity is non-specific and provides the first line of 
defense during the critical period just after the host´s exposure to the 
pathogen. Innate immune recognition is mediated by pattern recognition 
receptor (e.g. Toll-like receptors), which bind to conserved microbial 
structures, the so-called pathogen-associated molecular patterns (PAMPs) 
such as lipopolysaccharides (LPS), peptidoglycans and lipoteichoic acids (Ishii 
et al., 2008). Among the several constituents of the innate immunity system, 
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phagocytes (e.g. macrophages and neutrophiles) are key components of the 
antimicrobial response, being responsible for killing and clearance of invading 
bacteria through phagocytosis. On encountering bacteria, phagocytes engulf 
microbes into a phagosome that fuses with intracellular granules, e.g. 
lysosome, to form a phagolysosome. Within the phagolysosome, bacteria 
faces a hostile environment with low nutrient availability, iron limitation, low 
pH (~4.8) and several antimicrobial products, which include reactive oxygen 
species (ROS) and reactive nitrosative species (RNS) (Figure 1.6) (Underhill & 
Ozinsky, 2002; Mayer-Scholl et al., 2004; Radtke & O'Riordan, 2006; Slauch, 
2011). In particular, ROS and RNS are considered essential antimicrobial 
agents of the immune system. Indeed, simultaneous deletion of the nitric 
oxide synthase and NADPH oxidase, which produces nitric oxide and 
superoxide, respectively (described below), result in massive death of mice 
caused by spontaneous infections with commensal microorganisms (Shiloh et 
al., 1999).   
 
1.3.1 Oxidative stress 
Oxidative stress in phagocytes is initiated by the NADPH oxidase (also 
designated as phagocyte oxidase, Phox). Activated upon phagocytosis, this 
multicomponent membrane-bound enzyme uses NADPH to catalyze the 
reduction of dioxygen to superoxide, leading to a burst of oxidative stress as 
schematized in Figure 1.6 (Babior, 2000). Briefly, superoxide dismutates 
spontaneously by reacting with itself or enzymatically via superoxide 
dismutase (SOD), leading to the formation of hydrogen peroxide and dioxygen 
(Babior, 2000). In eukaryotes two types of SODs have been identified: the 
citoplasmatic and constitutive Cu/Zn-SOD, and the mitochondrial and stress 
inducible Mn-SOD (Babior, 2000).  










Figure 1.6| Schematic representation of a phagolysosome generating reactive
oxygen and nitrosative spe cies. NO synthase (NOS) and NADPH oxidase (Phox)
produce nitric oxide (•NO) and superoxide (O2•-), respectively. Superoxide is
dismutated by superoxide dismutase (SOD) releasing hydrogen peroxide (H2O2).
H2O2 is converted into radical hydroxil (•OH) and hydroxide ion (OH-) by the Fenton
reaction, and is used by myeloperoxidase (MPO) to synthesize hypochlorous acid
(HOCl). Superoxide reacts with •NO generating peroxynitrite (OHOO-). Peroxynitrite
is decomposed into •OH and nitrogen dioxide (•NO2) or reacts with carbon dioxide
(CO2) producing carbonate (CO3•-) and •NO2. •NO also reacts with dioxygen (O2)
forming nitrogen trioxide (N2O3), which is rapidly converted to nitrite (NO2-)
followed by reducion to NO. Ferroportin pumps Fe2+ out of the phagosomal lumen
and granules release their content (e.g. lysozyme, cathepsins) into the































In neutrophils, hydrogen peroxide reacts with chloride producing 
hypochlorous acid by the action of myeloperoxidase (MPO), an enzyme that is 
absent in macrophages. Hydrogen peroxide, which diffuses freely through 
membranes, may lead to the formation of the highly reactive hydroxyl radical 
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through the iron-catalyzed Fenton reaction (H2O2 + Fe
2+ –> •OH + OH- + Fe3+). 
Although the major source of hydroxyl radical results from the Fenton 
reaction, the radical can also be produced by the reaction of superoxide with 
hypochlorous acid (O2
•- + HOCl –> •OH + O2 + Cl
-) (Liochev, 1999; Babior, 2000; 
Bogdan et al., 2000).  
In phagocytes, the importance of antimicrobial properties of ROS 
against a broad range of pathogens has been comprehensively reported. For 
example, a Phox-deficient macrophage is unable to restrict Salmonella  
typhimurium infection and exhibit distinct disadvantage in the ability to 
eliminate infectious organisms as S. aureus, E. coli, Aspergillus fumigates and 
Mycobacterium tuberculosis (Jackson et al., 1995; Pollock et al., 1995; Adams 
et al., 1997; Vazquez-Torres et al., 2000; Gao et al., 2002; Pizzolla et al., 2012). 
Additionally, mice deficient in MPO display higher sensitivity to Candida 
albicans infection (Aratani et al., 1999; Babior, 2000). In humans, the presence 
of a nonfunctional Phox leads to immunodeficiency characterized by recurrent 
bacterial and fungal infections (Baehner & Nathan, 1967). On the other hand, 
the deletion of bacterial defense mechanisms involved in ROS detoxification 
increases the susceptibility of pathogens to be killed in phagocytes (see 
section 1.3.3) (Basu et al., 2004; La Carbona et al., 2007). In bacteria, the 
cellular oxidative stress arises from an imbalance between ROS inflicted from 
the external environment and the antioxidant bacterial defenses, which 
results in damage of the major cellular macromolecules - DNA, lipids and 
proteins (Cabiscol et al., 2000; Scandalios, 2002; Avery, 2011; Fang, 2011). 
Although, superoxide and hydrogen peroxide do not react directly with 
DNA at physiological levels, the hydroxyl radical is able to attack sugars and 
DNA bases (purines and pyrimidines), generating a multitude of products. 
Among the products formed, one of the most well-known is the highly 










mutagenic 8-hydroxyguanine, generated by guanine oxidation (Imlay & Linn, 
1988; Michaels & Miller, 1992; Fang, 2004; Avery, 2011). In general, oxidative 
DNA damages include bases modifications, and DNA single and double strand 
breaks (Fang, 2011). 
Hydroxyl radical is also able to initiate the process of lipid peroxidation 
in membranes, which alters the membrane proprieties by disrupting the 
membrane-bound proteins and lowering the membrane fluidity, which leads 
to the loss of membrane integrity (Cabiscol et al., 2000; Avery, 2011; Pradenas 
et al., 2012).  
Proteins can undergo a range of oxidative modifications of the amino 
acid side chains. In particular, cysteine amino acid residues are prone to be 
damaged by ROS, as thiols group are highly susceptible to be attack generating 
disulphide bonds (2RSH -> RS-SR + 2 H+ + 2e-). Aromatic amino acid such as 
tyrosine, phenylalanine and tryptophan are also among the most oxidation-
prone residues together with methionine, which is oxidized to methionine 
sulfoxide (Cabiscol et al., 2000; Fang, 2004; Avery, 2011). Other targets of ROS 
are the iron-sulphur (Fe-S) clusters present in several proteins that have a key 
role in many cellular processes. In particular, solvent exposed Fe-S clusters, 
such as those of the [4Fe-4S] family of dehydratases, which are present in key 
enzymes of the citric acid cycle (e.g. aconitase and fumarase), are highly 
susceptible to oxidative damage. Moreover, the dismantling of these clusters 
results in an increase of free iron, which reacts with hydrogen peroxide via the 
Fenton reaction, exacerbating the effects of oxidative stress (Brzoska et al., 
2006; Imlay, 2006; Jang & Imlay, 2007). Overall, these oxidative modifications 
lead to protein structure alteration and, consequently, to functional changes 
that disturb the bacterial cellular metabolism. 
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   1.3.2 Nitrosative stress 
 Within the phagossome, NO is generated by NO synthase (NOS) 
through the oxidation of L-arginine to citruline in the presence of oxygen and 
NADPH (Figure 1.6) (MacMicking et al., 1997; Stuehr, 1999). Mammals contain 
three types of NOS isoforms: the endothelial (eNOS), the neural (nNOS) and 
the inducible (iNOS). Although, the first two isoforms are constitutively 
expressed, the iNOS is inducible by several immunological or inflammatory 
signals, like cytokines (e.g. IFN-y) and the bacterial LPS (MacMicking et al., 
1997; Alderton et al., 2001). NO is a small (30 Da) non-polar uncharged 
molecule and a free radical with a high diffusion coefficient, which allows 
rapid diffusion across the biological membranes (Fang, 1997). NO reacts with 
other molecules giving rise to species with higher reactivity and toxicity, the 
so-called reactive nitrogen species (RNS). In particular, the powerful oxidizing 
peroxynitrite is formed from the reaction of NO with superoxide. This reaction 
is extremely fast, occurring at a higher rate than the decomposition of 
superoxide by SOD (Huie & Padmaja, 1993; Hughes, 2008). Peroxynitrite can 
be then decomposed to form nitrogen dioxide and •OH radicals, and in the 
presence of carbon dioxide also produces nitrogen dioxide and carbonate ion 
radicals. NO also reacts rapidly with dioxygen yielding nitrogen dioxide (Figure 
1.6) (Goldstein & Merenyi, 2008; Ferrer-Sueta & Radi, 2009).  
 The antimicrobial activity of RNS has been demonstrated by a variety 
of approaches, in strong analogy with studies bearing on the role of ROS. In 
animal models, it has been shown the increased expression of iNOS and NO 
production at sites of infection. In accordance, NOS inhibitors contribute to 
increase bacteria survival and mice deficient in iNOS are more susceptible to 
microbial infection (Fang, 1997; MacMicking et al., 1997; Shiloh & Nathan, 
2000; Chakravortty & Hensel, 2003). Other evidence for the role of RNS in 










reducing bacterial proliferation comes from the correlation of microbial 
resistance with the expression of NO-detoxifying enzymes (see section 1.3.3), 
similar to what happens to ROS (MacMicking et al., 1997). The antimicrobial 
action of NO as well as the NO-derivates products consists in damaging several 
cellular components, like DNA, lipids and proteins.  
 Concerning DNA, although NO per se does not react with this 
macromolecule, nitrogen dioxide, nitrogen trioxide or peroxynitrite derivatives 
can lead to nitrosative deamination of DNA bases such as guanine and 
cytosine. Peroxynitrite and nitrogen dioxide also damage DNA resulting in 
abasic sites and strand breaks (Fang, 1997).  
 Another important biological target of RNS are lipids. Although NO is 
not a strong oxidant and does not initiate lipid peroxidation, peroxynitrite and 
nitrogen dioxide are powerful oxidizing species capable of initiating and 
propagating lipid peroxidation (Radi et al., 1991; Hogg & Kalyanaraman, 1999). 
 In relation to proteins, RNS may react with multiple targets including 
thiols, aromatic amino acid residues and metal centres (e.g. haem groups, Fe-S 
clusters and non-haem iron) (Hughes, 2008). In particular, thiols are among 
the most important protein targets, in which the end product is the formation 
of S-nitrosothiols, a modification of the sulphur atom of cysteine residues, also 
called S-nitrosation or S-nitrosylation. Although NO itself cannot act as a 
nitrosating agent, its congeners, such as nitrogen dioxide, nitrogen trioxide or 
peroxinitrite are particularly potent in this context. S-nitrosoglutathione 
(GSNO) is the most abundant S-nitrosothiol in eukaryotic cells in a 
concentration range of µM. GSNO is formed by the nitrosylation of glutathione 
(GSH), a tripeptide with potent antioxidant properties that is composed by 
glutamate, cysteine and glycine (Fang, 1997; Gaston, 1999). Most bacteria 
encounter GSNO intracellularly at the sites of infections, since glutathione and 
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NO are present in host cells at high concentrations (Singh et al., 1996). The 
GSNO formed is able to participate in transnitrosylation reactions with thiol-
containing proteins unless it is decomposed by GSNO reductases (Arnelle & 
Stamler, 1995). Although cysteine residues are in general the preferred 
targets, aromatic amino acid residues (such as histidine, tyrosine, 
phenylalanine and tryptophan) and methionine may also react with RNS like 
peroxynitrite or nitrogen dioxide (Fang, 1997). Among the reactions of NO 
with metal-containing proteins, the reactions with iron are by far the most 
studied, especially those involving haem groups and Fe-S centres. For 
example, the binding of NO to the ferrous haem iron of cytochrome oxidase 
and to the ferric haem of catalase has been reported to inhibit the activity of 
both enzymes (Brown, 1995; Giuffre et al., 1996; Cooper, 1999; Hughes, 2008). 
The reaction of NO with Fe-S centres leads to the formation of dinitrosyl-iron-
dithiol complexes (DNIC), which results in the inactivation of the enzymes with 
important metabolic functions (e.g. aconitase, NADH and succinate 
dehydrogenase) (Cooper, 1999; Hughes, 2008). 
 
1.3.3 Bacterial defense mechanisms 
To counteract the toxic effects of ROS and RNS, bacteria posse 
protective detoxification systems, besides DNA and protein repairing systems. 
The major detoxification systems present in bacteria used in this study are 
described on Tables 1.2 and 1.3. 
Regarding oxidative stress, bacteria comprise superoxide dismutase 
(SOD) that catalyses the dismutation of superoxide to dioxygen and hydrogen 
peroxide (2O2
•- + 2H+ -> O2 + H2O2). Four types of SODs have been identified in 
prokaryotes, which differ by the metal centre present in the active site, 
namely manganese, iron, copper-zinc and nickel (Fridovich, 1995). The Fe-SOD 










and Mn-SOD are both cytoplasmatic, but while the first is constitutively 
expressed the second is induced by dioxygen and other stress agents (e.g. 
metals) (Geslin et al., 2001). Bacterial Cu/Zn-SOD is periplasmatic and seems 
to be critical for survival during the stationary phase of growth (St John & 
Steinman, 1996). In addition, the periplasmic SOD has also been reported to 
play an essential role in several bacterial pathogens, by withstanding the 
oxidative burst imposed by the host macrophages (De Groote et al., 1997; 
Rushing & Slauch, 2011). The Ni-SOD has been described in Streptomyces, and 
is proposed to be regulated by nickel (Youn et al., 1996; Kim et al., 1998).  
In order to scavenge hydrogen peroxide, bacteria use catalases and 
peroxidases, which are ubiquitous oxidoreductases that catalyze the following 
reactions, 2H2O2 -> O2 + 2H2O and RH2 + H2O2 -> R + 2H2O, respectively (Imlay, 
2008). In addition, peroxidases such as alkyl hydroperoxidase reductase (Ahp) 
are described to reduce peroxynitrite, and toxic organic peroxides to the 
corresponding alcohols (Chen et al., 1998; Bryk et al., 2000; Poole, 2005). The 
hybrid-cluster protein (Hcp) of E. coli has been also reported to have 
peroxidase activity, thus conferring protection against oxidative stress 
(Almeida et al., 2006). 
Hydroxyl radical has been considered as extremely toxic and acutely 
lethal, not only due to the damages that it inflict on bacteria, but also because 
no enzyme able to detoxify this ROS is apparently present in bacteria. 
Table 1.2 summarizes the major defense mechanisms used by bacteria 
studied in this thesis against oxidative stress. 
The bacterial response to oxidative stress is controlled by two major 
transcriptional regulators, OxyR and SoxRS. The first responds to increased 
levels of hydrogen peroxide, while the second senses superoxide, hydrogen 
peroxide and redox-cycling drugs (e.g. paraquat and menadione) (Zheng et al., 
Introduction| Chapter 1 
30 
 
2001; Gu & Imlay, 2011; Lushchak, 2011). These regulators are well studied in 
E. coli, with katG, ahpC and hcp belonging to the OxyR regulon, and sodA 
controlled by SoxRS (Imlay, 2008; Lushchak, 2011; Seth et al., 2012). 
Interestingly, none of these regulators are apparently present in S. aureus and 
H. pylori.  
 
Table 1.2| Major defense mechanisms used by bacteria studied in this thesis 







(Keele et al., 1970) 
Fe-SOD 
(SodB) 
(Yost & Fridovich, 1973) 
Cu/Zn-SOD 
(SodC) 
(Benov & Fridovich, 1994) 
KatG (HPI) (Triggs-Raine & Loewen, 1987) 
KatE (HPII) (Loewen, 1996) 
AhpC (Seaver & Imlay, 2001) 




(Clements et al., 1999) 
Mn-Sod 
(SodM) 
(Valderas & Hart, 2001) 
KatA (Cosgrove et al., 2007) 




(Spiegelhalder et al., 1993) 
KatA (Hazell et al., 1991) 
AhpC (Lundstrom & Bolin, 2000) 
 
Concerning nitrosative stress, the three major known bacterial NO 
detoxification systems are the membrane-bound respiratory NO reductases, 










the flavodiiron proteins and microbial globins (Hendriks et al., 2000; Saraiva et 
al., 2004).  
The membrane-bound respiratory bacterial NO reductases catalyzes 
the reducing of NO to nitrous oxide (2NO -> N2O + H2O) as part of the 
denitrification pathway (e.g. Pseudomonas stutzeri and Paracoccus 
denitrificans) (Zumft, 2005; Tavares et al., 2006). However, their role in the 
protection against NO produced by macrophages is well established also in 
non-denitrifying organisms (e.g. Neisseria meningitidis and Pseudomonas 
aeruginosa) (Anjum et al., 2002; Stevanin et al., 2005; Kakishima et al., 2007). 
 The flavodiiron proteins (FDPs) are considered a prominent family of 
NO detoxifying enzymes for their ability to reduce NO. In particular, 
flavorubredoxins (NorV) were the first member of the FDPs to be assigned as 
an NO reductase (Gomes et al., 2002; Saraiva et al., 2004). 
 Microbial globins belong to the haemoglobin family of proteins and are 
considered one of first line of microbial defense against NO. In particular, 
flavohaemoglobins (Hmp), which is the best-studied class, are able to detoxify 
NO either aerobically by oxidizing NO to nitrate or anaerobically by reducing 
NO to nitrous oxide (Gardner et al., 1998; Hausladen et al., 1998; Kim et al., 
1999).  
 In E. coli, other bacterial proteins have also been implicated in 
resistance to nitric oxide, such as the pentahaem nitrite reductases (Nrf) and 
Hcp (van Wonderen et al., 2008; Vine & Cole, 2011; Seth et al., 2012). 
Interestingly, H. pylori is an extremely peculiar bacteria since it can 
counteract host NO production by expressing an arginase that competes with 
iNOS for the same substrate. In fact, inactivation of arginase restored NO 
production by macrophages (Gobert et al., 2001). Recently, our laboratory 
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identified the first system of NO detoxification in H. pylori, which belongs to a 
novel family of microbial NO reductases (Justino et al., 2012).  
Table 1.3 summarizes the major defense mechanisms used by bacteria 
studied in this thesis to fight nitrosative stress. 
 
Table 1.3| Major defense mechanisms used by bacteria studied in this thesis  





Hmp (Poole et al., 1996) 
FlRd (NorV) (Gomes et al., 2002) 
Hcp (Seth et al., 2012) 
Nfr 
(van Wonderen et al., 
2008) 
S. aureus Hmp (Goncalves et al., 2006) 
H. pylori NorH (Justino et al., 2012) 
 
The knowledge of microbial defense mechanisms against phagocytic 
cells is quite important to design new strategies to fight pathogens. In the 
Chapter 3, it will be presented a novel GSNO detoxifying system active in S. 
aureus, which was studied during this PhD work.  
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 “Science progresses best when observations force us to alter our 
preconceptions” - Vera Rubin 











2.1 Chemical, physical and biological properties of carbon monoxide  
 The discovery of carbon monoxide (CO) is usually attributed to Joseph 
Priestley in the late 18th century. Even so, the existence of a “poisonous gas” 
resultant from burning coals has been known since Greek and Roman times. 
Interestingly, CO is thought to be one of the oldest molecules on Earth that 
might have participated in the origin of life along with oxygen and nitrogen 
(Schlesinger & Miller, 1983; Miyakawa et al., 2002). This colourless, odourless 
and tasteless gas results in nature from the incomplete oxidation of organic 
materials such as wood, natural gas, coal and tobacco.  
 The CO molecule has ten valence electrons, four from carbon and six 
from oxygen, distributed among the three bonds and one lone pair on each 
atom. CO is considered a chemically 
stable molecule due to the high 
strength of the triple bond. Thus, 
chemical reduction of CO requires 
temperatures well above 100ºC and 
the oxidation of CO to carbon 
dioxide (CO + H2O -> CO2 + H2) only 
occurs at high temperatures via the 
metal-catalyzed water-gas-shift 
reaction (Greenwood & Earnshaw, 
1997; Wu & Wang, 2005). Albeit CO 
is sparingly soluble in water, at standard temperature and pressure, it 
dissolves in organic solvents such as chloroform, benzene, ethanol and 
methanol (Von Berg, 1999). CO does not readily react with the most common 
reducing agent – hydrogen, and the reaction with dioxygen is slow and has a 
high energy of activation (213 kJ mol-1) (Wu & Wang, 2005). Nevertheless, CO 
Table 2.1| Properties of Carbon Monoxide.
*at room temperature
Adapted from (Greenwood NN & 
Earnshaw A, 1997). 
Properties of CO
Molecular weight (g/mol) 28.01
Melting point (ºC) -205
Boiling point (ºC) -191.5
Density (g/L) 1.25 
Interatomic distance (pm) 112.8 
Dissociation energy (kJ/mol) 1072 
Solubility in water (mM) 1* 




reacts with transition metals in low oxidation states as molybdenum, 
manganese, ruthenium, nickel, iron or cobalt (Boczkowski et al., 2006). Hence, 
CO readily forms relatively stable metal carbonyls complexes through the 
donation of a pair of electrons from the lone pair on the carbon atom 
(Greenwood & Earnshaw, 1997; Piantadosi, 2002; Romão et al., 2012).  
 In biological systems, CO binds preferentially and almost exclusively to 
transition metals that are present in structural and functional proteins, 
particularly to ferrous haem (Boczkowski et al., 2006). In fact, due to the high 
affinity of CO to haemoglobin of red blood cells, the harmful action of CO in 
mammals has been extensively documented. In 1857, Claude Bernard first 
described the physiological effects of CO on the human body through its 
reversible binding to haemoglobin, forming carboxyl-haemoglobin (COHb) and 
leading to asphyxia (Bernard, 1857). After inhalation via the lungs, CO reaches 
the blood stream where it competes with dioxygen for binding to the four 
haem iron centres of haemoglobin (Haldane, 1927; Wu & Wang, 2005). The 
toxicity of CO is attributed to its much higher affinity (200–230 times) for 
haemoglobin when compared with that of dioxygen. This results in lower 
number of dioxygen molecules transported and released in the tissues, leading 
to hypoxia and, ultimately, to cell death and organ failure (Haldane, 1927; Wu 
& Wang, 2005). In particular, the brain and the heart are the most vulnerable 
to CO toxicity due to their high demand for dioxygen (Wu & Wang, 2005; 
Prockop & Chichkova, 2007).  
 The “silent killer” CO has been recognized as one of the most common 
causes of accidental and suicidal poisoning, being responsible for a great 
number of deaths worldwide (Raub et al., 2000; Prockop & Chichkova, 2007). 
The adverse health outcome of CO intoxication depends on the concentration 
and duration of exposure since the binding of CO to haemoglobin is reversible, 











as once ceased CO dissociates from haemoglobin and is eliminated through 
the lungs. Therefore, dioxygen is the “natural antidote” and a therapy with 
100% dioxygen should be undertaken in order to hasten CO elimination (Raub 
et al., 2000; Prockop & Chichkova, 2007; Weaver, 2009).  
 The atmosphere contains approximately 10 parts per million (ppm) of 
CO, but it can reach 50 ppm in metropolitan areas (Godin et al., 1972; 
Otterbein, 2009). Currently, USA entities have stipulated a limit of 50 ppm for 
8h/day, which generate a safe COHb level of 8-10% (Chin & Otterbein, 2009). 
While the basal level of COHb in normal tissues is less than 1%, it can reach 3% 
in non-smokers and may be as 
high as 10-15% in smokers (Von 
Berg, 1999; Ryter & Otterbein, 
2004). COHb levels up to 10% 
caused by CO inhalation are 
usually asymptomatic. As COHb 
increases above 20%, symptoms 
of CO poisoning as headache, 
dizziness and nausea begin to 
appear, whilst coma and seizures 
due to cerebral edema are 
common for levels greater that 
40%, and death is likely above 
60% (Figure 2.1) (Romão et al., 
2012). 
 Besides CO binding to haemoglobin, which represents 80% of CO 
loaded in the body, CO also binds and compromises the activities of other 
mammalian haemoproteins, such as cytochrome c oxidase and cytochrome 
Figure 2.1| Symptoms after CO inhalation in
humans. COHb levels obtained after
inhalation of air with increasing
concentrations of CO, and the consequently



































P450. Nonetheless, the contribution of such mechanisms to the overall toxicity 
of CO remains controversial, since inhalation of sufficient CO to inhibit 
respiration and xenobiotic metabolism may likely be preceded by death due to 
tissue hypoxia (Piantadosi, 2002; Wu & Wang, 2005; Otterbein, 2009). 
 
2.2 Endogenous production and physiological role of carbon monoxide 
 Paradoxically to the well-known toxicity associated to CO, it was found 
around 1950s that CO is endogenously generated as a normal cellular function 
in humans, and more importantly, it is involved in crucial physiological 
functions (Sjostrand, 1949). The major source of endogenous CO production is 
through the haem oxygenase (HO) activity, which accounts for about 86% of 
total CO produced in humans. The remaining CO arises from a mixture of 
sources, which includes photo-oxidation, lipid peroxidation and xenobiotics 
(Rodgers et al., 1994; Ryter & Otterbein, 2004; Mann & Motterlini, 2007). 
Interestingly, the daily production of CO measured in exhaled air of adults can 
reach 6 mL, and this value may increase in patients with diseases such as 
asthma, bronchiectasis, cystic fibrosis and diabetes (Mann & Motterlini, 2007). 
 HO is the rate-limiting enzyme in haem degradation, catalyzing the 
oxidation of the α-methene bridge carbon of haem, and generating equimolar 
quantities of three biological active products: CO, ferrous iron and biliverdin 
(Figure 2.2) (Tenhunen et al., 1970). Biliverdin is, in turn, reduced to bilirubin 
by biliverdin reductase (Figure 2.2), and both metabolites have been reported 
to possess strong antioxidant potential, by scavenging peroxyl radicals and 
inhibiting lipid peroxidation (Baranano et al., 2002; Abraham & Kappas, 2005; 
Bilban et al., 2008). More recently, bilirubin was shown to have a potent 
antiviral activity (Santangelo et al., 2012). The iron formed is rapidly 
sequestered into the iron-storage protein - ferritin, thus preventing Fenton 











reaction and conferring cytoprotection against oxidative stress (Bilban et al., 
2008). Contrary to the common perception that CO is a harmful molecule, 
several reports had demonstrated that CO is a primarily signaling molecule 
with many physiological roles in the neuronal, cardiovascular, and immune 
systems, as well as in the respiratory, reproductive, gastrointestinal and 
urogenital apparatus (Wu & Wang, 2005; Kim et al., 2006; Gullotta et al., 
2012a; Gullotta et al., 2012b). Indeed, CO confers cytoprotection by 
modulating signaling pathways, such as the soluble guanylate cyclase (sGS), 
mitogen-activated protein kinases (MAPKs) and calcium-activated potassium 
(Kca) (Ryter et al., 2006). In turn, these pathways mediate the vasoregulatory, 
anti-inflammatory, anti-apoptotic and anti-proliferative effects of CO (Ryter & 
Otterbein, 2004).  
 
 In mammals, three HO isoforms have been identified, namely HO-1, 
HO-2, and HO-3 (Maines, 1988; McCoubrey et al., 1992; McCoubrey et al., 
1997; Ryter et al., 2006). The inducible HO-1 presents low percentage of 
sequence identity and similarity with the two constitutively isoforms (HO-2 
and HO-3), which share about 90% of amino acid similarity (Wagener et al., 
2003). HO-1 isoform occurs at undetectable levels in most tissues until being 
Figure 2.2| Oxidative haem degradation. Haem oxygenase (HO) catalyses the
oxidation of haem, in the presence of three molecules of dioxygen and NADPH,
yielding biliverdin, ferrous iron and CO. Biliverdin is subsequently converted to















stimulated by stress conditions that threaten cellular homeostasis, such as 
hypoxia, oxidative stress (e.g. hydrogen peroxide), UV radiation, bacterial 
endotoxins (e.g. LPS) and pro-inflammatory cytokines (e.g. IL-1, IL-6 and INF-γ) 
(Ryter et al., 2002; Wagener et al., 2003; Wu & Wang, 2005). The central role 
of HO-1 in the re-establishment of homeostasis has been demonstrated in 
models in which deletion of this isoform worsens the pathologic outcome of 
diseases, such as severe sepsis, atherosclerosis and myocardial infarction (Yet 
et al., 2003; Chung et al., 2008; Soares & Bach, 2009). Importantly, a human 
case of HO-1 deficiency exhibited severe growth retardation, persistent 
haemolytic anemia, abnormal coagulation/fibrinolysis system, and a persistent 
endothelial damage, that lead to patient death (Yachie et al., 1999). Notably, 
several reports reveal that exogenous administration of CO gas exert 
beneficial effect that to some extent mimics the cytoprotective action elicited 
by HO-1 stimulation (Kim et al., 2006). In fact, CO administration seems to be 
able to rescue HO-1 deficiency by suppressing the inflammatory response that 
otherwise would lead to enhanced pathologic progression of disease (Ryter et 
al., 2006; Bilban et al., 2008; Chung et al., 2008; Chin & Otterbein, 2009; 
Soares & Bach, 2009). In HO-1-deficient mice challenged with endotoxin, a 
component of the Gram-negative cell wall, results in exaggerated organ injury 
and increased mortality (Wiesel et al., 2000). The exogenous administration of 
CO to animals previously treated with endotoxin improves survival, and 
suggests the importance of CO in mediating protection against bacterial 
infections (Otterbein et al., 2000).  
 The HO-2 is present under normal conditions in organs and tissues, 
such as brain, liver and endothelium, and its function is associated with 
neurotransmission and regulation of vascular tone (Maines, 1997; Foresti & 
Motterlini, 1999). Although HO-2 is considered a constitutive isoform, its 











transcription is responsive to opiates and adrenal glucocorticoids (Maines & 
Panahian, 2001; Wagener et al., 2003). Nevertheless, HO-2 has been pointed 
out to be a less likely candidate than HO-1 to have a central role in protection 
against disease, with a maximal activity of less than 10% of that reported to 
HO-1 (Maines & Panahian, 2001; Wagener et al., 2003).  
 The biological function of HO-3, which is found in most tissues, 
remains to be elucidated as it is not able to degrade haem, and its role seems 
to be limited to haem binding and/or sensing (McCoubrey et al., 1997; 
Wagener et al., 2003). It is proposed that HO-3 derives from the 
retrotransposition of HO-2 as HO-3 does not contain introns (McCoubrey et 
al., 1997). 
 
2.3 Carbon Monoxide-Releasing Molecules  
 The discovery that CO endogenously produced has an essential role in 
biological systems triggered great interest in the potential pharmacological 
application of this molecule (Wu & Wang, 2005). However, the therapeutic use 
of CO gas seems unlikely, since inhalation of CO exhibited some drawbacks 
related to the manipulation and direct delivery of this gas to a specific tissue in 
an accurate, safe and measurable way (Figure 2.3) (Foresti et al., 2008; 
Motterlini & Otterbein, 2010). In order to overcome these limitations, 
Motterlini and co-workers developed a novel class of compounds capable of 
safely storing and releasing controlled amounts of CO in biological systems, 
the so-called Carbon Monoxide-Releasing Molecules (CO-RMs) (Figure 2.3) 
(Motterlini et al., 2002). In particular, metal carbonyl complexes (MCC) seem 
to be the most suitable class of compounds acting as carriers of CO (Romão et 
al., 2012). These complexes contain a transition metal, such as manganese, 
molybdenum, ruthenium or iron, coordinated to carbonyl groups, and have 




the ability to release CO to myoglobin/haemoglobin as indicated by the 
formation of carboxy-myoglobin/haemoglobin (Motterlini et al., 2002; Choi et 
al., 2003; Stanford et al., 2003; Motterlini et al., 2005a; Taille et al., 2005; 
Chen et al., 2009).  
  
 Several CO-RMs confirmed the beneficial effects of CO gas in different 
animal models of disease. Importantly, the biological properties of CO-RMs are 
attributed to the release of CO since addition of reduced myoglobin, and/or 
the substitution of CO-RM by an inactive form (iCO-RM), which does not 
contain carbonyl (CO) groups, impairs its bioactivity (Motterlini et al., 2005a). 
Interestingly, CO-RMs seem to be able to avoid the biological trapping by 
haemoglobin, since the intravenous application of CO-RMs on mice does not 
increase COHb to dangerous levels (COHb levels < 10%) (Vera et al., 2005; 
Foresti et al., 2008). 
  
Figure 2.3| Advantages and disadvantages of CO gas and CO-RM for the
therapeutic delivery of CO to diseased tissues. Adapted (Romão CC et al., 2012).
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 The first CO-RMs to be produced were the diamanganese 
decacarbonyl [Mn2(CO)10] molecule and the tricarbonyldichloro ruthenium(II) 
dimer ([Ru(CO)3Cl2]2), subsequently termed CORM-1 and CORM-2, respectively 
(Motterlini et al., 2002). These CO-RMs are insoluble in water, but while 
CORM-1 requires light to release CO, CORM-2 rapidly promotes carboxy-
myoglobin formation upon dissolution in dimethyl sulfoxide (DMSO) 
(Motterlini et al., 2002; Motterlini et al., 2003). Once dissolved in DMSO, 
CORM-2 converts from a dimer to a mixture of two distinct monomers, 
[Ru(CO)3Cl2(DMSO)] and [Ru(CO)2Cl2(DMSO)2], with a ratio of 40:60, 
respectively (Motterlini et al., 2002). Upon stimulation with light, CORM-1 
induces vasodilatation of cerebral arterioles and attenuates the coronary 
vasoconstriction in isolated rat hearts perfused (Fiumana et al., 2003; Xi et al., 
2004; Motterlini et al., 2005a). This manganese-based carbonyl has also been 
described to play a protective role in acute renal failure by increasing renal 
blood flow and glomerular filtration rate in rats (Arregui et al., 2004). 
Furthermore, in mice CORM-1 reduced the migration, rolling and adhesion of 
neutrophils to the endothelium in the inflammatory site (Freitas et al., 2006). 
CORM-2 has been extensively used in several approaches and shown to mimic 
the known physiological functions of CO. In particular, CORM-2 elicits 
vasodilatation of aortic rings pre-contracted, attenuates coronary 
vasoconstriction in hearts, and prevents the increase of the mean arterial 
pressure in a rat model of acute hypertension (Motterlini et al., 2002). 
Importantly, administration of CORM-2 to rats did not apparently change the 
levels of oxy-haemoglobin (Motterlini et al., 2002). Interestingly, aortic 
transplantation in HO-1 deficient mice treated with CORM-2 significantly 
improved survival (Chen et al., 2009). In addition, this ruthenium-based 
carbonyl has been demonstrated to have an anti-inflammatory effect as it is 




able to reduce the production of ROS and NO by LPS-stimulated macrophages 
through inhibition of the haemoproteins activity, NADPH oxidase and iNOS, 
respectively (Sawle et al., 2005; Srisook et al., 2006). Moreover, CORM-2 
impairs neutrophil adhesion to human umbilical vein endothelial cells 
(Cepinskas et al., 2008; Sun et al., 2008b). Furthermore, treatment of 
thermally injured mice with CORM-2 significantly attenuated neutrophils 
accumulation in kidney, liver and small intestine of burned mice (Sun et al., 
2007; Liu et al., 2008; Sun et al., 2008a). The beneficial role of this CO-
releasing molecule in cell proliferation was also reported, with CORM-2 
inhibiting the proliferation of both human airway and pulmonary artery 
smooth muscle cells in vitro (Stanford et al., 2003; Taille et al., 2005). The 
reno-protective, anti-carcinogenic and anti-apoptotic effects of CORM-2 have 
been also reported in several studies (Choi et al., 2003; Vera et al., 2005; Li et 
al., 2006; Allanson & Reeve, 2007).  
 To improve CO-RMs compatibility with biological system, water soluble 
CO-releasing molecules have been synthesized and their biological activities 
assessed in various experimental models (Motterlini et al., 2005a). The most 
promising results were obtained with the tricarbonylchloro(glycinate) 
ruthenium (II) (Ru(CO)3Cl(glycinate)) and the sodium borancarbonate 
Na2[H3BCO2], known as CORM-3 and CORM-A1, respectively. CORM-3 is, like 
CORM-2, a ruthenium-based carbonyl and a CO releaser by ligand substitution, 
to which the presence of a glycine coordinated to the metal centre confers 
water solubility (Table 2.2). CORM-A1 is a boron-containing carboxylic acid 
that releases CO upon hydrolysis. This non-transition metal-based compound 
liberates CO at a slow rate, which is dependent on pH and temperature (Table 
2.2). In fact, the CO release is accelerated by decrease of pH and increase of 
temperature (Motterlini et al., 2003; Motterlini et al., 2005b). 







































































   Adapted from (Motterlini et al., 2005a; Gullotta et al., 2012a).  
  
 The chemical differences of the two water soluble CO-RMs dictate the 
way CO causes vasorelaxation and hypotension: CORM-3 elicits a prompt and 
rapid vasodilatory effect whereas CORM-A1 promotes mild vasorelaxation and 
hypotension (Foresti et al., 2004). Nevertheless, both CO-RMs are associated 
with anti-ischaemic effects that have been observed primarily in cardiac and 
renal tissues of rats and rabbits (Musameh et al., 2006; Sandouka et al., 2006). 
CORM-3 has also been shown to prevent hypoxia-reoxygenation damage in rat 
cardiomyocytes and protect against ischaemia/reperfusion injury in isolated 
hearts of rats (Clark et al., 2003; Varadi et al., 2007). In addition, 
administration of CORM-3 to mice reduced the infarct size and prolonged the 




viability of cardiac allografts following transplantation (Clark et al., 2003; Guo 
et al., 2004). Reno-protective effects of CORM-3 were observed in mice 
following ischaemia-induced renal failure (Vera et al., 2005). Additionally, 
CORM-3 contributed to mesenteric vasodilatation in cirrhotic rats (Bolognesi 
et al., 2007). Notably, CORM-3 induced inhibition of human platelet 
aggregation in vitro (Chlopicki et al., 2006). CORM-3 also has an anti-
inflammatory action by decreasing the level of NO production and reducing 
the TNF-α release in microglia and macrophage cells (Sawle et al., 2005; Bani-
Hani et al., 2006a, 2006b). Moreover, intravenous injection of CORM-3 in mice 
lowered the number of neutrophil extravasation and attenuated acute 
inflammation (Urquhart et al., 2007). Finally, CORM-3 was shown to have anti-
proliferative and anti-apoptotic effects in porcine aortic endothelial cells and 
in primate peripheral blood mononuclear cells (Motterlini et al., 2005a). 
Unlike CORM-3, the biological activities of CORM-A1 remain largely 
unexplored. This boron-containing compound has been described to produce 
vasodilatation in isolated vessels from rats, and to promote reduction in 
arterial pressure in vivo at a rate that correlates with the CO release. 
Moreover, the inactive form (sodium borate) does not promote any beneficial 
effect (Motterlini et al., 2005b). Moreover, administration of CORM-A1 causes 
an increase in renal blood flow and a decrease in vascular resistance in mice 
(Ryan et al., 2006). Recently, CORM-A1 has been suggested as a novel strategy 
for the treatment of multiple sclerosis, since it was able to prevent the 
development of clinical and histological signs of the disease in rats (Fagone et 
al., 2011). 












seem to be able to mimic 
the beneficial effects of CO 
gas (Table 2.2), representing 
so far the safest way to 
delivery CO to tissues and 
organ. The range of 
pathological conditions, in 
which these compounds 
may be beneficial, is shown 
in Figure 2.4 (Motterlini & 
Otterbein, 2010; Gullotta et 
al., 2012a). 
 
2.4 Carbon monoxide and bacteria  
             2.4.1 Carbon monoxide metabolism 
The use of CO as a source of carbon and energy for growth has been 
reported for several bacteria (Ragsdale, 2004; Oelgeschlager & Rother, 2008). 
In both aerobic and anaerobic CO-metabolizing bacteria, the oxidation of CO 
to carbon dioxide is done by CO dehydrogenase (CODH) (CO + H2O -> CO2 + 
2H+ + 2e-), which also catalyses the reverse reaction. CODH contains iron and 
either molybdenum (aerobes) or nickel (anaerobes) in its active site 
(Oelgeschlager & Rother, 2008). Interestingly, CO oxidation is coupled to 
several respiratory processes in which the reducing equivalents generated are 
received by electron acceptors into a respiratory chain, leading to the 
reduction of the terminal electron acceptor (King & Weber, 2007; 
Oelgeschlager & Rother, 2008). The best studied aerobic CO-oxidizing bacteria 



















are Oligotropha carboxidovorans and Pseudomonas thermocarboxydovorans, 
which contain a CO-insensitive respiratory chain and the reducing equivalents 
from CO oxidation are used for oxygen reduction or, in some cases, nitrate 
reduction (Jacobitz & Meyer, 1989; King & Weber, 2007; Oelgeschlager & 
Rother, 2008). Under anaerobic conditions, the respiratory processes that are 
coupled to CO metabolism distinguish three groups of CO-utilizing bacteria: (i) 
sulphate reducers (e.g. Desulfovibrio vulgaris), in which CO oxidation yields 
carbon dioxide and molecular hydrogen that is subsequently utilized for 
sulphate reduction (4CO + SO4
2- + H+ -> 4CO2 + HS
+); (ii) hydrogenogens, such 
as the well characterized Rhodospirillum rubrum, which oxidize CO and reduce 
the protons derived from water to hydrogen. This process occurs in the 
absence of an electron acceptor and is analogous to the water-gas-shift 
reaction (CO + H2O -> CO2 + H2); and (iii) acetogens, such as Moorella 
thermoacetica, that contain a bifunctional CODH/acetyl-coenzyme A synthase, 
which produces acetyl-CoA from a methyl group, coenzyme A and CO (4CO + 
2H2O -> CH3COO
- + 2CO2 + H
+) (Ragsdale, 2004; Drake et al., 2008; 
Oelgeschlager & Rother, 2008; Gullotta et al., 2012b). 
 
 2.4.2 Carbon monoxide sensing 
 The ability of bacteria to sense small gaseous molecules is a key 
attribute that allows adaptation to different environments. Since CO binds 
virtually all haem-containing proteins in ferrous state, haem-based 
transcriptional regulators might be considered potential CO sensors. The best 
studied CO sensor is CooA from R. rubrum, a haem-containing transcriptional 
factor that in the presence of exogenous CO binds to DNA and promotes the 
CODH gene expression (Bonam et al., 1989; Aono, 2003). An interesting 
feature of this CO-sensing protein is its ability to discriminate between 











gaseous molecules, as in spite of binding both CO and NO, only the CO-CooA 
promotes CODH expression (Reynolds et al., 2000). Other CO-sensor is RcoM, 
a haem-containing protein present in both aerobic and anaerobic bacteria. 
The best studied is RcoM from Burkholderia xenovorans, that binds both CO 
and NO but not oxygen, and respond to exogenous CO by promoting 
transcription of several genes involved in CO oxidation (Kerby et al., 2008; 
Marvin et al., 2008). The two-component system DosST from M. tuberculosis is 
another example of a CO-sensor. In this case, CO is primarily sensed through 
DosS that induces the Dos regulon, whereas DosT plays a less prominent role. 
Binding of CO to the haem-containing sensors DosST induces the dormancy 
regulon shifting the bacteria to a latent state, characterized to be 
unresponsive to drug therapy (Kumar et al., 2007; Kumar et al., 2008). As 
usually observed for bacterial sensors, DosS and DosT are not specific as CO 
sensors, since they are also responsive to dioxygen and NO (Kumar et al., 
2007; Kumar et al., 2008). 
 Other haem-based proteins have also been reported to bind CO, albeit 
its role in responding to CO is still unknown. This is the case of the dioxygen 
sensors FixL of Sinorhizobium meliloti, EcDos of E. coli and AxPDEA1 of 
Acetobacter xylinum (Gilles-Gonzalez et al., 1994; Delgado-Nixon et al., 2000; 
Chang et al., 2001; Sasakura et al., 2002). 
 
  2.4.3 Production of Carbon Monoxide 
 Like humans (see section 2.2), several bacteria encompass haem 
oxygenases that upon haem degradation produce CO along with iron and 
biliverdin. When compared with the eukaryotic counterparts, bacterial HOs 
are smaller and soluble enzymes that lack the C-terminal membrane anchor 
(Frankenberg-Dinkel, 2004). The first bacterial HO was identified in 




Corynebacterium diphtheria due to the high homology with the human HO-1 
(70% similarity) (Schmitt, 1997), and later recognized in several other bacteria 
(Table 2.3). The major role of bacterial HOs has been attributed to acquisition 
of iron, which is essential for growth and particularly important for pathogens 
during the infection process (Frankenberg-Dinkel, 2004). Indeed, bacterial HOs 
promote degradation of the haem imported from the external environment, 
via the haem acquisition systems, providing iron to the cell (Wandersman & 
Stojiljkovic, 2000; Andrews et al., 2003). Hence, the use of HOs as a target for 
antimicrobials has been explored. Several compounds were shown to have 
high affinity to HOs of P. aeruginosa and N. meningitidis with some of them 
being able to inhibit bacterial growth when using haemoglobin as the only iron 
source (Furci et al., 2007). 
 In addition to the role in iron acquisition, HOs seem also to protect 
bacterial cells against haem toxicity. In particular, strains of B. anthracis and N. 
meningitidis deleted in HOs genes exhibit growth impairment in the presence 
of haemin (Zhu et al., 2000a; Skaar et al., 2006). Furthermore, HO in the 
anaerobic bacterium C. tetani has been proposed to act as dioxygen scavenger 
in the process of wound colonization (Bruggemann et al., 2004). 
 Besides iron, the fate of other HO-products remains elusive. Due to the 
lack of bacterial genes encoding homologues of mammalian biliverdin 
reductase, it seems unlikely that, biliverdin is metabolized to bilirubin. It has 
been suggested that in bacteria, biliverdin acts as antioxidant such as in 
mammalians or is only a waste product (Wilks, 2002; Frankenberg-Dinkel, 
2004). The relevance of the CO produced by bacteria remains so far unclear. 
Whether CO in bacteria is able to participate in signaling pathways as it occurs 
in eukaryotes remains to be investigated (Frankenberg-Dinkel, 2004). 
 











Table 2.3| Bacterial haem oxygenases. 
Bacteria HO References 
Bacillus anthracis IsdG (Skaar et al., 2006) 
B. subtillis 
HmoA 






(Puri & O'Brian, 2006) 
HmuD 
Brucella abortus BhuQ (Ojeda et al., 2012) 
Campylobacter jejuni ChuZ (Ridley et al., 2006) 
Clostridium perfringens HemO (Hassan et al., 2010) 
Clostridium tetani HemT (Bruggemann et al., 2004) 
C. diphtheria HmuO (Schmitt, 1997) 
E. coli O157:H7 ChuS (Suits et al., 2005) 
H. pylori HugZ (Guo et al., 2008) 
N. meningitidis HemO (Zhu et al., 2000a; Zhu et al., 2000b) 
P. aeruginosa 
PigA (Ratliff et al., 2001) 
BphO (Wegele et al., 2004) 
Shigella dysenteriae ShuS (Wyckoff et al., 2005) 
S. aureus 
IsdG 
(Skaar et al., 2004) 
IsdH 
Synechocystis 
HO-1 (Migita et al., 2003) 
HO-2 (Zhang et al., 2005) 
Vibrio cholerae HutZ (Wyckoff et al., 2004) 
          Adapted from (Tavares et al., 2012). 
 
2.5 Carbon monoxide and Carbon Monoxide-Releasing Molecules as 
bactericides 
  The first indication that CO could affect bacteria viability came out in 
the early 1970s, when it was observed that CO administration to E. coli 
cultures caused a decrease in DNA replication (Weigel & Englund, 1975). 
Another indirect evidence was the report that CO administration to packing 




systems on meat preservation resulted in less bacterial growth (Brashears & 
Brooks, 2006). An interesting work performed by Otterbein and collaborators 
found that exogenous treatment of macrophages with CO gas enhances the 
phagocytic clearance of E. coli. However, in this work the results obtained 
were associated with an increase of surface expression of Toll-like receptor 4 
in macrophages, and not directly with the antimicrobial activity of CO 
(Otterbein et al., 2005).  
 More recently, administration of both CO gas and CO-RMs was shown 
to strongly decrease the cell viability of the Gram-negative E. coli and Gram-
positive S. aureus (Nobre et al., 2007; Nobre, 2010). In particular, ruthenium 
based carbonyls CORM-2 and CORM-3 revealed to have an efficient 
bactericidal activity, as only after 30 min of treatment 50-80% of bacteria were 
killed, and after 4 h cells were unable to resume growth (Nobre et al., 2007). 
Other CO-RMs, as ALF021 and ALF062, which contain manganese and 
molybdenum, respectively, also reduced significantly the viability of the two 
bacterial species. Importantly, cultures supplemented with haemoglobin, a CO 
scavenger, abolished the bactericidal effect of all CO-RMs. In addition, inactive 
forms, i.e. compounds devoid of CO display any antimicrobial effect. Hence, 
the antimicrobial action of these compounds seems to be dependent on the 
CO-released (Nobre et al., 2007). Interestingly, CO-releasers have the ability to 
get inside bacteria cells as demonstrated by the increase of metal content in 
bacterial cells exposed to CO-RMs (Nobre et al., 2007; Davidge et al., 2009).  
An interesting feature reported in the initial study performed by Nobre 
et al. is the higher effectiveness of CO-RMs as bactericides under anaerobic 
conditions. This fact was rationalized considering the preferential binding of 
CO to the ferrous state of proteins, which are predominant under anoxic 
conditions. Noteworthy that pathogen colonization occurs in nearly-anaerobic 











environments. Furthermore, these results also reveal that other targets of CO-
RMs action should be considered as inhibition of cell growth is not to be 
restricted to impairment of aerobic respiratory chain, which is the classic 
target of CO in bacteria (Nobre et al., 2007).  
Davidge and collaborators also showed that CORM-3 impairs E. coli 
growth, but they do not observe the same effect for the CO gas (Davidge et al., 
2009). The authors reported that CORM-3-derived CO binds to the terminal 
oxidases of the E. coli respiratory chain, leading to c. 50s% inhibition of 
respiration after 10 min (Davidge et al., 2009). Studies on P. aeruginosa also 
show that both CORM-3 and CO gas are able to impair bacterial growth, even 
in antibiotic-resistant strains (Desmard et al., 2009). In this study, CORM-3 
treated P. aeruginosa exhibited lower dioxygen consumption, in accordance 
with the inhibition of the respiratory chain by the CO-releasing molecule 
(Desmard et al., 2009). Interestingly, Ru-based compounds (CORM-2 and 
CORM-3) have been reported to exhibit higher bactericidal activity than the 
borocarbonates (CORM-A1) towards P. aeruginosa (Desmard et al., 2011).  
More recently, it was reported that the microaerophilic pathogen C. 
jejuni was not able to be eradicated by CORM-3, although its respiratory chain 
was inhibited (Smith et al., 2011).  
The work presented in Chapter 5 of this thesis demonstrates that CO-
RMs are also able to eliminate H. pylori. 
The potential antimicrobial action of CO-RMs has also been explored in 
infection models. In particular, Chung et al. demonstrated that administration 
of CORM-2 to HO-1 deficient mice, which display enhanced susceptibility to 
polymicrobial infections, decreases the number of viable bacteria and rescues 
mice from sepsis-induced lethality (Chung et al., 2008). Moreover, 
administration of CORM-3 to P. aeruginosa infected mice prolongs their 




survival and decrease bacterial cell viability in the host spleen (Desmard et al., 
2009). More recently, a Ru-based compound (ALF492) was shown to protect 
mice against malaria infection caused by the parasite Plasmodium falciparum 
(Pena et al., 2012). 
 Altogether, the data so far available clearly demonstrated that CO-RMs 
have antimicrobial properties. 
 
2.5.1 Transcriptional response of bacteria to Carbon Monoxide- 
Releasing Molecules 
The discovery that CO and particularly CO-RMs have a potent 
bactericidal effect triggered the interest to find bacterial CO targets, besides 
the respiratory chain. Therefore, the transcriptional response of E. coli to Ru-
based carbonyls (CORM-2 and CORM-3) was analysed by DNA microarray 
experiments (Davidge et al., 2009; Nobre et al., 2009). In agreement with the 
higher susceptibility of E. coli to CORM-2 under anaerobic conditions, a higher 
number of genes were altered under these conditions (Nobre et al., 2007). In 
contrast, cells treated with CORM-3 are more sensitive under aerobic 
conditions, and consequently a higher number of genes were affected when E. 
coli cells were grown in the presence of oxygen (Davidge et al., 2009). This 
discrepancy could be related to different experimental conditions utilized to 
performed microarray experiments.  Nevertheless, both microarray 
experiments reveal several potential targets for CO-RMs antimicrobial action. 
Figure 2.5 summarizes the metabolic pathways affected by CO-releasing 
molecules under aerobic and anaerobic conditions. 
Under aerobic conditions most of genes involved in the citric acid cycle 
were repressed (sdhCD, fumA and sucAB), indicating that the energy 
production is strongly compromised in the presence of CO-RMs (Davidge et 











Figure 2.5| Metabolic pathways affected by CO-RMs. E. coli genes whose
transcription was modified by CORM-2 and CORM-3 in cells grown aerobically (left
side) or anaerobically (right side). The middle panel depicts genes commonly
altered by both oxygen growth conditions. Arrows pointing up used for genes that
were induced, and arrows pointing down for genes repressed by CORM-2 (dashed















































al., 2009; Nobre et al., 2009). Additionally, a marked decreased in cyo operon 
expression, that encodes cytochrome oxidase, observed in cells growing in the 






CO-RMs were found to interfere with the methionine biosynthetic 
pathway. Indeed, both CO-RMs induce the expression of metF, and CORM-2 
up-regulated other methionine related genes as metNI, metBL and metR, 
which regulates the transcription of genes for methionine biosynthesis 
(Davidge et al., 2009; Nobre et al., 2009). Additionally, E. coli strains deleted in 




metR, metI and metN exhibited enhanced susceptibility to CORM-2 (Nobre et 
al., 2009).  
Alterations in the sulphate and sulphur metabolism were also 
observed upon CO-RMs treatment. In fact, transcription of sbp, involved in 
sulphate uptake, which is crucial to cysteine biosynthesis, was induced by both 
CO-releasing molecules under aerobic conditions (Davidge et al., 2009; Nobre 
et al., 2009). Moreover, CORM-2 up-regulated genes involved in sulphur 
metabolism, such as tauABC, ssuAD and cysWA (Nobre et al., 2009). In 
addition, thiC which is involved in thiamine biosynthesis, where cysteine is 
required, was repressed in E. coli cultures exposed to both CO-releasing 
molecules (Davidge et al., 2009; Nobre et al., 2009). In the presence of CORM-
3, expression of other E. coli genes involved in thiamine biosynthesis were 
repressed namely, thiG and thiH (Davidge et al., 2009). 
Interestingly, genes related to metal homeostasis were altered upon 
CO-RMs treatment. In fact, ftnA, encoding an iron storage protein was 
repressed by both CO-releasing molecules under anaerobic conditions 
(Davidge et al., 2009; Nobre et al., 2009). Moreover, the transcription of bfr 
and bcp, coding for bacterioferritin and bacterioferritin comigratory protein, 
respectively, were repressed by CORM-2 (Nobre et al., 2009). Under aerobic 
conditions, bfr was also down regulated by CORM-3 (Davidge et al., 2009). 
Genes involved with zinc homeostasis were also altered, such as the zinc 
binding protein zraP, which was induced by both CO-RMs under anaerobic 
conditions (Davidge et al., 2009; Nobre et al., 2009). CORM-3 also induces the 
expression of other zinc-related gene, znuA under anaerobic conditions, and 
CORM-2 up-regulated the transcription of zntR, a zinc-responsive 
transcriptional regulator under both oxygen growth conditions (Davidge et al., 











2009; Nobre et al., 2009). However, no alteration of the intracellular zinc 
content was detected in CORM-3 treated cells (Davidge et al., 2009). 
Microarray data also revealed that several genes involved in protein 
folding, namely, heat-shock proteins, chaperons and proteases were up-
regulated by CO-RMs. In particular, the genes ibpA and ibpB, two heat-shock 
proteins that are directly connected with protein stability, were highly induced 
by CORM-2 in cells grown under both oxygen conditions (Nobre et al., 2009). 
Accordingly, the deletion of these genes decreased the resistance of E. coli 
cells to CORM-2. In addition, CO-RMs seem to affect the integrity of cell 
envelope proteins as periplasmic combact stress gene cpxP, and an envelope 
stress induced periplasmic gene spy were up-regulated by both CO-RMs under 
both oxygen growth conditions (Davidge et al., 2009; Nobre et al., 2009). 
Further studies also revealed that CORM-2 interferes with biofilm 
formation. In fact, genes related to biofilm formation such as tqsA and bhsA 
were up-regulated by CORM-2, and its deletion increased bacteria resistance 
to CO releaser (Nobre et al., 2009). Genes related to defense mechanism as 
the multidrug efflux system (mdtABC) were also induced by CO-releasing 
molecules (Davidge et al., 2009; Nobre et al., 2009). Interestingly, genes 
directly related to oxidative stress such as oxyR and soxS were up-regulated by 
CORM-2 under both oxic and anoxic conditions, suggesting a possible 
involvement of ROS in CO-RMs action (Nobre et al., 2009). 
Although, CO and CO-releasing molecules potential for managing 
microbial infections is now recognized, further studies need to be performed 
in order understand the CO-RMs action and their targets in bacteria. Chapter 4 
of this thesis will present recent findings that unravel the mode of CO-RMs 
action, and which changes the perception that CO-RMs are only CO-delivers. 
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Summary| In this study we report that inactivation of the putative 
nitroreductase SA0UHSC_00833 (ntrA) increases the sensitivity of 
Staphylococcus aureus to S-nitrosoglutathione (GSNO) and augments its 
resistance to nitrofurans. S. aureus NtrA is a bifunctional enzyme that exhibits 
nitroreductase and GSNO reductase activity. A phylogenetic analysis suggests 
that NtrA is a member of a novel family of nitroreductases that seems to play 
a dual role in vivo, promoting nitrofurans activation and protecting the cell 
against transnitrosylation.  




Staphylococcus aureus is a Gram-positive pathogen responsible for a 
large number of human infections that range from mild to potential lethal 
systemic infections. The incidence of methicillin-resistant S. aureus (MRSA) 
infections, which is rapidly increasing particularly among HIV/AIDS-infected 
patients (Crum-Cianflone et al., 2007), reveals that the antibiotic of choice for 
the treatment of S. aureus is becoming ineffective and shows the need for 
using alternative compounds. Strains of Staphylococcus are sensitive to 
nitrofuran derivatives such as nitrofurazone and nitrofurantoin, and are 
utilized in the treatment of burns, skin grafts and genitourinary infections 
(Guay, 2001). The action of nitrofurans is dependent on the presence of 
specific microbial enzymes, the nitroreductases, which catalyze the reduction 
of the drug, a step that is essential for its activation. The activation of 
nitroaromatic compounds by bacterial nitroreductases is also used as a cancer 
therapy, since the cytotoxic hydroxylamine derivative compounds are able to 
destroy tumors (Johansson et al., 2003).  
In microorganisms subjected to nitrosative stress, S-nitrosoglutathione 
(GSNO) is formed by reaction of NO with the intracellular glutathione. The 
GSNO formed reacts with thiol-containing proteins promoting thiol nitrosation 
which modifies the function of proteins that are essential to many cellular 
processes. To control the level of S-nitrosylated proteins, organisms use S-
nitrosoglutathione reductases (GSNOR), namely the widespread glutathione-
dependent formaldehyde dehydrogenase (FALDH) also known as class III 
alcohol dehydrogenase (Liu et al., 2001). However, GSNO is also a NADPH-
dependent oxidizing substrate of other enzymes such as the thioredoxin 
system, glutathione peroxidase, γ-glutamyl transpeptidase, and xantine 
oxidase, indicating that GSNO reductase activity is frequently associated with 



















other enzymatic activities (Hou et al., 1996; Nikitovic & Holmgren, 1996; Hogg 
et al., 1997; Trujillo et al., 1998). 
Our microarray studies revealed that the staphylococcal gene 
SA0UHSC_00833 of S. aureus NCTC 8325 encoding a putative nitroreductase is 
induced by GSNO. Hence, we have analysed the in vivo role of this protein in 
the metabolism of GSNO and nitrofurans, and performed the biochemical 
characterization of the recombinant protein SA0UHSC_00833 (named NtrA).  
 
3.2 Results and discussion 
 S. aureus NtrA is involved in GSNO metabolism 
In a DNA microarray study of S. aureus NCTC 8325 we detected that 
GSNO significantly up-regulates the SA0UHSC_00833 gene (herein named 
ntrA) which encodes a putative nitroreductase (our unpublished data). To 
perform quantitative real-time RT-PCR analysis, cells of S. aureus NCTC 8325 
were grown in LB to an OD600nm = 0.4, and treated for 10 min with GSNO (150 
µM). The bacterial strains, plasmids and oligonucleotides used in this study are 
listed in suplemmentary data in Tables S3.1 and S3.2 (see section 3.5). Real-
time PCR experiments were performed with LightCyclerR FastStart DNA Master 
SYBR Green I Kit (Roche Applied Science), using 400 ng of cDNA prepare from 
total RNA and 0.5 µM of oligonucleotides SaNrNhe and SANrEco (Table S3.2) 
for the SA0UHSC_00833 (ntrA) gene, 16S_Fwd and 16S_Rev for S. aureus 16S 
rRNA. The results confirm that GSNO causes a strong transcriptional induction 
of the ntrA gene (13.4 ± 3.8-fold). The expression of a homolog gene in S. 
aureus COL, SACOL0874, was also reported to be induced by nitrosative stress 
conditions (Richardson et al., 2006). Since these results suggest the 
involvement of the ntrA gene in nitrosative metabolism, a strain defective in 
the gene was constructed and analysed. For the construction of mutant, the S. 
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aureus NCTC 8325 SA0UHSC_00833 (ntrA) gene was PCR amplified using 
SA0833MutEco and SA0833MutBam oligonucleotides (Table S3.2), ligated to 
pSP64D-E (pSP64-SA0833), electroporated into S. aureus RN4220, and selected 
on Tryptone Soy Agar plates (TSA) containing erythromycin (10 µg/mL). The 
correct integration of pSP64-SA0833 into the chromosome of S. aureus was 
confirmed by PCR, and the generated mutant strain designated LMSA833. For 
the GSNO sensitivity tests, wild type and LMSA833 (ΔntrA) were grown 
overnight in Tryptone Soy Broth (TSB), inoculated in fresh LB and exposed for 
1 h to GSNO (100 μM). The cultures were treated for another 4 h with 1 mM of 
GSNO and serial dilutions were spotted on TSA. After overnight incubation, the 
plates revealed that ΔntrA exhibited a higher degree of GSNO inhibition than 
the parental strain. Furthermore, expression of NtrA from the pMK4 plasmid 
restored the wild type phenotype (Figure 3.1). Nevertheless, we did not 
observe enhanced susceptibility of the ntrA mutant when using NO gas (data 
not shown). 
  
 S. aureus ntrA mutant is more resistant to nitrofurans 
Since SA0UHSC_00833 is annotated as a putative nitroreductase, its 
role in the metabolism of nitrofurans was also examined. To this end, 
overnight cultures of S. aureus wild type (RN4220) and ΔntrA (LMSA833) 
Figure 3.1| Sensitivity of S. aureus ntrA
mutant (ΔntrA) to GSNO. S. aureus wild
type (wt), ΔntrA and ΔntrA harboring
pMK4ntrA or the vector alone were grown
in LB medium and treated with 1 mM of
GSNO (+) or left untreated (-). Sensitivity
tests were assayed after 4 h of GSNO


































Figure 3.2| Resistance of S. aureus ntrA mutant (ΔntrA) to nitrofurantoin and
nitrofurazone. Wild type S. aureus RN4220 ( ) and ΔntrA (■) were grown in LB
medium and treated with 20 µg/mL nitrofurantoin (A) and 25 µg/mL nitrofurazone




































grown in TSB were used to inoculate fresh LB medium, supplemented with 
nitrofurantoin (20 µg/mL) or nitrofurazone (25 µg/mL). In the absence of 
antibiotics, the wild type and mutant strains displayed similar growth kinetics. 
After the addition of nitrofurans the growth of both strains was immediately 
inhibited. While after 22 h the wild type showed almost limited recovery 
(recoveries of 17% and 9% for nitrofurantoin and nitrofurazone, respectively), 
the mutant strain had resumed growth at a rate similar to the untreated 
culture, exhibiting a recovery of 67% for cells treated with nitrofurantoin and 
of 71% for cells submitted to nitrofurazone (Figure 3.2).  
 
Furthermore, cells of the ntrA mutant strain expressing NtrA, from a 
multi-copy plasmid bearing only the ntrA gene, regained the sensitivity to 
nitrofurans with a phenotype similar to the one observed for the wild type 
strain (data not shown). In conclusion, the presence of an active ntrA gene 
product contributes to the sensitivity of S. aureus to nitrofurans.  
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 Mutation of ntrA decreases the nitroreductase activity of S. aureus 
The activity of cell-free extracts of S. aureus wild type and ntrA mutant 
strain were analyzed by following the reduction of nitrofurantoin and 
nitrofurazone using NADH or NADPH as electron donors. To this end, cells 
from TSB overnight cultures of wild type and ΔntrA (LMSA833) were 
harvested, resuspended in cold 20 mM Tris-HCl buffer pH 7.6 (buffer A) and 
incubated with lysostaphin (50 µg/mL) (37 ºC, 15 min). Following addition of 
DNAse (50 µg/mL), cells were centrifuged for 30 min (13000 g, 4ºC). The 
enzymatic assays were recorded in a Shimadzu UV-1700 spectrophotometer 
(25ºC) following the decrease of the nitrofuran absorbance (nitrofurazone 
(є400nm=12960 M
-1cm-1) and nitrofurantoin (є420nm=12000 M
-1cm-1)). The 
mixture contained buffer A, nitrofuran, NADPH or NADH (100 µM) and the 
reaction was initiated by addition of the cell extract. The NADPH-dependent 
activity was found to be higher than NADH-dependent activity and the higher 
activity values were measured when using nitrofurantoin. Inactivation of the S. 
aureus ntrA led to a significant decrease of the nitrofurantoin and 
nitrofurazone reductase activity values (Table 3.1), which correlates with the 
increase in the nitrofuran resistance observed in the ntrA mutant strain. 
 
Table 3.1| Nitroreductase activity (nmol.min-1.mg-1 protein) assayed 
 in cell extracts of S. aureus wild type (wt) and ntrA mutant strain (ΔntrA). 
 Nitrofurantoin Nitrofurazone 
S. aureus NAPDH NADH NADPH NADH 
wt 9.5 ± 0.7 4.7 ± 0.5 4.8 ± 0.4 2.8 ± 0.4 
























 S. aureus NtrA protein reduces GSNO and nitrofurans 
 To further characterize the function of the S. aureus NtrA, the protein 
was produced and characterized. Hence, S. aureus NCTC 8325 
SA0UHSC_00833 (ntrA) gene was amplified using two oligonucleotides, 
SA0833NheIEx and SA0833EcoRIEx (Table S3.2), and cloned into pET28a(+) 
yielding pET28SA0833, that was transformed in E. coli BL21-Gold(DE3). Cells 
were grown, in LB with 30 µg/mL kanamycin, to an OD600nm of 0.3 and induced 
for 7 h with isopropyl-ß-D-thio galactopyranoside (IPTG, 500 µM). Since the 
NtrA protein produced contain a His-Tag, the soluble extract was loaded onto 
a HisTrap Hp Column (GeHealthcare). Elution with ~200 mM imidazole yielded 
a pure fraction of NtrA, as judged by SDS-PAGE, which had an apparent 
molecular mass of 
~21 kDa.  The 
GSNO reductase 
activity of S. 
aureus NtrA was 
measured in 
buffer A plus S. aureus NtrA protein (0.6 µM), NADPH or NADH (250 µM) and 
GSNO (50-400 µM). The reaction was initiated by addition of GSNO and 
monitored following the oxidation of NAD(P)H (є320nm=6220 M
-1cm-1). Activity 
values were corrected taking into account the reaction of GSNO with NAD(P)H. 
The kinetic data were fitted to the Michaelis-Menten equation using 
SigmaPlot. All values presented are the average of at least two assays. S. 
aureus NtrA enzyme showed to be specific for GSNO since no activity was seen 
for NO, S-nitrosocysteine and S-nitrosohomocysteine. Kinetic analysis of the S. 
aureus NtrA gave a KM value  (pH=7.6) for GSNO of ~ 181 µM (Table 3.2), a 
value which is lower than the one measured for the E. coli FALDH (KM ~ 700 
Table 3.2| GSNO reductase and nitroreductase activity                 






GSNO 180.6 ± 43.4 1.5 ± 0.2 1.2
Nitrofurantoin 18.8 ± 4.8 13.7 ± 1.5 22.8
Nitrofurazone 25.7 ± 5.8 15.3 ± 1.6 25.5
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µM, pH=7 (Liu et al., 2001), thus indicating higher affinity of NtrA for this 
substrate. The nitroreductase activity of the purified S. aureus NtrA was also 
determined using nitrofurantoin and nitrofurazone as substrates (5-50 µM) 
and as electron donors NADPH or NADH (250 µM), which were used to initiate 
the reaction. Since the S. aureus NtrA (0.6 µM) was previously incubated with 
FMN/FAD (5 µM), all activities were corrected taking into account the 
chemical reduction of the nitrofuran compound generated by the same 
amount of flavin utilized in the protein mixture. We observed that while S. 
aureus NtrA incubated with FMN exhibited nitroreductase activity, no 
significant activity was measured when FAD was incorporated into NtrA. As 
observed for the GSNO reductase activity of S. aureus NtrA, the nitroreductase 
activities using NADH or NADPH as source of reducing equivalents were of the 
same order of magnitude (data not shown). The NADPH-dependent nitrofuran 
activity of the S. aureus NtrA (Table 3.2) is within the range of values usually 
observed. In particular, the only nitroreductase so far studied from S. aureus, 
the SA0UHSC_00366 protein (named NfrA), exhibits nitrofurazone and 
nitrofurantoin specific activities of 20 and 15 µmol.min-1.mg-1 protein, 
respectively, and the E. coli NsfA nitroreductase has a specific activity of ~80 
µmol.min-1.mg-1 protein (Streker et al., 2005). 
 
 The bifunctional S. aureus NtrA belongs to a novel family of 
nitroreductases 
A search in the genome of S. aureus NCTC 8325 revealed that in 
addition to the SA0UHSC_00833 (NtrA), three other genes encoding putative 
nitroreductases are present, namely SA0UHSC_00366 (NfrA), 
SA0UHSC_02829, and SA0UHSC_02258. The four S. aureus nitroreductases 
gene products share a low percentage of sequence identity among them, 



















which ranges between 4% and 11%. Since the E. coli nitroreductases are well 
characterized (Whiteway et al., 1998), we performed an amino acid sequence 
alignment with these enzymes which revealed that SA0UHSC_00366 (NfrA) 
shares the highest percentage of identity with E. coli b0851 (NfsA), 
SA0UHSC_02829 with E. coli b0578 (NfsB), and SA0UHSC_00833 (NtrA) and 
SA0UHSC_02258 present less than 10% identity with the two E. coli 
nitroreductases. A search, in the completed microbial genome databases, for 
homologs of S. aureus nitroreductases yielded several gene products with a 
percentage of sequence identity and similarity that varies between 17% and 
42%, and 10% and 36%, respectively. A dendrogram was constructed based on 
the alignment of selected amino acid sequences of proteins found to be 
similar to SA0UHSC_00366 (NfrA), SA0UHSC_00833 (NtrA), SA0UHSC_02258, 
SA0UHSC_02829, E. coli NfsA and E. coli NfsB (identity within the selected 
sequences ranges between 4 and 90%) (Figure 3.3). The dendrogram suggests 
three main groups. The first contains E. coli NfsB, SA0UHSC_02829 and 
SA0UHSC_02258, being SA0UHSC_02258 the more distantly related member 
of this group, and the second branch includes E. coli NfsA and SA0UHSC_00366 
(NfrA). The NtrA protein (SA0UHSC_00833) is located in a third independent 
group that does not contain any of the E. coli or S. aureus nitroreductases, 
thus suggesting that S. aureus NtrA is a member of a novel family of 
nitroreductases. Interestingly, the genome region comparison of the ntrA loci 
among the nine completely sequenced S. aureus genomes showed that in all 
cases the ntrA gene is flanked upstream by a gene encoding a protein similar 
to a 3-dehydroquinate dehydratase and downstream by a thioredoxin 
encoding gene, which is transcribed from the opposite strand.  




Figure 3.3| Dendrogram of representative nitroreductases families. Organism and 
protein sequence gi number corresponding to each abbreviation: Actinobacillus A 
(152979535) and B (152979206) – Actinobacillus succinogenes, Aeromonas – Aeromonas 
salmonicida (145298746); Bacillush – Bacillus halodurans (15612866), Bacilluss A 
(16080862) and B (16077850) – Bacillus subtilis; Burkholderia – Burkholderia thailandensis 
(83716954), Chromohalobacter A (92112337) and C (92113480) – Chromohalobacter 
salexigens; Corynebacterium – Corynebacterium jeikeium (68536654); Clostridium –  
Clostridium difficile (126700824); Desulfovibrio – Desulfovibrio desulfuricans G20 
(78355133); E. coli NfsA – E. coli K-12 b0851 (16128819); E. coli NfsB – E. coli K-12 b0578 
(16128561); Enterococcus – Enterococcus faecalis (29375756); Erythrobacter – 
Erythrobacter litoralis (85374565); Erwinia – Erwinia carotovora (50121266); Geobacter – 
Geobacter uraniumreducens (148263412); Klebsiella – Klebsiella pneumoniae 
(152969124); Lactococcus – Lactococcus lactis (125623424); Listeria A (16799400) and C 
































































Neisseria gonorrhoeae (59800832); Nitrobacter – Nitrobacter winogradskyi (75676226); 
Pseudomonasp – Pseudomonas putida (148548471); Pseudomonass – Pseudomonas 
stutzeri (146282796); Psychrobacter – Psychrobacter sp. (148653797); Rubrobacter – 
Rubrobacter xylanophilus (108804130); SA0U02258 – S. aureus SA0UHSC_02258 
(88195929); SA0U00366 – S. aureus SA0UHSC_00366 (88194164); SA0U002829 - S. aureus 
SA0UHSC_002829 (88196463); SA NtrA – S. aureus SA0UHSC_00833 (88194591); Shigella – 
Shigella flexneri (24112221); Streptococcuss – Streptococcus sanguinis (125718603); 
Streptococcust – Streptococcus thermophilus (55821160); Thermosynecoccus – 
Thermosynecoccus elongatus (22299744); Thiomicrospira – Thiomicrospira crunogena 
(78484399) ; Vibrioc A (15640734) and B (15601395) – Vibrio cholera; Vibriof – Vibrio 
fischeri (59713296); Vibriov – Vibrio vulnificus (27366397).  
 
In conclusion, we have shown that S. aureus NtrA is a bifunctional 
enzyme able to catalyze the reduction of GSNO and nitrofurans. Although the 
existence of a single protein that combines two activities seems to be a 
common feature among the so far known GSNO reductases, the S. aureus NtrA 
is the first staphylococci nitroreductase shown to metabolize toxic 
nitrosothiols. 
Even though the presence of NtrA contributes to the activation of 
nitrofurans, in the absence of these antibiotics NtrA acts as a defense system 
allowing the decomposition of GSNO formed endogenously, which occurs 
when S. aureus is exposed to nitrosative stress, and avoids the harmful effects 
caused by transnitrosylation reactions. 
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3.5 Supplementary data 
 
 Table S3.1| Bacterial strains and plasmids used in this study. 
Strain or plasmid Description Source or Reference 
E. coli   
XL2-Blue 



















gal λ(DE3) endA Hte Stratagene 
S. aureus   
NCTC 8325 Wild type (with 11-bp deletion in rbsU) Laboratory stock 
RN4220 
NCTC8325-4-r (restriction negative derivate of 




 This study 
Plasmids   
pSP64D-E 
Cloning vector carrying an erythromycin resistance 
cassette 
(de Lencastre et al., 
1994; Pinho et al., 
2000) 
pSP64-SA0833 
DNA fragment (851 bp) containing the coding region of 
SA0UHSC_00833 gene cloned into pSP64D-E 
This study 
pET28a(+) 
Protein expression vector carrying a (His)6-tag at the N-
terminal and a kanamycin resistance cassette 
Novagen 
pET28SA0833 S. aureus SA0UHSC_00833 gene cloned into pET28a(+) This study 
pMK4 
Shuttle vector containing a chloramphenicol resistance 
cassette 
BGSC (Sullivan et al., 
1984) 
pMK4ntrA SA0UHSC_00833 gene cloned into pMK4 This study 
 
                    Table S3.2| Oligonucleotides used in this study. 
























4.1 Introduction                           104 
4.2 Material and methods                         106 
4.3 Results                              112 
4.4 Discussion                             125 
4.5 Acknowledgments                           128 
4.6 References                             128 






























































whether  the  generation  of  reactive  oxygen  species  by  CO‐RMs may  indeed 
result  in the  inhibition of bacterial cellular function. We now report that two 
CO‐RMs (CORM‐2 and ALF062) stimulate the production of ROS in Escherichia 
coli,  an  effect  that  is  abolished  by  addition  of  antioxidants.  Furthermore, 
deletion of genes encoding E. coli systems involved in reactive oxygen species 




images  reveal  that  CORM‐2  causes  DNA  lesions  to  bacterial  cells. We  also 
demonstrate that cells treated with CORM‐2 contain higher levels of free iron 
arising from destruction of iron‐sulfur proteins. Importantly, we show that CO‐
RMs  generate  hydroxyl  radicals  in  a  cell‐free  solution,  a  process  that  is 









Carbon  monoxide  (CO)  is  generated  in  the  human  body  by  the 
degradation  of  haem  mediated  by  haem  oxygenase  (HO)  enzymes.  The 
endogenous  CO  production  has  benefits  in  the  neural,  cardiovascular  and 
renal systems, having a cytoprotective effect  in several pathologic conditions 
such  as  atherosclerotic  vascular  disease  and  inflammation  (Li  et  al.,  2007). 
Nevertheless, high concentrations of CO are toxic resulting primarily from the 





of  oxidized  proteins  and  lipid  peroxidation,  and  decreases  the  ratio 
reduced/oxidized glutathione. As expected, these effects are counteracted by 
the presence of superoxide dismutase and iron chelators (Zhang & Piantadosi, 
1992). One  of  the  three  isoforms of mammalian haem oxygenase  enzymes, 
HO‐1,  is  inducible by  several  stress agents,  including haem, heat  shock, pro‐
inflammatory  cytokines  and hypoxia.  Since  these  agents  share  the  ability  to 
directly or indirectly generate ROS, the elevated HO‐1 expression is considered 
as  a  cellular  indicator  of  oxidative  stress  (Ryter  et  al.,  2002; Wu  & Wang, 
2005).  On  the  other  hand,  HO‐1‐derived  CO  has  been  reported  to  have 
remarkable  benefits  on  microbial  sepsis,  as  HO‐1  deficient  mice  display 
enhanced susceptibility  to polymicrobial  infections and  the administration of 
exogenous CO  rescues  the HO‐1‐deficient mice  from  sepsis‐induced  lethality 
(Chung  et  al.,  2008).  Exogenous  administration  of  CO,  via  CO‐releasing 
molecules  (CO‐RMs),  also  showed  to  be  able  to  kill  bacteria  (Nobre  et  al., 












bacteria  addressed  by  global  transcriptional  analysis  revealed  that  CO‐RMs 
induce  a  significant  alteration  on  the  bacterial  transcriptome.  In  particular, 
induction of genes encoding  two main  redox‐sensing  regulators  that  control 
the  bacterial  oxidative  response,  SoxS  and OxyR,  occurs  in  cells  exposed  to 
CORM‐2,  and  E.  coli  strains  lacking  oxyR  and  soxS  genes  exhibit  enhanced 
susceptibility  to  CORM‐2,  altogether  suggesting  that  CO  potentiates  the 
generation of reactive oxygen species (Nobre et al., 2009). 
The generation of intracellular ROS causes deterioration of DNA, lipids, 
and  proteins  and  several  targets  have  been  linked  to  loss  of  cell  integrity 
and/or  viability  (Cabiscol  et  al.,  2000).  DNA  is  especially  prone  to  iron‐
catalysed  oxidation,  as  iron  binds  directly  to  the  phosphodiester  backbone 
where  •OH  radicals  are  subsequently  generated  (Imlay &  Linn,  1988; Avery, 
2011).  In particular, guanine residues on DNA are targets of oxidation as well 
as  thiol  groups  and  iron‐sulfur  clusters  of  proteins  (Cabiscol  et  al.,  2000; 
Brzoska  et  al.,  2006).  Besides  loss  of  function,  denaturation  of  iron‐sulfur 
clusters  contributes  itself  to  toxicity  since  the  iron  that  is  released  upon 
oxidation of the clusters provokes additional oxidative damage via the Fenton 
reaction (Keyer & Imlay, 1996; Avery, 2011).  
Nevertheless,  bacteria  have  several  mechanisms  to  avoid  this 
outcome.  The  typical  responses  to  ROS  include  DNA  repair  systems  (e.g. 
RecA), the action of scavenging molecules (e.g. glutathione) and detoxification 








In  the  present  work  we  have  exposed  bacterial  cultures  to  CO‐
releasing molecules  and  determined  the  effect  of  these  compounds  on  cell 
viability upon addition of antioxidants, measured  the  level of ROS, analysed 
the deletion of ROS scavenging systems, observed the degree of DNA damage, 







 The bacterial strains used  in  this work are described  in Table 4.1. All 
Escherichia coli cells, grown aerobically  in minimal medium salts (MS) (Nobre 
et al.,  2007)  at  37  ºC  and  150  rpm, were  cultured until  reaching  an optical 
density at 600 nm (OD600nm) of 0.3 at which point the CO‐releasing molecules 
were  added.  Tricarbonyldichlororuthenium  (II)  dimer  (CORM‐2)  from  Sigma‐
Aldrich  (Sintra,  Portugal)  and  tetraethylammonium  molybdenum 
pentacarbonylbromide (ALF062) from Alfama (Oeiras, Portugal) (Nobre et al., 
2007) were used as CO donors; these compounds were freshly prepared as 10 
mM  stock  solutions  by  dissolution  in  dimethyl  sulfoxide,  and  methanol, 
respectively. Ru(II)Cl2(DMSO)4  from Strem Chemicals  (Bischhein, France) was 
used as  the  inactive  form of CORM‐2  (iCORM‐2) and  the  inactivated  form of 






































Sigma‐Aldrich),  reduced  glutathione  (5 mM;  Calbiochem,  Lisbon,  Portugal), 
glutamate  (50  mM;  Sigma‐Aldrich),  cysteine  (600  μM;  Sigma‐Aldrich)  and 
methionine  (3  mM;  Sigma‐Aldrich)  were  added  to  the  growth  culture.  To 
determine  the  cell  viability  of  E.  coli  strains,  the  number  of  colony  forming 
unit(s)  (CFU)  was  evaluated  in  the  presence  of  the  compounds  and  their 
inactive  forms. The percentage of survival was determined as the number of 
colonies obtained after CO‐RMs treatment divided by the number of colonies 
formed  in  the cultures  treated with  the  inactive  form. Wild  type E. coli cells 
were treated with 250 μM CORM‐2 and 50 μM ALF062, while for the analysis 
of  the E. coli mutant  strains and  their parent  strains CORM‐2 was used at a 
concentration of 150 μM. The experiments were performed  in duplicate with 























coli  total RNA,  from  two  independent cultures, grown with 250 μM CORM‐2 
and  control  compound  for  1 h, was used  to  synthesize  cDNA with  the  First 
Strand  cDNA  Synthesis  Kit  for  RT‐PCR  from  Roche  Applied  Science  (Lisbon, 




template,  and  each  reaction  mixture  contained  0.5  µM  specific 
oligonucleotides  (recA_up 5´‐CCTTGCGGCACGTATGATGA‐3´ and  recA_low 5´‐












Applied  Science).  The  expression  ratio  of  the  target  gene  was  determined 
relatively  to  a  reference  gene,  the  E.  coli  16S  rRNA,  whose  transcription 





H2O2  (as  control),  250 µM  CORM‐2  and  iCORM‐2  and  treated  and  analysed 
according  to  the  manufacturer’s  instructions  of  hOGG1  FlareTM  assay  kit 
(Trevigen, UK). Briefly, cells were centrifuged, washed and resuspended in PBS 
to obtain a bacterial concentration of 108 CFU/mL. The cells were mixed with 







acid);  Sigma‐Aldrich) by  free  thiol  groups  releases 5‐thio‐2‐nitrobenzoic  acid 
(TNB), which  can  be monitored  spectrophotometrically  at  412  nm  (Ellman, 
1959).  Increasing  amounts  of  CORM‐2,  iCORM‐2  and  iodocetamide  were 
mixed with 100  μM  glutathione  (GSH)  in  100 mM phosphate buffer  (pH  7). 
After 1 h at room temperature, 500 μM DTNB was added and the absorbance 











The  intracellular  free  iron  content was  determined  by  EPR  in whole 
cells of E. coli grown for 1 h with 250 µM CORM‐2 and iCORM‐2, collected by 
centrifugation, resuspended in 9 mL of fresh MS and treated with 1 mL 0.2 M 
deferoxamine mesylate  (Sigma‐Aldrich)  for 10 min at 37  ºC. Cells were  then 
washed once with ice‐cold 20 mM Tris‐HCl (pH 7.4) and resuspended in 0.4 mL 
of the same buffer supplemented with 10% (v/v) glycerol. Aliquots of 0.3 mL 





the  amplitude  of  the  EPR  signal  and  normalizing  it  for  the  total  protein 
concentration, which was determined by the bicinchoninic acid method (BCA) 




Applied Bioanalytical  Labs  (Bradenton, USA) was used as a  spin‐trap  for  the 
detection of reactive oxygen species. This spin trap allows one to distinguish 
between  the  superoxide  anion  and  the  hydroxyl  (Zhao  et  al.,  2001). 
Experiments were conducted with 5 mM BMPO, 2 mM of CORM‐2 and iCORM‐






















in  a  French  press.  The  aconitase  activity  was  measured,  under  anaerobic 




mM  Tris‐HCl  (pH  7.6),  0.6  mM  MnCl2,  0.2  mM  NADP
+  and  1  U  isocitrate 
dehydrogenase  (Sigma‐Aldrich).  The  reaction  was  initiated  with  30  mM 
sodium citrate. One unit of aconitase activity was defined as 1 μmol NADPH 






5 mM  α‐ketoglutarate. One  unit  of  GOGAT  activity was  defined  as  1  nmol 
NADPH  consumed  per  min  at  25ºC.  The  glutamate  dehydrogenase  (GDH) 
activity was determined as  the above described GOGAT activity, using 5 mM 










Previous  studies  have  shown  that  CO‐RMs  alter  the  transcription  of 
several genes  involved  in oxidative  stress  response,  suggesting  that CO‐RMs 
elicit  the  production  of  reactive 
oxygen  species  (Nobre  et  al., 
2009).  To  infer  if  biological 
antioxidants  attenuate  the 
bactericidal  effect  of  CO‐RMs, we 
have  evaluated  the  viability  of  E. 
coli  cells upon  treatment with  two CO donors, namely CORM‐2  and ALF062 
(Figure  4.1),  in  the  presence  of  exogenous  reduced  glutathione  (GSH)  and 
cysteine. The data  showed  that GSH was able  to  restore  the viability of  the 
microbial  cells by  approximately  95%.  Furthermore,  supplementation of  the 
culture medium with cysteine allowed a cell growth recovery of approximately 
80%  (Figure  4.2A  and  B).  These  results  revealed  that  the  presence  of 
antioxidants  causes  reduction  of  the  CO‐RMs  efficiency.  Since  E.  coli  cells 
submitted to oxidative stress develop a methionine auxotrophy (Masip et al., 
2006), and  it was previously detected that CORM‐2  interferes with the E. coli 
methionine  metabolism  (Nobre  et  al.,  2009),  we  have  now  analysed  the 
growth behavior of cells exposed  to CORM‐2  in  the presence of methionine. 
















 Next,  we  have  examined  the  level  of  endogenous  reactive  oxygen 
species formed in cells treated with CORM‐2 and ALF062. The data revealed a 
significant  increase  of  ROS  content  in  cells  exposed  to  either  compound, 
(Figure 4.3A and B).  Importantly, the  level of ROS  formed was dependent on 
the  CORM‐2  concentration  utilized  (Figure  4.3C).  Furthermore,  a  strong 
decrease  of  ROS  production  was  observed  upon  addition  of  glutathione 
Figure 4.2| Lethality of CO‐releasing molecules is abolished by antioxidants. E.
coli cells were grown under aerobic conditions and exposed to 250 µM CORM‐2 (A)
and 50 µM ALF062 (B) for 1 h, in a medium containing the CO‐releaser (black bars),
and supplemented with haemoglobin (Hb, grey bars), glutathione (GSH, white
bars), cysteine (Cys, black striped bars) and methionine (Met, grey striped bars).
Survival percentage was calculated in relation to cultures treated with the
respective inactive compound. The results represent the average of, at least, two
independent cultures performed in duplicate, and error bars represent the
standard error of the mean values obtained. Sensitivity tests performed in cultures






































































Figure 4.3| CO‐RMs increase intracellular
ROS content. ROS were quantified in E.
coli cells treated, for 1 h, with 250 µM
CORM‐2 (A) and 50 µM ALF062 (B) with
the CO‐releasers (black bars) and in the
presence of haemoglobin (grey bars) or
glutathione (white bars). In (C) cells were
treated with increased concentrations of
CORM‐2, 150 µM (grey striped bars), 200
µM (black striped bars) and 250 µM (black
bars). The fluorescence intensities (FI) are
represented as the subtraction of cultures
treated with the inactive compound from
cultures exposed to CO‐releasing
molecules and normalized in relation to
the OD600nmof the respective culture. Each
data bars represents the average of three
independent measurements with the




















































shown  to  be  strictly  dependent  on  CO  since  cells  treated  with  inactive 
compounds, namely  iCORM‐2 and  iALF062,  that are CO depleted molecules, 
exhibited ROS  levels similar to that of untreated cells (FI/OD600nm ~ 30 at 120 
min).  Furthermore,  when  the  medium  was  supplemented  with  the  CO 






























Since  the activity of glutamate dehydrogenase was  recently  reported 
to  decrease  under  oxidative  stress  (Mailloux  et  al.,  2009),  we  tested  this 
activity  that was  found  to  be  indeed  lowered  by  26%  in  cells  treated with 
CORM‐2  (Figure  4.4A).  Moreover,  supplementation  of  E.  coli  culture  with 
glutamate, which  is  the  substrate  of  GDH,  abolishes  the  effect  of  CORM‐2 
(Figure 4.4B). 
   
Altogether,  these  results  showed  that  cells  exposed  to  CORM‐2  are 
under  oxidative  stress.  As  both  CORM‐2  and  ALF062  caused  to  E.  coli  cells 














































Figure 4.4| Glutamate dehydrogenase activity is lower in cells treated with
CORM‐2. (A) Activity of glutamate dehydrogenase (GDH) in cell extracts of E. coli
treated for 1 h with iCORM‐2 (black bars) and CORM‐2 (white bars). The error bars
represent the standard error of the mean values obtained (*P <0.05). (B) Effect of
250 μM CORM‐2 on E. coli viability of aerobically grown cells exposed to the CO
releaser in the absence (black bars) and in the presence of glutamate (Glu, grey
bars). The percentage of survival was calculated in relation to cultures treated with
the respective inactive compound, and error bars represent the standard error of
the mean values obtained. Sensitivity tests performed in cultures treated, for 1 h,







 The  observation  that  CO‐RMs  increase  ROS  production  led  us  to 
hypothesize  that  strains deleted  in  the major antioxidant  systems  should be 
more prone to killing by CO‐RMs. Therefore, we have analysed the phenotype 
of  E.  coli  strains  deleted  in  catalases  (∆katEG)  and  superoxide  dismutases 
(∆sodAB), in the presence of CORM‐2. 
  The  data  regarding  viability  of  ΔkatEG  and  ΔsodAB mutants  showed 
that these strains have increased susceptibility to CORM‐2 when compared to 
the wild  type, and  that  the effect  is higher  for  the  catalases deficient  strain 
(Figure  4.5A).  In  agreement,  CORM‐2  treated  cells  of  ΔkatEG  have  higher 
amounts of ROS (Figure 4.5B and C). However, the ROS content of the ΔsodAB 
mutant  strain  did  not  vary,  a  result  that  may  be  due  to  the  fact  that 
superoxide anions do not directly oxidize the DCFH fluorescent probe (LeBel et 
al.,  1992).  Therefore,  it  was  concluded  that  the  addition  of  CORM‐2  to 














































































































Figure 4.5| Bactericidal effect of CORM‐2 is enhanced upon deletion of ROS
scavenger systems. (A) Cell viability of the parental E. coli strain (black bars) and
mutant strains, ΔkatEG (grey bars) and ΔsodAB (white bars) were determined upon
treatment with 150 µM CORM‐2 and iCORM‐2 for 1 h and 4 h. For the same times,
sensitivity tests were performed in cultures treated with CORM‐2 (+) and iCORM‐2
(‐). ROS intracellular content of parental (black bars), ΔkatEG (grey bars) and
ΔsodAB (white bars) strains determined in cells exposed to 1 h (B) and 4 h (C) to
150 µM CORM‐2 and iCORM‐2. The fluorescence intensities (FI) are represented as
a subtraction of the cultures treated with iCORM‐2 from cultures treated with
CORM‐2 and normalized in relation to OD600nm of each culture. The error bars
represent the standard error of the average values obtained from at least two







increase  the  ROS  production  in  E.  coli  cells,  we  examined  if  the  effect  of 
CORM‐2 was  potentiated  in  a  recA mutant  strain.  RecA  participates  in  the 
double‐strand  break  repair,  catalyzing  the  homologous  recombination  and 
function as a regulatory protein to  induce the SOS response to DNA damage 
(Courcelle  &  Hanawalt,  2003).  We  observed  that  CORM‐2  increases  the 
expression of recA by ~2.5 fold and that the deletion of recA yielded an E. coli 






CORM‐2  and  hydrogen  peroxide  revealed  the  presence  of  long  comet  tails 
characteristic  of  damaged  DNA.  In  contrast,  cells  exposed  to  the  inactive 



















Fenton reaction. Hence, the  intracellular  levels of free  iron upon exposure to 





Figure 4.6| CORM‐2 causes damages to bacterial DNA. (A) Cell viability of E. coli
recA mutant (white bars) and its parental strain (grey bars) grown under aerobic
conditions and exposed to 150 μM CORM‐2 and iCORM‐2 was determined after 7
h. Error bars represent the standard error of the mean values obtained (*P <0.05).
Sensitivity tests were also performed in cultures treated with CORM‐2 (+) and
iCORM‐2 (‐). (B) Fluorescent microscopy of E. coli cells challenged, for 1 h, with 250






































come  from extracellular sources due to alterations  in  iron  import or have an 
intracellular origin arising from destruction of iron containing proteins. To test 
the first hypothesis, we have examined the viability of cells lacking tonB, which 
is one of  the major  iron  import  systems of E. coli  (Moeck & Coulton, 1998). 
However, no effect was observed on  the  viability of CORM‐2‐treated E.  coli 
tonB  mutant  (Figure  4.8A),  and  no  differences  were  detected  in  ROS 
production in the same mutant when compared with its parental strain (Figure 
4.8B  and  C).  These  results  indicate  that  exogenous  iron  does  not  play  a 
significant  role  in  oxidative  damage‐mediated  cell  killing.  We  have  next 
evaluated  if  upon  exposure  of  cells  to  CORM‐2  denaturation  of  iron‐sulfur 
clusters were supplying iron intracellularly for ROS generation. To this end, we 
have  analysed  the  impact  of  CORM‐2  on  the  phenotype  of  E.  coli  strains 
deleted  in genes  involved  in Fe‐S assembly, namely  the cysteine desulfurase 




sufS  remained  essentially  unaltered  when  compared  to  their  respective 
Figure 4.7| CORM‐2 increases the level of
intracellular free iron. Determination of the iron
content of E. coli cells challenged with 250 μM
CORM‐2 (white bars) and iCORM‐2 (black bars)
by EPR in whole cells. Arbitrary units correspond
to the amplitude of the EPR signal normalized






































































































Figure 4.8| CORM‐2 efficiency depends on iron‐sulfur cell content. (A) Viability of
E. coli parental strain (black bars), ΔiscS (striped bars), ΔtonB (dark grey bars), ΔiscR
(white bars) and ΔsufS (light grey bars) determined upon exposure to 150 µM
CORM‐2 and iCORM‐2, for 1 h and 4 h. Sensitivity tests were also performed in
ΔiscS cells treated with CORM‐2 (+) and iCORM‐2 (‐), for 1h and 4 h. ROS
intracellular content evaluated in the parental strain (black), ΔiscS (striped), ΔtonB
(dark grey) upon exposure for 1 h (B) and 4 h (C) to 150 µM CORM‐2 and iCORM‐2.
The fluorescence intensities (FI) represent the subtraction of the cultures treated
with iCORM‐2 from cultures treated with CORM‐2 normalized in relation to OD600nm
of the respective culture. The error bars are the standard error of the average
values obtained from, at least, two independent biological samples performed in
duplicate (*P <0.05, **P <0.01).
parental strains (Figure 4.8A). The viability of the CORM‐2‐treated ΔiscS strain 
was significantly higher and exhibited a lower content of ROS (Figure 4.8A‐C). 



















Figure 4.9| CORM‐2 lowers the activity of
iron‐sulfur containing proteins. Aconitase
and glutamate synthase ac tivities
determined in cells extracts of E. coli
challenged for 1 h with CORM‐2 (white
bars) and iCORM‐2 (black bars). The results
are the average of, at least, three

























The  higher  level  of  intracellular  iron  in  cells  exposed  to  CORM‐2 
suggests  that  Fe‐S  containing  enzymes  are  being  degraded.  This  is 
corroborated by the  lower activity of two enzymes measured  in cells treated 
with the CO‐releaser, namely aconitase and glutamate synthase (GOGAT). We 
observed  that  exposure  of  cell  extracts  to  this  bactericide  resulted  in  a 
significant decrease on  the  activity of  the  two  enzymes  (~75%  and  82%  for 
aconitase and GOGAT, respectively) while no alterations occurred when using 
iCORM‐2 (Figure 4.9). Overall, these results revealed that the ROS‐associated 
action of CORM‐2 relies on  the  intracellular  iron released  from Fe‐S clusters, 
with concomitant decrease in the enzymatic activity of key metabolic enzymes 









of  CORM‐2  (Figure  4.2A), we  sought  to  investigate whether  CORM‐2  could 
react in vitro with thiol groups. To this end, the Ellman’s reagent, DTNB, which 
is  reduced  by  free  thiol  groups  to  TNB,  was  added  to  a  buffer  solution 
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Figure 4.10| CORM‐2 impairs
reduction of thiols by the Ellman’s
reagent. Production of TNB, upon
incubation, for 1 h, of increased
amounts of iodoacetamide (▲),
CORM‐2 ( ) and iCORM‐2 (■) with
glutathione were determined in
the presence of the Ellman´s
reagent. Error bars represent the
standard error of average values.















radicals  in  vitro,  i.e.  in  the  absence of  cells. To  this end,  the EPR  spectra of 
samples containing CORM‐2 and  the BMPO spin trap were done. The results 
showed  that  the mixture  of  CORM‐2 with  BMPO  gives  rise  to  a  EPR  signal 
attributable  to  the  formation of a BMPO‐OH adduct  (Figure 4.11A), while no 
signal was detected upon mixture of iCORM‐2 with the same spin trap (Figure 
4.11B). Notably, the signal arising from the BMPO‐OH adduct was completely 
quenched  upon  incubation  of  CORM‐2  with  haemoglobin  (Figure  4.11C). 









The  signal of  the BMPO‐OH  adduct was observed upon bubbling O2  (Figure 
S4.1  in Supplementary Data), while  in a degassed  solution no EPR  spectrum 
was seen. In this case it is clear that the OH radicals arise from the reaction of 
the  electron‐rich  metal  in  the  [Mo(CO)5Br][NEt4]  complex  with  molecular 
oxygen in the protic solvent H2O.  
However, the  formation of OH radicals  from CORM‐2 solution and  its 
dependence on CO is not so obvious. We propose that these OH radicals result 
from  the  reduction  of O2  by  low  valent Ru  species, which  intermediate  the 
water‐gas  shift  reaction  initiated with  the attack of water on one of  the CO 
ligands  of  the  RuII(CO)3 moieties  of  CORM‐2  (Johnson  et  al.,  2007;  Seixas, 
2010;  Santos‐Silva  et  al.,  2011). Addition  of  haemoglobin  removes  CO  from 
RuII(CO)3  forming  oxygen  stable  Ru
II(CO)2  complexes  which  are  no  longer 
attacked by water under  these conditions. Thus,  the  formation of  radicals  is 
inhibited by haemoglobin through scavenging of CO. 
Figure 4.11| CORM‐2 generates ROS in vitro. EPR spectra of samples containing 2
mM CORM‐2 (A), iCORM‐2 (B) and CORM‐2 plus haemoglobin (Hb, C) acquired in

























carbonyls,  were  shown  to  have  bactericidal  properties  against  several 
pathogens including E. coli, S. aureus and Pseudomonas aeruginosa (Nobre et 
al.,  2007; Desmard  et  al.,  2009).  These  effects  have  been  attributed  to  CO 
release  since  the  compounds  lacking  CO  ligands  are  no  longer  bacterial 
inhibitors. Moreover, DNA microarrays indicate that CO is effectively delivered 
to  intracellular  targets  causing a plethora of  transcriptional modifications as 





Importantly,  ROS  generation  from  the  pioneering  CORM‐2  increases 
with the concentration of the CO‐RM and is abolished once the CO groups are 
absent or  scavenged by haemoglobin, providing a clear  indication  that CO  is 
required for the formation of reactive oxygen species. Our data also show that 
E.  coli  strains  mutated  in  genes  that  encode  ROS  detoxifiers,  namely  in 
superoxide  dismutases  (sodAB)  and  catalases  (katEG)  exhibited  a  sharp 
decreased  survival  indicating  that  impairment  of  ROS  detoxification 
potentiates the effect of CORM‐2.  
  Furthermore, CORM‐2 was found to activate recA transcription and we 
observed  that  the bactericidal effect of CORM‐2  is accentuated by  knocking 
out  recA, most probably due  to  the  inability of  triggering  the SOS  response. 
Accordingly,  we  observed  by  a  fluorimetric  assay  that  cells  treated  with 





exposed  to  the  inactive  form  of  the  compound.  The  presence  of  degraded 
DNA may  be  explained  by  the  ROS  generated  by  the  bactericide  as  these 
species are known to cause DNA lesions (Imlay & Linn, 1988).    
  The  results also  revealed  that cells  treated with CORM‐2 have higher 
levels of free iron, which does not arise from exogenous sources but from the 










consequently  it  is  a  source  of  ROS,  as  demonstrated  for mitochondria  and 
embryonic kidney cells (D'Amico et al., 2006). However, our results show that 
CORM‐2 generates hydroxyl  radicals per  se, and  this ability  seems  to be not 
restricted to this CO‐releaser compound since not only ALF062 but also other 
transition  metal  carbonyls,  like  Na[Mo(CO)3(histidinate)]  and 
Na3[Mo(CO)3(citrate)],  are  reported  to  promote  hydroxyl  radical  formation 

















suggesting  that  CORM‐2  oxidizes  free  thiol  groups  of  amino  acids,  most 
probably  due  to  its  ability  to  produce  ROS  in  vitro.  These  results  are  in 
agreement with the fact that thiol donors, like cysteine, are able to cancel the 
effects  of  CORM‐2  on  bacterial  growth,  which  was  observed  by  us  in  the 
present work and by other authors when using CORM‐3 against P. aeruginosa 
(Desmard et al., 2009). 
  The  work  described  herein  shows  that  bacterial  cells  treated  with 
CORM‐2  have  higher  amounts  of  ROS.  The  fact  that  other  authors  did  not 
observe  any  increase  in  H2O2  production  in  P.  aeruginosa  cells  exposed  to 
CORM‐3 may be due to the experimental conditions utilized. Nevertheless, the 
addition  of  the  antioxidant N‐acetyl  cysteine  (NAC)  abolished  the  CORM‐3‐
mediated  inhibition  of  bacterial  growth  (Desmard  et  al.,  2009). Moreover, 




mediate  cell  death  through  hydroxyl  radical  formation  in  bacteria  and  that 
there exists a relationship between antibiotic susceptibility and production of 
ROS  (Becerra  &  Albesa,  2002;  Kohanski  et  al.,  2007;  Dwyer  et  al.,  2009). 
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Figure S4.1| ALF062 generates ROS in vitro. EPR spectra of ALF062 in an
oxygenated (A) and degassed solution (B).
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Summary| Helicobacter pylori is a pathogen that establishes long life 
infections responsible for chronic gastric ulcer diseases and a proved risk 
factor for gastric carcinoma, which is a leading cause of cancer-related death 
in the world. In spite of the use of a multi-antibiotic therapeutics, the 
increasing number of resistant H. pylori strains makes urgent the development 
of alternative treatments. We report that H. pylori is killed by carbon-
monoxide releasing molecules, such as CORM-2 and CORM-3, with minimal 
inhibitory concentration (MIC) of 200 and 420 mg/L, respectively. In particular, 
CORM-2 is shown to inhibit the urease activity and bacterial respiration of H. 
pylori. Analysis of several clinical isolates of H. pylori that are resistant to 
metronidazole showed to be susceptible to CORM-2 treatment. Moreover, the 
MIC values for metronidazole of H. pylori clinical strains significantly decrease 
upon exposure to sub-lethal doses of CORM-2. In key cells of the innate 
immune system, such as macrophages, CORM-2 alone and together with 
metronidazole was found to strongly reduce the survival of H. pylori. Thus, CO-
RMs represent a novel class of antimicrobial therapeutic agents with potential 
to be clinically useful in the treatment of H. pylori infections.  





Helicobacter pylori is a pathogen that colonizes the gastric mucosa of 
humans and is ubiquitous in over half the world’s population. Once acquired, 
H. pylori establishes lifelong infections that are the major cause of gastric and 
duodenal ulcer diseases, and malignant gastric cancer (Graham, 2000; Kusters 
et al., 2006; McColl, 2010; Sachs & Scott, 2012). H. pylori uses several factors 
that enable colonization (Clyne et al., 2007; Fischer et al., 2009; Molnar et al., 
2010). In particular, the activity of the nickel-dependent urease is essential for 
the survival and pathogenesis of the bacterium as this enzyme hydrolyses urea 
to ammonia, which neutralizes the stomach acidity (Stingl & De Reuse, 2005; 
Zanotti & Cendron, 2010). The more widely used antibiotics for treatment of 
H. pylori are metronidazole, clarithromycin, amoxicillin and tetracycline 
(Rimbara et al., 2011). Other antibiotics such as ciprofloxacin, levofloxacin and 
furazolidone are also utilized, in particular, as alternative or second line 
treatment (Dore et al., 2012; Fakheri et al., 2012; Gisbert et al., 2013). 
However, when given as monotherapy none of these drugs are effective 
enough to eradicate H. pylori. Hence, infections with H. pylori are usually 
treated with a combination of drugs, which consists of two or three antibiotics 
together with an acid-suppressive drug (a proton pump inhibitor, e.g. 
omeoprazole) (Rimbara et al., 2011). However, the efficacy of these multiple 
antibiotic therapies is decreasing mainly due to the crescendo occurrence of 
antibiotic-resistant H. pylori strains. Especially, metronidazole resistant strains 
are a major cause of H. pylori treatment failure (Megraud, 2004; Graham et 
al., 2007). 
 The endogenous production of carbon monoxide (CO), via the 
mammalian haem oxygenase (HO), exerts benefits in the neural, 
cardiovascular and renal systems (Li et al., 2007). Moreover, it has remarkable 



















impact on microbial sepsis as HO-1 deficient mice display enhanced 
susceptibility to polymicrobial infections, and the administration of exogenous 
CO rescues the HO-1-deficient mice from sepsis-induced lethality (Chung et al., 
2008). The CO-releasing molecules (CO-RMs) are metal carbonyls that have 
been used to administrate CO exogenously (Mann, 2010; Motterlini & 
Otterbein, 2010), and have potential medical applications. More recently, CO-
RMs were demonstrated to kill pathogens such as Escherichia coli, 
Staphylococcus aureus (Nobre et al., 2007), and Pseudomonas aeruginosa 
(Desmard et al., 2009). The antimicrobial action of CO-RMs results from the 
binding of CO to haemoproteins, including those of the respiratory chain, 
together with the generation of intracellular oxidative stress, which 
deteriorates DNA, lipids, and proteins (Tavares et al., 2011). In this work, the 
bactericidal effect of CO-RMs was analysed for several H. pylori strains, and 
the mechanisms that underpin the antimicrobial properties were addressed. 
The effect of CO-RM on H. pylori during infection of animal cell lines was also 
studied.  
5.2 Material and methods 
Reagents  
 Two different sources of CO were used, namely the 
tricarbonylchloro(glycinate)ruthenium (II), CORM-3 (Alfama), and the 
tricarbonyldichlororuthenium (II) dimer, CORM-2 (Sigma). These compounds 
were freshly prepared as a 10 or 20 mM stock solution by dissolution in pure 
distilled water and dimethyl sulfoxide (DMSO), respectively. 
Dichlorotetrakis(dimethyl sulfoxide) ruthenium (II) (Strem chemicals) dissolved 
in DMSO, was used as the inactive form of Ru-based CORM-2 (iCORM-2). To 
take into consideration that CORM-2 is a dimer, the iCORM-2 concentration 




used in each assay was always twice the concentration of CORM-2. 
Metronidazole (MTZ), amoxicillin (AMX), and clarithromycin (CH) (all from 
Sigma) were dissolved in pure distilled water.  
 
Bacterial strains, growth conditions and viability assays 
 Helicobacter pylori 26695 was used as the reference strain and the 
clinical strains were isolated from human gastric biopsies, the latter belonging 
to the Instituto Nacional de Saúde Doctor Ricardo Jorge collection, Portugal. 
All H. pylori strains were routinely cultured, at 37ºC, under a microaerobic 
atmosphere (6% O2, 7% CO2, 3.5% H2 and 83.5% N2) created by means of an 
Anoxomat system (MART Microbiology). Growth was performed in horse 
blood-agar (HBA, Oxoid) plates and in brain heart infusion (BHI, Oxoid) liquid 
medium, both supplemented with an antibiotics/fungicide cocktail. The 
cocktail consisted in a mixture of vancomycin (12.5 mg/L), polymyxin B (0.3 
mg/L), trimethoprim (6.3 mg/L) and amphotericin B (5.0 mg/L). The liquid 
medium was further supplemented with 10% (v/v) decomplemented fetal calf 
serum (FCS, Gibco-Invitrogen) or with 0.2% β-cyclodextrin (βCD, Sigma). 
 To analyse the susceptibility of H. pylori to CO-RMs, cells cultured on 
HBA plates, for 24 h were used to inoculate 10 mL of BHI-FCS liquid media 
contained in 25 cm3 cell culture flasks (Nunc). After a 16 h incubation period, 
these cultures were used as starter cultures to inoculate H. pylori in 10 mL 
BHI-βCD at an optical density at 600 nm (OD600nm) ~0.05. Immediately after 
inoculation, CORM-3, CORM-2, iCORM-2 and/or MTZ were added to cultures 
and growth was monitored by recording the OD600nm for 20 h. At selected 
times, the number of viable cells was evaluated by measuring the colony-
forming unit per milliliter (CFU/mL) formed upon plating serial dilutions on 
HBA plates, which were incubated three days, at 37ºC, under a microaerobic 



















atmosphere. When indicated, the H. pylori growth was performed as 
described above in the presence of 5 mM reduced glutathione (Sigma) and 5 
mM cysteine (Fluka). The H. pylori morphology was examined after staining 
the bacteria with the Gram-staining kit (Fluka) and using a Leica DMRB 
microscope with 100 x objective. 
 
Determination of the minimal inhibitory concentration and minimal 
bactericidal concentration   
 The minimal inhibitory concentration (MIC) and the minimal 
bactericidal concentration (MBC) were determined for CORM-3, CORM-2 and 
antibiotics accordingly with (Albertson et al., 1998). To this end, starting 
cultures of H. pylori 26695 and clinical isolates, prepared as described above, 
were used to inoculate fresh BHI-βCD medium to an OD600nm of ~0.05, and 
aliquots of 1.2 mL were distributed in 24 well-plates (Sarstedt). For each 
antibiotic the following range of concentrations were used with increasing 
doubling concentrations: MTZ 0.5-256 mg/L, AMX 0.001-0.250 mg/L and CH 
0.001-0.250 mg/L. CORM-3 and CORM-2 were used from 50-600 mg/L with 50 
mg/L intervals. After microaerobic incubation for 72 h, at 37ºC and 90 rpm, 
MICs were determined by reading the optical density at 600 nm. For the MBCs 
determination, 10 µL of each culture was then applied on HBA plates and 
incubated for another 72 h.  
 
Oxygen consumption assays 
 H. pylori cultures grown for 15 h in BHI-βCD were harvested by 
centrifugation (5 min, 12000 × g, 4 °C), washed and resuspended in 10 mM 
potassium phosphate buffer (pH 7.0). Bacterial suspensions were incubated, 
for 5 min, with CORM-2 (25 mg/L), iCORM-2 (50 mg/L) or left untreated. The 




O2 consumption of H. pylori was stimulated by addition of sodium pyruvate (5 
mM), and monitored in a Rank Broths oxygen electrode (Hansatech). 
 
Urease activity assay 
 The urease activity was measured in H. pylori 26695 cultures, grown as 
described previously, for 15 h, in BHI-βCD in the absence and in the presence 
of 200 mg/L CORM-2 or iCORM-2, which, before analysed, were diluted in the 
same medium, to achieve a final concentration of 1 x 108 CFU/mL (OD600nm 
~0.1). The effect of CORM-2 was also analysed in vitro, using increasing 
concentrations of CORM-2. In this case, a H. pylori suspension was prepared in 
PBS at 2x108 CFU/mL (OD600nm ~0.2), using cells grown for 24 h on HBA plates, 
and treated with CORM-2 (0, 2.5, 5, 12.5, 25, 50, 100 and 200 mg/L) for 15 
min.  
 Urease activity was determined by mixing 50 µL of each cellular 
suspension with 500 µL of a buffered solution (pH 6.9) containing 0.7 mM 
KH2PO4 (Roth), 0.7 mM Na2HPO4 (Roth), 300 mM urea (Sigma) and 0.1 mM 
phenol red (Sigma) for 30 min and assessed spectrophotometrically at 560 nm 
(Gu et al., 2004). 
 
Assay of Helicobacter pylori viability in macrophages 
 Murine macrophage cell line RAW264.7 (ATCC Tib71) was seeded with 
5 x 105 cells per well, in 24-well plates (Sarstedt) containing Dulbecco’s 
modified Eagle’s medium with 4.5 g/L glucose and 110 mg/mL sodium 
pyruvate (DMEM glutamaxTM, Gibco-Invitrogen) supplemented with 10% FCS, 
70 U/mL penicillin and 70 µg/mL streptomycin (Gibco-Invitrogen), and grown 
for 3 h at 37º C in humidified 5% CO2 atmosphere. At this point, macrophages 
were activated with 0.3 µg/mL gamma interferon (IFN-γ, Sigma), for 12 h. 



















Cultures of H. pylori 26695, grown as described above for the viability assays, 
in the presence of CORM-2, iCORM-2 and/or MTZ for 15 h, were washed three 
times with PBS (pH 7.4) and resuspended in infection medium (DMEM 
glutamaxTM supplemented with 10% FCS, without addition of antibiotics), at an 
initial bacterial content of ~5x108 CFU/mL). These bacterial suspensions (100 
µL) were used to infect macrophages contained in the same medium, at a 
multiplicity of infection (MOI) of ~100, for 3 and 6 h, at 37°C and 5% CO2. The 
bacterial content was determined by plating serial dilutions onto HBA plates, 
which were incubated for 3 days at 37ºC under microaerobic conditions. After 
counting the number of viable bacteria, the values were normalized to the 
initial value of CFU/mL obtain (before cultures were used to infect 
macrophages), and the percentage survival was determined by dividing the 
number of colonies obtained for treated cultures by those counted for 
untreated cultures, assuming that the CFU/mL of untreated cultures 
correspond to 100 % survival.  
 
Statistical analyses  
 Statistical analyses were performed with GraphPad Prism 5 (GraphPad 
Software), using, as indicated in each case, either One-way or Two-way 
ANOVA followed by a Bonferroni multiple comparison test. The Mann Whitney 
t test was used for the analysis of the MIC and MBC data, with the significance 
threshold at P < 0.05 (95 % confidence level). Data are presented as mean ± 








Figure 5.1| CO-RMs affect H. pylori 26695
viability. Cell viability of H. pylori 26695 left
untreated (filled circle) and treated with 100,
150 and 200 mg/L CORM-2 (open square,
triangle and diamond, respectively) (A), and
after exposure to 120, 240 and 300 mg/L
CORM-3 (open diamond, inverted triangle and
circle, respectively) (B). The number of viable
cells were determined for four biological
samples and are expressed as means ± SE.
*p<0.05, **p<0.01 and ***p<0.001 (Two-way
ANOVA and Bonferroni test).
5.3 Results and discussion 
Helicobacter pylori viability is inhibited by CO-RMs  
 To examine how CO-RMs affect the growth of H. pylori, CORM-2 and 
CORM-3 were added to cultures 
of H. pylori 26695 growing in 
BHI-βCD and incubated in a 
microaerobic atmosphere 
containing 6% O2, 7% CO2, 3.5% 
H2 and 83.5% N2. Both CO-RMs 
inhibited bacterial viability 
during a 20 h period, in a 
concentration-dependent 
manner (Figure 5.1). The effect 
mediated by CORM-2 was 
stronger than that exerted by 
CORM-3. Exposure of H. pylori 
to 200 mg/L CORM-2, for  15  h, 
induced a 4-log loss of viability 
(Figure 5.1A), while for the same 
period of time 300 mg/L CORM-
3 lowered the cell viability by 2-
logs (Figure 5.1B). Interestingly, 
for the same period of time,  the 
decrease of the H. pylori 
bacterial count exerted by 300 
mg/L CORM-2 was comparable 
to that caused by 1.5 mg/L 



















metronidazole (Figure 5.1A and S5.1). 
 Next, we determined for H. pylori 26695 the minimal inhibitory  
concentration (MIC) and the minimal bactericidal concentration (MBC) for the  
two CO-RMs, having obtaining the following values: for CORM-2 a MIC of 200 
mg/L and MBC of 250 mg/L, and for CORM-3 a MIC of 420 mg/L and MBC of 
510 mg/L. Furthermore, the ratio MBC/MIC was lower than 4 revealing the 
bactericidal character of the two drugs (Pankey & Sabath, 2004).  
Since some antibiotics were report to induce in H. pylori the formation 
of coccoid forms (She et al., 2001), we tested whether CO-RMs could promote 
similar modifications. However, even after 20 h exposure to 200 mg/L CORM-
2, the shape of the treated cells remained unaltered and the presence of 
coccoid forms was not observed (data not shown).  
CO-RMs used in this study are ruthenium-containing compounds that 
release CO when exposed to biological systems. To infer if the transition metal 
contributed to the antimicrobial effect induced by CO-RMs, the growth of H. 
pylori was analysed in the presence of dichlorotetrakis(dimethyl sulfoxide) 
ruthenium (II), the iCORM-2. However, iCORM-2 elicited no growth 
impairment up to 400 mg/L (Figure S5.2). Although ruthenium is not toxic by 
itself, we have previously demonstrated that the presence of the transition 
metal is needed to elicit the antimicrobial action, which relies on effects 
mediated by a network that involves CO liberation and ROS formation (Tavares 
et al., 2011). 
These data revealed that CO-RMs are effective antimicrobials against 
H. pylori, as previously reported for other pathogens as E. coli, S. aureus and P. 
aeruginosa (Nobre et al., 2007; Desmard et al., 2009). Since H. pylori was more 
effectively killed by CORM-2, the following experiments were performed with 
this compound. 




CORM-2 hinders H. pylori respiration  
 Given the high affinity of CO to haem-containing proteins, we next 
examined whether the lower viability of H. pylori in the presence of CO-RMs 
was mediated by inhibition of the cellular respiration. H. pylori cells, cultured 
as described above, were grown to the mid-exponential phase (~15 h), 
harvested, resuspended in buffer, and the O2 consumption rates determined 
by amperometric measurements with Clark-type O2 electrode. Cells left 
untreated and stimulated with pyruvate had a considerable oxygen reductase 
specific activity (~1.2 nmol O2/min/CFU). Incubation of the cells with 25 mg/L 
CORM-2 caused more than 50 % decrease in oxygen consumption when 
compared with untreated and iCORM-2-treated cells (Figure 5.2A). Similar 
findings have been reported for other bacteria as Campylobacter jejuni and E. 
coli (Davidge et al., 2009; Smith et al., 2011). 
 These results showed that CORM-2 inhibits cellular respiration, which 
is expected to induce the formation of reactive oxygen species (ROS). 
Furthermore, due to its chemical nature CO-RMs self-generated ROS that 
impact on bacterial survival (Tavares et al., 2011). In agreement, we observed 
that supplementation of H. pylori growth medium with antioxidant agents 
























CORM-2 inhibits the urease activity of H. pylori 
 In spite of the antimicrobial effect of CO-RMs on bacteria, the cellular 
targets remain largely unknown. H. pylori expresses significant amounts of a 
nickel-containing urease, which is a key enzyme in the metabolism of this 
pathogen during gastric colonization (Stingl & De Reuse, 2005). Since CO binds 
transition metals, we next determined whether CORM-2-derived CO altered 
the H. pylori urease activity. To this end, the urease activity of H. pylori grown 
in BHI-βCD and left untreated or treated for 15 h with iCORM-2 and with 
CORM-2 was compared.  The results showed  that while no differences were 
observed upon exposure to iCORM-2, the urease activity suffered a decrease 
of ~65% in cells treated with 200 mg/L CORM-2 (Figure 5.3A).  
Figure 5.2| CORM-2 inhibits the H.
pylori 26695 respiration. (A) Cellular
suspensions of H. pylori were left
untreated (black) and treated for 5 min
with 25 mg/L CORM-2 (white) and the
inactive form, 50 mg/L iCORM-2 (grey).
Oxygen consumption was measured,
after the addition of piruvate (5 mM) in
a Clark-type O2 electrode for two
biological samples of H. pylori assayed
in triplicate. Values are expressed as
means ± SE.***p<0.001, ns - non
significant (One-way ANOVA and
Bonferroni test). (B) H. pylori viability in
BHI-βCD medium (black) and after exposure to 200 mg/L CORM-2 alone (white)
and in the presence of 5 mM glutathione (dark grey) or 5 mM cysteine (light grey).
Values represent average of three biological samples with the respective SE.




Figure 5.3| Inhibitory effect of CORM-2
on urease activity of H. pylori 26695. (A)
Urease activity was measured in H. pylori
cells left untreated (black), treated for
15 h with 400 mg/L iCORM-2 (grey) and
200 mg/L CORM-2 (white). The results
represent the average of three biological
samples performed in duplicate, and
error bars represent the SE. ***p<0.001,
ns - non significant (One-way ANOVA
and Bonferroni test). (B) Urease activity
of H. pylori cell suspensions treated, for
15 min, with several concentrations of
CORM-2 (see Materials and methods) .
The results are the average of five
biological samples and error bars
represent SE.
To determine the half-maximal inhibitory concentration (IC50) of 
CORM-2 for the urease activity, cells of H. pylori grown for 24 h on HBA plates 
were used to prepare cell suspensions that were incubated for 15 min with 
increasing concentrations of CORM-2. Using CORM-2 concentrations up to 200 




These data revelead that the antimicrobial effect of CORM-2 on H. 
pylori is also associated with inhibition of urease activity, most probably due to 
the binding of CO to nickel for which CO has high affinity (Ermler et al., 1998; 
Drennan et al., 2001). Due to the crucial role of urease in the persistence of H. 
pylori in the gastric niche (Stingl & De Reuse, 2005), an urease inhibitor such as 
CORM-2 gains relevance as a novel way to control infections. Moreover, and 



















contrary with other potent urease inhibitors such as acetohydroxamic acid and 
fluorofamide (Phillips et al., 1993; Pope et al., 1998), CORM-2 is stable under 
the acidic conditions encountered by H. pylori, representing a clear advantage 
for H. pylori treatment {Johnson, 2007 #47; Funaioli, 1999 #48. 
 
CORM-2 is able to kill metronidazole-resistant H. pylori strains 
 H. pylori is a pathogen with a high degree of adaptation to the human 
stomach, which is reflected in high diversity of phenotype and antibiotic-
resistance of the clinical isolates. Hence, we next investigated the toxicity of 
CO-RMs towards H. pylori clinical strains 
isolated from human gastric biopsies 
with different degree of MTZ resistance 
(Table 5.1). The behavior of the clinical 
isolates when treated with CORM-2 
differed significantly, exhibiting MICCORM-2 
between 100 and 200 mg/L (Table 5.1). 
Moreover, CORM-2 acted as a 
bactericidal since the MBC/MIC ratios 
determined for all isolates were lower 
than four (Table S5.1). More importantly, 
while the MTZ-susceptible strains had the highest MICs to CORM-2 (MICCORM-2 
= 200 mg/L) (Table 5.1), the growth of MTZ-resistant clinical isolates (MICMTZ > 
8 mg/L) was inhibited by lower concentrations of CORM-2 (MICCORM-2 ≤ 150 
mg/L). The only exception occurred for the MTZ-resistant strain 4597, which 
exhibited the same MIC for CORM-2 than the MTZ-susceptible strains (Table 
5.1).  
 
Table 5.1| MICs of CORM-2 and 
metronidazole to the reference strain 
26695 and clinical isolates of H. pylori.
*S: Sensitive (MIC< 8 mg/L)















Combination of CORM-2 and antibiotics attenuates in vitro H. pylori 
viability 
 Since H. pylori infections are usually eradicate by means of triple or 
even quadruple therapies in which at least two drugs are antibiotics, we 
sought to analyse the effect of CORM-2 as an adjuvant of the currently used 
antibiotics. For this purpose, CORM-2 was conjugated with each one of the 
three most commonly antibiotics used to treat H. pylori, namely MTZ, 
amoxicillin (AMX) and clarithromycin (CH), and the MIC and MBC values were 
evaluated.   
 To this end, H. pylori 26695 was exposed to sub-lethal doses of CORM-
2 and, for each antibiotic, the MICs and MBC values were determined (Table 
S5.2). The addition of MTZ (1.5 mg/L) for 15 h resulted in a decrease of less 
than 2-log while a non significant alteration occurred with CORM-2 (100 mg/L) 
alone (Figure 5.4).  Simultaneous exposure to the two drugs resulted in a four-
log drop in recovered viable bacteria after 20 h of treatment (Figure 5.4). The 
effect of 100 mg/L CORM-2 in MTZ translated into a reduction of 50% of the 
MICMTZ (Figure 5.5 and Table S5.2). Likewise, conjugation of CORM-2 with AMX 
and CH led to a significant decrease of the MIC and MBC (Figure 5.5 and Table 
S5.2) that, like for MTZ, was more pronounced for higher concentrations of 
CORM-2 further confirming the influence of the drug on the measure values 
(Figure 5.5). The effect of combining MTZ with CORM-2 was also tested for all 
H. pylori clinical isolates. At least, a twofold decrease of the MICMTZ was 
observed, with the highest MTZ resistant strains exhibiting the more 
significant drop of the MIC and MBC values (Figure 5.6). For example, the 
clinical isolate H. pylori 5611 (MICMTZ = 64 mg/L) become susceptible (MICMTZ = 
8 mg/L) when the MTZ was administrated together with 100 mg/L CORM-2 
(Tables S5.3 and S5.4).  



















Figure 5.4| Effect of combined metronidazole and CORM-2 treatment on H. pylori
viability. Cell viability of H. pylori 26695 left untreated (black) and exposed to
iCORM-2 (dark grey), 100 mg/L CORM-2 (white), 1.5 mg/L metronidazole (light
grey), 1.5 mg/L me tronidazole and 200 mg/L iCORM-2 (light grey, diagonal strips)
and 1.5 mg/L metronidazole and 100 mg/L CORM-2 (light grey, horizontal strips).
The number of viable cells were determined for four independent cultures and are
















































Figure 5.5| CORM-2 decreases the MIC and MBC values of metronidazole,
amoxicillin and clarithromycin for H. pylori 26695. (A) MICs and (B) MBCs of H.
pylori 26995 for metronidazole, amoxicillin and clarithromycin determined in the
absence (black) and in the presence of 100 mg/L (dark grey) and 150 mg/L CORM-2
(light grey). Results representing the median of five biological samples are
significantly different in all cases (p<0.05 in Mann Whitney t test).





CO-RM treated H. pylori compromises in vivo bacterial survival  
 Upon pathogen invasion the mammalian immune system triggers an 
arsenal of weapons aiming to eliminate the harmful microbe. Professional 
phagocytes, such as macrophages, play a key role due to the damage inflicted 
to invaders. Since H. pylori is known to trigger the innate immune system it is 
important to evaluate the effect of CORM-2 upon bacterial infection of 
macrophages. Hence, the viability of CORM-2-treated H. pylori was analysed in 
the murine macrophage cell line RAW264.7. To this end, H. pylori 26695 cells 
remained unexposed, and exposed to the inactive form iCORM-2, and to 
CORM-2 were incubated with activated macrophages and their viability 
evaluated by colony formation after 3 and 6 h post-infection. For similar viable 
bacterial loads, the iCORM-2-treated H. pylori was as resistant to macrophages 
as untreated bacterial cells. On the contrary, the survival of the CORM-2-
Figure 5.6| CORM-2 lowers the MIC and MBC of metronidazole for H. pylori
clinical isolates. (A) MIC of metronidazole was determined for each H. pylori
clinical isolate in the absence (grey) and in the presence of 50 mg/L (strains 5846
and 5587), 100 mg/L (strains 5611 and 4574) and 150 mg/L CORM-2 (strains
5599 and 4597) (black). (B) MBC of metronidazole obtained for H pylori clinical
isolates, in the absence (grey) and in the presence of 100 mg/L (strains 5846 and
5587) and 150 mg/L (strains 5611, 4574, 4597 and 5599) CORM-2 (black). In all
cases, values representing the median of five biological samples were


































































Figure 5.7| CORM-2-treated H. pylori 26695 is more susceptible to macrophage
killing. Macrophages RAW264.7, pre-activated with IFN-γ (0.3 µg/mL) for 12 h,
were infected (MOI ~100) with H. pylori untreated (black), treated with 400 mg/L
iCORM-2 (grey) or 200 mg/L CORM-2 (white). Bacterial survival was determined
after 3 and 6 h of infection for five biological samples analysed in triplicate. Error
bars represent the SE. ***p<0.001, ns - non significant (Two-away A NOVA and
Bonferroni test).
treated H. pylori was approximately 98% lower in comparison to cells exposed 











Combined CORM-2-MTZ strongly reduces in vivo survival of H. pylori 
 Given that the combination of CORM-2 with MTZ reduced the in vitro 
viability of H. pylori, we sought to determine the survival of the double-treated 
H. pylori when in contact with activated macrophages. Sub-lethal 
concentrations of CORM-2 conjugated with MTZ led to a ~98% decrease in 
bacterial count, while no significant alteration was seen when infecting with 
cells treated with CORM-2 or iCORM-2 alone, and a ~30% survival was 
observed for cells exposed to MTZ alone or MTZ plus the inactive form of 




CORM-2 (Figure 5.8). This allows concluding that the co-administration of 
MTZ-CORM-2 renders H. pylori more susceptible to in vivo macrophage killing. 
 
In conclusion, this work provides evidences that CO-RMs constitute a 
promising therapeutic strategy for the treatment of H. pylori, as they are 
efficient antimicrobials both alone and as co-adjuvants with the antibiotics 
currently used to treat H. pylori. This is important data since chronic 
colonization with H. pylori antibiotic-resistant strains is difficult to eradicate 
and combined therapies are among the more effective means to combat 
resistant strains. 
 
Figure 5.8| H. pylori 26695 treated with metronidazole plus CORM-2 are higly
susceptible to macrophage killing. Macrophages RAW264.7, pre-activated with
IFN-γ (0.3 µg/mL) for 12 h, were infected at a MOI of ~100 with H. pylori untreated
(black), treated with 200 mg/L iCORM-2 (dark grey), 100 mg/L CORM-2 (white), 1.5
mg/L metronidazole (light grey), metronidazole with iCORM-2 (grey, diagonal
strips) and metronidazole with 100 mg/L CORM-2 (grey, horizontal strips). Bac terial
survival was determined after 3 and 6 h of infection. The results are the average of
five biological samples performed in triplicate, and error bars represent the SE.
*p<0.05, **p<0.01, ns - non significant (Two-way ANOVA and Bonferroni test).
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Figure S5.2| iCORM-2 has no effect on H. pylori viability. H. pylori 26695 left
untreated (black) and after exposure to 200, 300 and 400 mg/L iCORM-2 (dark
grey, white and light grey bars, respectively). Cell viability was determined as
described in Material and Methods. Values represent the average values of three
biological samples with SE.
5.6 Supplementary data 
 
 
Figure S5.1|Effect of MTZ on H. pylori viability. H. pylori 26695, grown as
described in Material and Methods, was treated with 1.5 and 2 mg/L
metronidazole (black and white squares, respectively) or left untreated (black
circle). Cell viability was analysed at the indicated times by determining CFU/mL.
Values represent average values of two biological samples with the respective SE.




Table S5.1| MIC and MBC of CORM-2 and metronidazole (MTZ)







MBC/MICMIC MBC MIC MBC
26695 200 250 1.3 8 16 2
5599 200 200 1.0 2 8 4
5611 150 200 1.3 64 64 1
5846 100 150 1.5 16 64 4
4597 200 200 1.0 32 128 4
4574 150 200 1.3 32 64 2
5587 100 150 1.5 32 32 1
*S: Sensitive (MIC<8 mg/L)
R: Resistant (MIC>8 mg/L)
Table S5.2| MIC and MBC of metronidazole (MTZ), clarithromycin (CH) and amoxicillin (AMX)
for H. pylori 26695 determined in the presence of sub-lethal doses of CORM-2. 
CORM-2 
(mg/L)
MIC (mg/L) MBC (mg/L) MBC/MIC
MTZ CH AMX MTZ CH AMX MTZ CH AMX
0 8 0.016 0.125 16 0.032 0.25 2 2 2
100 4 0.008 0.064 16 0.008 0.125 4 1 2



















































Table S5.3| MIC of metronidazole with sub-lethal doses of CORM-2 




5599 5611 5846 4597 4574 5587
0 2 64 16 32 32 32
50 2 16 8 32 32 16
100 1 8 - 4 16 -
150 0.5 - - 1 - -
Table S5.4| MBC of metronidazole with sub-lethal doses of CORM-2 




5599 5611 5846 4597 4574 5587
0 8 64 64 128 64 32
50 8 64 16 64 64 32
100 2 16 8 16 32 16
150 1 8 - 8 4 -
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Antibiotics revolutionized the treatment of infectious diseases having 
saved countless lives since their introduction in clinical practice in the middle 
of the last century. However, due to its widespread use many antibiotics are 
not as effective as they used to be, because bacteria have developed 
mechanisms to avoid the deleterious effects of these drugs (e.g. mutations in 
existing genes and acquisition of resistance genes from other organisms). In 
order to overcome this problem, it is crucial to have a deeper understanding 
of the mechanisms of antibiotic action and to develop new approaches to fight 
antibiotic-resistant bacteria. 
 
6.1 The role of a novel S. aureus nitroreductase 
In an era of great concern about resistance of S. aureus to several anti-
infective agents, it is interesting to note that, even after several decades of 
clinical use, nitrofurans are still active against strains resistant to other drugs 
such as MRSA (Shah & Wade, 1989; Flournoy & Robinson, 1990; Johnson et al., 
1993; Johnson et al., 1999; Guay, 2001; Barisic et al., 2003; Ionescu et al., 
2010). Nitrofurans action is dependent on the reduction of the nitro group by 
bacterial nitroreductases (see section 1.2). Indeed, early studies have 
demonstrated an inverse correlation between nitrofurantoin MICs of urinary 
tract pathogens and their nitroreductase activity levels (McOsker et al., 1989). 
Later, Whiteway and co-workers established a direct link between mutations 
in nfsA and nfsB nitroreductases of E. coli, and the development of bacterial 
resistance to nitrofurans (Whiteway et al., 1998). Importantly, S. aureus 
clinical strains are usually susceptibility to both nitrofurantoin and 
nitrofurazone, which suggests the presence of enzymes capable of activating 
these nitroaromatic compounds to yield toxic species (Guay, 2001; Barisic et 
al., 2003; Ionescu et al., 2010). In fact, a search in the genome of S. aureus 




NCTC 8325 revealed the presence of four putative nitroreductases, namely 
SAOUHSC_00833, SAOUHSC_02829, SAOUHSC_02258 and SAOUHSC_00366. 
To date, the S. aureus nitroreductase SAOUHSC_00366, named NfrA, was the 
only one studied, which showed the ability to catalyze the NADPH-dependent 
reduction of nitrofurantoin and nitrofurazone (Table 6.1) (Streker et al., 2005). 
In this thesis, the role of the putative nitroreductase SAOUHSC_00833 of S. 
aureus in nitrofurans metabolism was addressed (Chapter 3). S. aureus 
SA0UHSC_00833, which was herein named NtrA, was demonstrated to reduce 
nitrofurans with values that are within the range of activities usually observed 
for bacterial nitroreductases (Table 6.1).  
 
                 Table 6.1| Bacterial nitroreductase activities. 





 of protein)) 
 
Bacteria NTR Nitrofurantoin Nitrofurazone References 
E. coli 
NfsA 82 73 (Zenno et al., 1996a) 
NfsB 21* 13* (Zenno et al., 1996b) 
S. aureus 
NfrA 15 20 (Streker et al., 2005) 
NtrA 14 15 (Tavares et al., 2009) 
H. pylori 
RdxA 0.0010 0.0019 (Olekhnovich et al., 2009) 
FrxA 2.0 0.5 (Sisson et al., 2002) 
B. subtillis NfrA1 ND 97 (Zenno et al., 1998) 
NADPH was used as electron donor 
* NADH was used as electron donor 
ND – not determined 
 
Since NtrA was capable of reducing nitrofurans under aerobic 
conditions, it could be inferred that this enzyme belongs to the family of 
oxygen-insensitive nitroreductases (see section 1.2.1). A previous phylogenetic 












insensitive nitroreductases into two main groups that are represented by NfsA 
and NfsB of E. coli (Roldan et al., 2008). Interestingly, the amino acid sequence 
of NtrA has no significant homology with either NfsA or NfsB family of 
nitroredutases, and our phylogenetic analysis revealed that S. aureus NtrA 
belongs to a novel family of bacterial nitroreductases (Figure 3.3). This family 
includes several other putative nitroreductases such as those from Listeria 
inocua, Rubrobacter xylanophilus and Nitrobacter winogradskyi (Table 6.2 and 
Figure 3.3). 
Similar to nitroreductases of the group represent by NfsB of E. coli, the 
S. aureus NtrA was able to use both NADH and NADPH as a source of reducing 
equivalents, unlike those from NfsA group that only could use NADPH (see 
section 1.2.1). Interestingly, FMN cofactor was reported to be the most 
effective electron acceptor in S. aureus NtrA, as previously acknowledged to 
nitroreductases from both NfsA and NfsB groups (Zenno et al., 1996a; 
Watanabe et al., 1998; Streker et al., 2005).  
In this work, S. aureus NtrA was shown to contribute to the in vivo 
antimicrobial activity of nitrofurans. Indeed, the ntrA mutation in S. aureus 
resulted in an increased nitrofuran resistance which is consistent with the 
involvement of NtrA in the activation of these antibiotics (Figure 3.2). In 
agreement with the increased resistance of S. aureus ntrA mutant to 
nitrofurans, lower nitroreductase activity was measured in cell extracts of this 
mutant strain (Table 3.1). Moreover, mutation of nfrA (SAOUHSC_00366) of S. 
aureus also led to a higher resistance to nitrofurans (our unpublished results). 
Hence, it is here recognized a relation between nitroreductases and the 
bacterial susceptibility to nitrofurans in S. aureus.  
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Ec- Escherichia coli; Sa – Staphylococcus aureus; Bs – Bacillus subtillis; Hp – Helicobacter 
pylori; Li – Listeria inocua. 
 
Further studies, as growth phenotype of strains mutated in the other 
two S. aureus nitroreductases, namely SAOUHSC_02829 and SAOUHSC_02258, 
as well as its biochemical characterization need to be performed to evaluate 
their contribution to S. aureus nitrofuran activation. Furthermore, it would be 
interestingly to analyse whether there is a relation between the degree of 
nitrofuran resistance in S. aureus clinical strains and mutations in the genes 












Nitroreductases co-administration could be used as a therapeutic 
strategy to increase bacterial susceptibility to nitrofurans, which could be 
relevant in case of multiple antibiotic resistances. Interestingly, co-
administration of E. coli nitroreductases for direct anticancer therapy has 
already been suggested, as they are also able to promote activation of 
prodrugs in tumor cells (Johansson et al., 2003; Searle et al., 2004; Vass et al., 
2009).  
Besides the role of S. aureus NtrA in nitrofurans activation, this work 
also showed the involvement of NtrA in the metabolism of GSNO, an 
important biological NO donor. GSNO induced the transcription of ntrA gene, 
as also previously seen in a DNA microarray study using S-nitroso N-acetyl DL-
penicillamine (SNAP) as NO donor (Richardson et al., 2006). In addition, we 
observed that H2O2 induced the transcription of ntrA gene (our unpublished 
results), consistent with earlier reports of the involvement of nitroreductases 
in oxidative stress response and cellular redox balancing (see section 1.2.1), 
such as, E. coli NfsA, Rhodobacter capsulatus NprA, B. subtilis NfrA and S. 
aureus NfrA (Liochev et al., 1999; Mostertz et al., 2004; Perez-Reinado et al., 
2005; Streker et al., 2005).  
In this work, S. aureus NtrA was demonstrated to be able to detoxify 
GSNO (Table 3.2). In S. aureus, only flavohemoglobin Hmp was until now 
reported to counteract nitrosative stress (Goncalves et al., 2006). 
Interestingly, our group has recently shown that Hmp is also involved in 
antibiotics action, by enhancing the antimicrobial activity of several imidazoles 
such as miconazole (Nobre et al., 2010).  
The fact that a single protein combines two activities seems to be a 
common factor among GSNO reductases. Indeed, GSNO reductase activity is 
always found in proteins that exhibit another enzymatic activity, namely, in 




glutathione-dependent formaldehyde dehydrogenase (FALDH), glutathione 
peroxidase, xanthine oxidase and thioredoxin system (Hou et al., 1996; 
Nikitovic & Holmgren, 1996; Trujillo et al., 1998; Liu et al., 2001; Laver et al., 
2012). However, S. aureus NtrA is the first case of a nitroreductase displaying 
GSNO reductase activity. The KM obtained in this work for S. aureus NtrA is in 
the same range of values usually observed for other GSNO reductases, despite 
the great variety of values reported (Table 6.3). S. aureus NtrA detoxifies 
GSNO with higher affinity than the E. coli FALDH, with a KM approximately 4-
fold lower than that reported for the E. coli FALDH (Table 6.3) (Liu et al., 2001). 
The KM of S. aureus NtrA for GSNO is similar to that of the Saccharomyces 
cerevisiae FALDH, whereas the human and rat FALDHs have higher affinities 
(Table 6.3) (Jensen et al., 1998; Fernandez et al., 2003). Concerning 
thioredoxins, the KM values for GSNO as a substrate for M. tuberculosis, 
human and Plasmodium falciparum were reported to be lower than that for S. 
aureus NtrA (Table 6.3) (Attarian et al., 2009). 
 




KM (µM) References 
S. aureus NtrA 181 (Tavares et al., 2009) 
E. coli FALDH 700 (Liu et al., 2001) 
Saccharomyces 
cerevisiae 
FALDH 150 (Fernandez et al., 2003) 
Human 
FALDH 27 (Fernandez et al., 2003) 
Thioreroxin 60 (Attarian et al., 2009) 
Rat FALDH 28 (Jensen et al., 1998) 
M. 
tuberculosis 
Thioreroxin 4 (Attarian et al., 2009) 
Plasmodium 
falciparum 












The mechanism by which nitroreductase NtrA detoxifies this S-
nitrosothiol (GS-N=O), which resembles the nitroso intermediate (R-N=O), may 
be analogous to the nitrofuran reduction via the hydroxylamine intermediate 
(see section 1.2 - Figure 1.5). Additionally, the S. aureus NtrA seems to be 
specific to GSNO, since no activity was observed for NO, S-nitrosocysteine and 
S-nitrosohomocysteine. Similar results were obtained for the E. coli FALDH (Liu 
et al., 2001). 
Our data also demonstrated that NtrA affords in vivo protection as a 
mutant strain exhibited increased susceptibility to GSNO killing (Figure 3.1). 
Similar results were reported for the FALDH mutant strains of Saccharomyces 
cerevisiae, Streptococcus pneumoniae and Haemophilus influenza (Liu et al., 
2001; Kidd et al., 2007; Stroeher et al., 2007). H. pylori mutants in thioredoxin 
systems also had increased susceptibility to GSNO (Comtois et al., 2003).  
In summary, this work showed that the S. aureus NtrA is a bifunctional 
enzyme involved in nitrofurans activation and protection against nitrotrosative 
stress. 
 
6.2 Dissecting the bactericidal action mechanism of Carbon Monoxide-
Releasing Molecules 
Previous work have shown that CO-RMs may constitute a therapeutic 
strategy to control bacterial infections due to its effectiveness in eliminating 
pathogens as E. coli, S. aureus and P. aeruginosa (Nobre et al., 2007; Desmard 
et al., 2009). In this thesis, the bactericidal mechanism underlying the action 
of CO-RMs was analysed (Chapter 4). So far, the antimicrobial effect of CO-
RMs has been attributed mainly to the inhibition of the aerobic respiratory 
chain through the binding of CO to terminal oxidases (Davidge et al., 2009; 
Desmard et al., 2009). Indeed, CO-RMs were shown to decrease the 




respiratory rates in E. coli, P. aeruginosa and C. jejuni (Davidge et al., 2009; 
Desmard et al., 2009; Smith et al., 2011).  
In mammals, the binding of CO to terminal oxidases with consequent 
inhibition of mitochondrial respiration and increased ROS production has been 
reported (Gutterman, 2005; Boczkowski et al., 2006; Zuckerbraun et al., 2007; 
Lo Iacono et al., 2011). The ROS produced are proposed to act as a second 
messenger for CO, mediating activation of signaling pathways (Boczkowski et 
al., 2006; Zuckerbraun et al., 2007). The activation of the signal transduction 
pathways, such as the mitogen-activated protein kinases (MAPK) mediate the 
anti-inflammatory, cytoprotective and anti-proliferative effects that CO 
exerted (Soares & Bach, 2009). In particular, administration of CO-RMs to 
cultured smooth muscle from human airways inhibits muscle proliferation by 
stimulating mitochondrial production of ROS (Taille et al., 2005). Interestingly, 
addition of N-acetylcysteine partially impairs the effects of CORM-2, 
suggesting a role for ROS in the anti-proliferative effect of CO in human airway 
smooth muscle (Taille et al., 2005). The anti-inflammatory effects of CO have 
also been reported to be dependent on ROS generated via inhibition of the 
cytochrome c oxidase since the effects are abolished when the ROS generation 
is impaired (Zuckerbraun et al., 2007; Bilban et al., 2008). Recently, it was 
established that CO confers protection in acute lung injury by promoting 
activation of autophagy also via mitochondrial ROS formation (Lee et al., 
2011). 
The data presented in this thesis reveal that oxidative stress mediates 
the bactericidal effect elicited by CO-RMs. Indeed, E. coli cells exposed to CO-
RMs, namely CORM-2 and ALF062, contained higher level of intracellular ROS, 
which was abolished by adding the antioxidant glutathione and the CO 












of CO were unable to generate ROS. In agreement with these results, Smith 
and co-workers detected H2O2 production in C. jejuni after exposure to CORM-
3 (Smith et al., 2011). More recently, increased ROS formation upon CORM-2 
treatment was also reported for P. aeruguinosa (Murray et al., 2012). In that 
study, although the treatment with the antioxidant cysteine only partly 
inhibited ROS formation, N-acetylcysteine was able to completely prevent the 
ROS production (Murray et al., 2012). Contrary to these findings, Desmard and 
co-workers reported that in P. aeruginosa, CO-RMs, such as CORM-2, CORM-3 
and CORM-A1, did not induce increase of ROS content (Desmard et al., 2011). 
However, the authors observed that N-acetylcysteine, cysteine and 
glutathione, well-known by their antioxidant properties, canceled the 
bactericidal effect of CO-RMs, which suggests that ROS are contributing to 
their antimicrobial action. The fact that these authors did not detect ROS 
production is most probably due to the conditions used in the assay. In those 
experiments, the fluorescence probe was added during the growth of bacteria 
that last for 60 min, and only then the cells were washed and incubated with 
CO-RM. As this probe crosses the membranes and is oxidized by several 
agents, the 60 min of incubation within cells is expected to significantly 
decrease the amount of probe molecules left available to be oxidized by the 
ROS produced by the CO-RM, therefore strongly limiting the detection of 
these species (Desmard et al., 2011).  
Other evidences linking the action of CO-RMs to the generation of ROS 
have been presented in this thesis. In particular, when ROS production was 
inhibited by antioxidants as glutathione and cysteine, the lethality of the CO-
RMs was abolished (Figure 4.2). Moreover, strains deleted in ROS detoxifying 
systems, namely catalase and superoxide dismutase had increased 
susceptibility to CORM-2, highlighting the contribution of ROS to drug killing 




(Figure 4.5). Additionally, CORM-2 was shown to induce DNA damage and to 
interfere with iron homeostasis (Figure 4.6, 4.7, 4.8 and 4.9). The intracellular 
levels of free iron increased by four times upon CORM-2 treatment, and Fe-S 
centres were shown to be one of the iron sources (Figure 4.7 and 4.9). 
Moreover, among the bacterial systems that remediate hydroxyl radical 
damage, recA, which is involved in triggering the DNA damage response, was 
shown to be required to counteract CO-RMs action (Figure 4.6). Finally, 
CORM-2 promoted oxidation of free thiols groups (Figure 4.10). Interestingly, 
reuterin, an antimicrobial compound that induces oxidative stress, was also 
described to oxidize thiol groups of proteins and small molecules, losing its 
antimicrobial effect upon supplementation of E. coli cultures with cysteine 
(Schaefer et al., 2010). Besides the critical role of cysteine in thiol-redox 
systems, this amino acid is also essential in the structure of Fe-S clusters, 
which are a well known target of oxidative stress (Figure 4.9). Altogether, 
these results allowed concluding that the mechanisms that underlay the killing 
effect of CO-RMs on bacteria include the production of ROS. 
Since CO-RMs mediate bacterial cell death through ROS formation, it is 
predictable that the gene expression profile of E. coli in the presence of CO-
RMs under aerobic conditions share similarities with the transcriptional 
response to hydrogen peroxide (Table 6.4) (Zheng et al., 2001; Davidge et al., 
2009; Nobre et al., 2009; Wang et al., 2009). In particular, genes involved in 
folding and stability of proteins, one of ROS main targets, such as the heat 
shock proteins hptX, ibpA and ibpB, and chaperones like dnaK, dnaJ and hslO 
were induced by oxidative stress and CO-RMs. The yqhD gene encoding an 
alcohol dehydrogenase proposed to protect cells against lipid oxidation, and 
yeeD, gene coding for a redox protein that regulates the formation of disulfide 












al., 2008; Nobre et al., 2009; Wang et al., 2009). Furthermore, CORM-2 
induced the expression of genes related with the two major transcriptional 
regulators of oxidative stress, OxyR and SoxRS (Nobre et al., 2009). In 
particular, CORM-2 increased the expression of the soxS gene and of members 
of the SoxRS regulon, such as the marAB operon, that encodes a multiple 
antibiotic resistance protein, and micF coding for a major outer membrane 
porin (Nobre et al., 2009). Moreover, the E. coli soxS mutant was shown to be 
more susceptibility to CORM-2 than the parental strain (Nobre et al., 2009). 
Although CORM-2 induced the transcription of oxyR, no gene of the regulon 
was found altered under the microarray experimental conditions utilized 
(Nobre et al., 2009). Nevertheless, oxyR mutant exhibited enhanced 
susceptibility to CORM-2 (Nobre et al., 2009). Previous studies in E. coli 
demonstrated that OxyR-regulated genes such as dps, katG, grxA, ahpCF and 
trxC are induced in cells exposed to sub-lethal concentrations of H2O2 (Zheng 
et al., 2001; Wang et al., 2009). Our unpublished results also revealed that 
when cells were treated with a sub-lethal 150 µM dose of CORM-2, up-
regulation of katG and ahpC were observed. Moreover, a significant induction 
of these genes (katG and ahpC) was also seen after treating E. coli cells with 
another CO-RM, namely ALF062 (our unpublished results).  
E. coli genes linked with the metabolism of cysteine, which plays a 
critical role in protection of bacteria against oxidative stress, were also altered 
upon CO-RMs treatment. Indeed, the transcription of sbp, involved in sulfate 
uptake, which is crucial to cysteine biosynthesis, was induced in both CO-RMs 
microarray experiments and was one of the most induced genes in the 
presence of H2O2 (Table 6.4) (Zheng et al., 2001; Davidge et al., 2009; Nobre et 
al., 2009). Moreover, CORM-2 up-regulates a significant number of genes 
involved in sulphur metabolism, such as tauABC, ssuAD and cysWA, being the 




latter also up-regulated in the presence of H2O2 (Nobre et al., 2009; Wang et 
al., 2009). Furthermore, CO-RMs seem to interfere with the metabolism of 
methionine, as judged by alterations observed in the expression of methionine 
biosynthesis related genes. In particular, metF, which is involved in methionine 
biosynthesis, was highly induced by the two CO-releasing molecules (Davidge 
et al., 2009; Nobre et al., 2009). CORM-2 also induced several other 
methionine–related genes, namely metNI, metBL and metR, the latter 
regulating the transcription of genes involved in methionine biosynthesis 
(Nobre et al., 2009). Consistent with these data, the deletion of metR, metI 
and metN enhances the susceptibility of E. coli cells to CORM-2 (Nobre et al., 
2009). Although no methionine related gene had their transcription altered 
under oxidative stress conditions, it has been demonstrated that the oxidative 
stress is associated with methionine auxotrophy (Hondorp & Matthews, 2004). 
Interestingly, our results revealed that methionine supplementation abolishes 
the CO-RMs bactericidal activity (Figure 4.2). Overall, these results indicate 
that CO-RMs interfere with cysteine and methionine biosynthetic pathways.  
The E. coli spy, encoding a periplasmic protein that is induced by cell 
envelope stress, is also up-regulated in the presence of CO-releasing 
molecules and H2O2, suggesting that the integrity of cell envelope is affected 
under both stress conditions (Davidge et al., 2009; Nobre et al., 2009; Wang et 
al., 2009). Another periplasmatic protein involved in cell envelope stress, cpxP 
was induced in the presence of CO-RMs (Davidge et al., 2009; Nobre et al., 
2009). Interestingly, cpxP was the most up-regulated gene during n-butanol 
stress, which also generates an increase in ROS formation (Rutherford et al., 
2010). Altogether, these previous findings reinforce the proposal that 





















spy Envelope stress induced periplasmic protein 30 
sbp Sulfate transporter subunit 11 
oxyR Hydrogen peroxide-inducible genes activator 4 
soxS DNA binding transcriptional dual regulator 15 
micF Regulatory antisense sRNA affecting ompF expression 4 
marA Multiple antibiotic resistance protein  10 
marB Multiple antibiotic resistance protein 7 
ibpA 16 kDa heat shock protein A 19 
ibpB 16 kDa heat shock protein B 79 
dnaK Chaperone Hsp70, co-chaperone with DnaJ 3 
dnaJ Chaperone protein Hsp40, co-chaperone with DnaK 4 
hslO Hsp33-like chaperonin 5 
cysW Sulfate/thiosulfate transporter subunit W 3 
cysA Sulfate/thiosulfate transporter subunit A 5 
yqhD Alcohol dehydrogenase, NAD(P)-dependent 4 
yeeD Predicted redox protein 3 
metB Cystathionine gamma-synthase, PLP-dependent 5 
metL Bi-functional aspartate kinase II/homoserine dehydrogenase II 3 
metN D-methionine transport ATP binding protein 10 
metI D-methionine transport system permease 7 
metF 5,10-Methylenetetrahydrofolate reductase 18 
metR DNA-binding transcriptional activator, homocysteine-binding 21 
CORM-3 
spy Envelope stress induced periplasmic protein 3 
sbp Sulfate transporter subunit 3 
metF 5,10-Methylenetetrahydrofolate reductase 11 
htpX Heat shock protein 3 
Adapted from (Tavares et al., 2012).  
250 µM CORM-2 (Nobre et al., 2009) and 30 µM CORM-3 (Davidge et al., 2009). 
 




In addition to the increase of ROS production in E. coli cells upon CO-
RMs treatment, it is herein shown that CO-RMs are able to produce hydroxyl 
radicals per se in a CO-dependent mode, as the presence of haemoglobin 
prevented their formation (Figure 4.11). These findings might explain the 
better efficiency of CO-RMs as bactericides than that of CO gas (Nobre et al., 
2007; Desmard et al., 2009).  The generation of hydroxyl radicals from CORM-
2 is proposed to result from the reduction of oxygen by the reduced 
ruthenium species, which mediate the water–gas shift reaction that is initiated 
with the attack of water on one of the CO ligands of the RuII(CO)3 moieties of 
CORM-2. Moreover, the ROS formation is not exclusively linked to the 
presence of ruthenium in the CO-RM, as ALF062, a Mo-containing CO-RM, also 
induces the formation of hydroxyl radicals. In this case, it is plausible that 
hydroxyl radicals originate from the reaction of the electron-rich metal in the 
[Mo(CO)5Br]-[NEt4] complex with oxygen. 
Interestingly, antibiotics from the ß-lactams, aminoglycosides and 
quinolones classes have been reported to mediate bacterial cell death through 
the stimulation of the deleterious hydroxyl radical formation (Becerra & 
Albesa, 2002; Dwyer et al., 2007; Kohanski et al., 2007; Dwyer et al., 2009). 
Indeed, the efficiency of these drugs was found to be dependent on ROS 
production since addition of antioxidants as thiourea decreased their lethality 
(Kohanski et al., 2007). The free intracellular ferrous iron released from Fe-S 
clusters was also established as a source for Fenton-mediated hydroxyl radical 
formation promoted by these antibiotics (Dwyer et al., 2007; Kohanski et al., 
2007).  
Overall, the results compiled in this thesis undoubtedly revealed that 
the formation of ROS by CO-RMs contribute to their killing properties and 












CO-RMs effect on bacteria disclosed so far is represented in Figure 6.1. 
Independently of their pharmacological applications, CO-RMs no longer should 
be seen as simple CO delivery systems. To which point in animal cells the 
cytoprotective and potent anti-inflammatory properties of CO-RMs are linked 
to ROS formation is an open question that requires investigation to fully 
understand the mode of action of this novel class of compounds that exhibit a 
wide range of therapeutic properties. 
 
Figure 6.1| Schematic representation of CO-RMs effect on bacteria. CO-RMs
release CO that binds to terminal oxidases inhibiting respiration and enhancing the
production of superoxide. Superoxide dismutase (SOD) converts superoxide to
hydrogen peroxide, which via the Fenton reaction generates hydroxyl radicals
(OH.). CO-RMs also produce hydroxyl radicals per se. ROS damage DNA, oxidize
thiol groups and degrade iron-sulfur (Fe-S) containing proteins releasing free iron






















6.3 Carbon Monoxide-Releasing Molecules as antimicrobial agents 
against H. pylori 
In this thesis, the effect of exogenous CO via CO-RMs was analysed on 
the pathogen H. pylori (Chapter 5). The results herein presented 
demonstrated that CO-RMs are able to eliminate H. pylori in a dose-
dependent manner, while a CO-depleted compound has no antimicrobial 
properties (Figure 5.1 and S5.2). Importantly, CORM-2 is shown to be a potent 
antibacterial molecule against clinical isolated strains of H. pylori, some of 
which displayed resistance to metronidazole (Table 5.1). Interestingly, no 
morphological alteration was found upon CORM-2 treatment, as reported for 
other antimicrobial agents, such as aspirin and NO (Wang et al., 2003). Our 
group has recently reported that although NO was able to efficiently eliminate 
H. pylori, no coccoid forms were observed (Justino et al., 2012). As previously 
reported for E. coli, P. aeruginosa and C. jejuni, CORM-2 were shown to 
decrease the respiratory rates in H. pylori (Figure 5.2) (Davidge et al., 2009; 
Desmard et al., 2009; Smith et al., 2011). 
The bactericidal effect of CORM-2 on H. pylori cultures occurs at higher 
concentrations (200 mg/L ± 400 µM) than those required to kill E. coli or S. 
aureus (250 µM). These results are most probably due to experimental 
conditions regarding growth medium and the growth of bacteria, since H. 
pylori is a fastidious bacteria that requires a complex growth media. 
Nonetheless, further assays presented in this work revealed that H. pylori cells 
previously treated with CORM-2 had increased sensitivity to macrophage 
killing (Figure 5.7). Importantly, the bactericidal effect of CORM-2 on H. pylori 
occurs at concentrations which are usually not cytotoxic to eukaryotic cells, as 
the treatment of macrophages or smooth muscle cells with CO-RMs at 












cytotoxicity (Motterlini et al., 2002; Motterlini et al., 2005; Desmard et al., 
2009). Nevertheless, a recent study shows that only 20 µM CORM-2 or the 
respective inactive compound compromise the cell viability of human and 
canine kidney cells (Winburn et al., 2012). Further studies need to be 
conducted in order to clarify the toxicological profile of CO-RMs. 
Besides iron, CO is known to bind other transition metals in biological 
systems such as nickel, as well documented for nickel containing CO-
dehydrogenase (Ermler et al., 1998; Drennan et al., 2001). In accordance, the 
H. pylori urease, a nickel containing enzyme was found to have its activity 
inhibited upon CORM-2 treatment (Figure 5.3). Due to the urease crucial role 
in survival and pathogenesis of H. pylori (see section 1.1.3), an urease inhibitor 
constitutes a potential strategy to control infections caused by this bacterium. 
In fact, many urease inhibitors have been investigated in the past decades, like 
phosphorodiamidates, hydroxamic acid derivatives and imidazoles, but part of 
them are prevented from in vivo utilization due to their toxicity, instability and 
harmful side effects (Amtul et al., 2002; Amtul et al., 2007).  
One of the mechanisms of CO-RMs bactericidal action relies on the 
generation of ROS, as herein proved. Accordingly, antioxidants such as 
glutathione and cysteine showed to suppress the antimicrobial effect of 
CORM-2 on H. pylori (Figure 5.2). Recently, CORM-3 was reported to be unable 
to inhibit the growth of the microaerophilic pathogen C. jejuni. However, it is 
possible that the presence in the growth media of high concentrations of 
methionine and cysteine (~0.7 mM and ~3 mM, respectively) prevented the 
bactericidal effect of CORM-3 (Smith et al., 2011) 
Importantly, we found that when CORM-2 is combined with the most 
commonly antibiotics used against H. pylori namely metronidazole, 
clarithromycin and amoxicillin, bacteria cell death is enhanced and antibiotic 




resistance could be relieved (Figure 5.5 and Table S5.2). Moreover, H. pylori 
cells, previously treated with sub-lethal doses of metronidazole and CORM-2, 
were more susceptible to macrophage killing (Figure 5.8).  
Some examples of higher efficiency of drugs when combined with CO-
RMs have been recently reported. The ruthenium-based carbonyl ALF492 is 
proposed to be an effective adjuvant for treatment of cerebral malaria when 
used in combination with the antimalarial drug artesunate (Pena et al., 2012). 
More recently, CORM-2 has been reported to act as an adjuvant when 
combined with tobramycin, a drug commonly used to treat P. aeruginosa lung 
infections (Murray et al., 2012). Additionally, aspirin which has been reported 
to inhibit the growth of H. pylori, enhances bacteria susceptibility to 
metronidazole (Wang et al., 2003).  
 
Altogether, the work developed during this thesis allowed concluding 
that CO-RMs represent a novel therapeutic strategy against bacterial 
pathogens by mediating cell death through ROS formation. In particular, CO-
RMs seem to eliminate H. pylori, as it has already been recognized to E. coli, S. 
aureus and P. aeruginosa. Nevertheless, the mechanisms underlying CO-RMs 
action need to be further explored, particularly under anaerobic conditions. 
Furthermore, it would be interesting to elucidate CO targets besides the well-
known haem proteins, and the nickel containing protein – urease, herein 
described. Moreover, for the clinical application in humans, novel CO-RMs 
need to be prepared in order to minimize doses and maximize not only 
efficacy but also safety.  
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